



(51) International Patent Classification:

C07K 14/605 (2006.01) A61P 1/16 (2006.01)
 A61K 38/00 (2006.01) A61P 3/06 (2006.01)
 A61K 38/26 (2006.01) A61P 3/08 (2006.01)
 A61P 3/04 (2006.01) A61P 9/10 (2006.01)
 A61P 3/10 (2006.01) A61P 9/12 (2006.01)
 A61P 1/00 (2006.01) A61P 25/30 (2006.01)

(21) International Application Number:

PCT/US2021/014302

(22) International Filing Date:

21 January 2021 (21.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/964,932 23 January 2020 (23.01.2020) US

(71) Applicant: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46206-6288 (US).

(72) Inventors: **ALSINA-FERNANDEZ, Jorge**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **BROWN, Robert, Andrew**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **CUMMINS, Robert, Chadwick**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **ELSAYED, Mohamed ElSayed Hamed**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **GEISER, Andrea, Renee**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **LAI, Xianyin**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **QU, Hongchang**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **WATSON, Brian, Morgan**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US).

(74) Agent: **VORNDRAN-JONES, MaCharri, R.** et al.; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: GIP/GLP1 CO-AGONIST COMPOUNDS

(57) Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. These compounds may be useful in the treatment of type 2 diabetes mellitus ("T2DM"). These compounds may be useful in the treatment of obesity.

GIP/GLP1 Co-Agonist Compounds

The present invention relates to compounds having activity at both the human
5 glucose-dependent insulintropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)
receptors. The present invention also relates to compounds having an extended duration
of action at each of these receptors. Furthermore, the present invention relates to
compounds that may be administered orally. These compounds may be useful in the
treatment of type 2 diabetes mellitus ("T2DM"). Also, the compounds may be useful in
10 the treatment of obesity.

Over the past several decades, the prevalence of diabetes has continued to rise.
T2DM is the most common form of diabetes accounting for approximately 90% of all
diabetes. T2DM is characterized by high blood glucose levels associated mainly with
insulin resistance. The current standard of care for T2DM includes diet and exercise,
15 treatment with oral medications, and injectable glucose lowering drugs, including
incretin-based therapies, such as GLP-1 receptor agonists. A variety of GLP-1 receptor
agonists are currently available for treatment of T2DM, although currently marketed
GLP-1 receptor agonists are generally dose-limited by gastrointestinal side effects such as
nausea and vomiting. Subcutaneous injection is the typical route of administration for the
20 available GLP-1 receptor agonists. When treatment with oral medications and incretin-
based therapies are insufficient, insulin treatment is considered. Despite the advances in
treatment available today, many patients with T2DM are unable to reach their glycemic
control goals. Uncontrolled diabetes leads to several conditions associated with increased
morbidity and mortality of patients. There is a need for a treatment to enable more
25 patients with T2DM to reach their glycemic treatment goal.

Obesity is a complex medical disorder resulting in excessive accumulation of
adipose tissue mass. Today obesity is a global public health concern that is associated
with undesired health outcomes and morbidities. Desired treatments for patients with
obesity strive to reduce excess body weight, improve obesity-related co-morbidities, and
30 maintain long-term weight reduction. Available treatments for obesity are particularly
unsatisfactory for patients with severe obesity. There is a need for alternative treatment
options to induce therapeutic weight loss in patients in need of such treatment.

WO2016/111971 describes peptides stated to have GLP-1 and GIP activity.
 WO2013/164483 also discloses compounds stated to have GLP-1 and GIP activity.

There is a need for T2DM treatments capable of providing effective glucose control for a larger portion of the patients in need of such treatment. There is a further
 5 need for T2D treatments capable of providing effective glucose control and with a favorable side effect profile. There is a need for alternate treatment options to provide therapeutic weight loss in a patient in need of such treatment. There is a need for an alternate treatment option for a patient in need of treatment for severe obesity.

There is a desire for compounds having agonist activity at the GIP and GLP-1
 10 receptors that are suitable for oral administration. Compounds with extended duration of action at each of the GIP and GLP-1 receptors are desirable to allow for less frequent dosing of the compound. Compounds with two acylation modifications in combination with an amino acid sequence to provide GLP-1 and GIP activity from a single compound are desired.

15 Accordingly, provided are a compound of Formula I

$X_1X_2EGTX_6TSDX_{10}X_{11}X_{12}X_{13}LDX_{16}X_{17}AQX_{20}X_{21}X_{22}IX_{24}X_{25}LIX_{28}GX_{30}$
 (SEQ ID NO:505)

wherein

X_1 is selected from the group consisting of Y and R_1Y ;

20 R_1 is an Ac modification of the N-terminal amino group;

X_2 is Aib;

X_6 is selected from the group consisting of α MeF and α MeF(2F);

X_{10} is selected from the group consisting of 4Pal, Y, α MeF, α MeF(2F), α MeL, α MeV, Ac4c, Ac5c, Ac6c, Bip, 1Nal, 2Nal, OMeY, hTyr, Nle, V, 4CPhe, ChG,

25 ChA, Bzt, 2FA, 4TAA, 2TA, 3TA, and KZ₁;

X_{11} is selected from the group consisting of S, α MeS, Aib, G, Dap, Ac5c, and Tle;

X_{12} is selected from the group consisting of I and KZ₁;

X_{13} is selected from the group consisting of α MeL and α MeF;

X_{16} is Orn;

30 X_{17} is selected from the group consisting of Q, I, and KZ₁;

X_{20} is selected from the group consisting of Aib, Orn, 4Pal, α MeF, Ac5c, and Ac6c;

X₂₁ is selected from the group consisting of E, KZ₁, G, Orn, and 4Pal;

X₂₂ is selected from the group consisting of F, 2ClPhe, 3ClPhe, 2FPhe, 3FPhe, 3,5FPhe, 1Nal, 2Nal, αMeF(2F), ChA, Bzt, and αMeF;

X₂₄ is selected from the group consisting of D-Glu, E, G, and KZ₁;

5 X₂₅ is selected from the group consisting of Y, αMeY, αMeF, and KZ₁;

X₂₈ is selected from the group consisting of E, Orn, and KZ₁;

X₃₀ is selected from the group consisting of G, Orn, KZ₁, K(Z₁)R₆, OrnR₂, and GR₂;

10 R₂ is selected from the group consisting of X₃₁, X₃₁SSG (SEQ ID NO:5), X₃₁SSG-R₃ (SEQ ID NO:6), X₃₁SSGX₃₅PPPX₃₉ (SEQ ID NO:7), X₃₁SSGX₃₅PPPX₃₉R₃ (SEQ ID NO:8), X₃₁SSGX₃₅PPPX₃₉X₄₀ (SEQ ID NO:9), X₃₁SSGX₃₅PPPX₃₉X₄₀R₃ (SEQ ID NO:10), and a modification of the c-terminal group wherein the modification is NH₂;

15 R₆ is selected from the group consisting of PSSG (SEQ ID NO:506), PSSG-R₃ (SEQ ID NO:507), PSSGX₃₅PPPX₃₉ (SEQ ID NO:508), PSSGX₃₅PPPX₃₉R₃ (SEQ ID NO:509), PSSGX₃₅PPPX₃₉X₄₀ (SEQ ID NO:510), PSSGX₃₅PPPX₃₉X₄₀R₃ (SEQ ID NO:511), and a modification of the c-terminal group wherein the modification is NH₂;

X₃₁ is selected from the group consisting of P and KZ₁;

20 X₃₅ is selected from the group consisting of A and Orn;

X₃₉ is selected from the group consisting of S and Orn;

X₄₀ is KZ₁;

25 R₃ is a modification of the C-terminal group, wherein the modification is NH₂; wherein two, and only two, of X₁₀, X₁₂, X₁₇, X₂₁, X₂₄, X₂₅, X₂₈, X₃₀, X₃₁, and X₄₀ are KZ₁ or K(Z₁)R₆;

Z₁ is selected from the group consisting of R₅ and -R₄R₅;

R₄ is a linker; and

R₅ is a fatty acid; or

a pharmaceutically acceptable salt thereof.

30 Provided is a compound of Formula II:

X₁X₂EGTX₆TSDX₁₀X₁₁X₁₂X₁₃LDX₁₆X₁₇AQX₂₀X₂₁X₂₂IX₂₄X₂₅LIX₂₈GX₃₀ (SEQ ID NO:4)

wherein

X₁ is selected from the group consisting of Y and R₁Y;

R₁ is an Ac modification of the N-terminal amino group;

X₂ is Aib;

5 X₆ is selected from the group consisting of αMeF and αMeF(2F);

X₁₀ is selected from the group consisting of 4Pal, Y, αMeF, αMeF(2F), αMeL, αMeV, Ac4c, Ac5c, Ac6c, Bip, 1Nal, 2Nal, OMeY, hTyr, Nle, V, 4CPhe, ChG, ChA, Bzt, 2FA, 4TAA, 2TA, 3TA, and KZ₁;

X₁₁ is selected from the group consisting of Ac5c, S, αMeS, Aib, G, Dap, and Tle;

10 X₁₂ is selected from the group consisting of I and KZ₁;

X₁₃ is selected from the group consisting of αMeL and αMeF;

X₁₆ is Orn;

X₁₇ is selected from the group consisting of Q, I, and KZ₁;

X₂₀ is selected from the group consisting of Aib, Orn, 4Pal, αMeF, Ac5c, and

15 Ac6c;

X₂₁ is selected from the group consisting of E, KZ₁, G, Orn, and 4Pal;

X₂₂ is selected from the group consisting of F, 2ClPhe, 3ClPhe, 2FPhe, 3FPhe, 3,5FPhe, 1Nal, 2Nal, αMeF(2F), ChA, Bzt, and αMeF;

X₂₄ is selected from the group consisting of D-Glu, E, G, and KZ₁;

20 X₂₅ is selected from the group consisting of Y, αMeY, αMeF, and KZ₁;

X₂₈ is selected from the group consisting of E, Orn, and KZ₁;

X₃₀ is selected from the group consisting of G, Orn, KZ₁, and GR₂;

R₂ is selected from the group consisting of X₃₁SSG (SEQ ID NO:5), X₃₁SSG-R₃

(SEQ ID NO:6), X₃₁SSGX₃₅PPPX₃₉ (SEQ ID NO:7), X₃₁SSGX₃₅PPPX₃₉R₃ (SEQ

25 ID NO:8), X₃₁SSGX₃₅PPPX₃₉X₄₀ (SEQ ID NO:9), X₃₁SSGX₃₅PPPX₃₉X₄₀R₃ (SEQ ID NO:10), and a modification of the c-terminal group wherein the modification is NH₂;

X₃₁ is selected from the group consisting of P and KZ₁;

X₃₅ is selected from the group consisting of A and Orn;

30 X₃₉ is selected from the group consisting of S and Orn;

X₄₀ is KZ₁;

R₃ is a modification of the C-terminal group, wherein the modification is NH₂;

wherein two, and only two, of X₁₀, X₁₂, X₁₇, X₂₁, X₂₄, X₂₅, X₂₈, X₃₀, X₃₁, and X₄₀ are KZ₁;

Z₁ is selected from the group consisting of R₅ and -R₄R₅; and

R₄ is a linker;

5 R₅ is a fatty acid; or

a pharmaceutically acceptable salt thereof.

Provided is a peptide of Formula I, or a pharmaceutically acceptable salt thereof, wherein Z₁ is selected from the group consisting of

- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
- 10 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₀-CO₂H,
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(4-(4-iodophenyl)butanoyl),
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(4-(4-*tert*-
- 15 butylphenyl)butanoyl),
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₄-CH₃,
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₂-CH₃,
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₀-CH₃,
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-CO-(CH₂)₁₂-CO₂H,
- 20 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(10-(4-carboxyphenoxy)decanoyl),
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₄-CH₃,
- 25 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₀-CH₃,
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₃-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₃-(γ-Glu)-CO-(CH₂)₁₄-CH₃,
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(εK)-CO-(CH₂)₁₂-CO₂H,
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(εK)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
- 30 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(εK)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,

- (ϵ K)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH₂)₁₂-CO₂H,
 -(ϵ K)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₂-CO₂H,
 -(ϵ K)-(γ -Glu)-CO-(CH₂)₁₂-CO₂H,
 -(ϵ K)-(γ -Glu)-(γ -Glu)-CO-(CH₂)₁₂-CO₂H,
 5 -(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-CO-(CH₂)₁₂-CO₂H,
 -(ϵ K)-(ϵ K)-(γ -Glu)-CO-(CH₂)₁₂-CO₂H,
 -(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO-(CH₂)₁₂-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(2-[2-(2-Amino-ethoxy)-
 ethoxy]-acetyl)-CO-(CH₂)₁₂-CO₂H,
 10 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(7-(4-
 carboxyphenoxy)heptanoyl),
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(8-(4-
 carboxyphenoxy)octanoyl),
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(4-(4-tert-
 15 butylphenyl)butanoyl),
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(11-(4-
 carboxyphenoxy)undecanoyl),
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₃-(γ -Glu)-(10-(4-
 carboxyphenoxy)decanoyl),
 20 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(2-[2-(2-Amino-ethoxy)-
 ethoxy]-acetyl)-CO-(CH₂)₁₂-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(2-[2-(2-Amino-ethoxy)-
 ethoxy]-acetyl)₂-CO-(CH₂)₁₂-CO₂H,
 -PEG3-(γ -Glu)-CO-(CH₂)₁₂-CO₂H,
 25 -PEG4-(γ -Glu)-CO-(CH₂)₁₂-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₃-(γ -Glu)-CO-(CH₂)₁₀-CH₃,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(11-(4-
 carboxyphenoxy)undecanoyl),
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₄-CO₂H,
 30 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Ahx-(γ -Glu)-CO-(CH₂)₁₂-CO₂H,

- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-(γ -Glu)-CO-(CH₂)₁₂-CO₂H,
 -Ahx-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH₂)₁₂-CO₂H,
 -Aoc-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH₂)₁₂-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Ahx-(γ -Glu)-(10-(4-
 5 carboxyphenoxy)decanoyl),
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-(γ -Glu)-(10-(4-
 carboxyphenoxy)decanoyl),
 -Ahx-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-
 carboxyphenoxy)decanoyl),
 10 -Aoc-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-
 carboxyphenoxy)decanoyl),
 -PEG4-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl),
 -PEG3-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl),
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-CO-(CH₂)₁₂-CO₂H,
 15 -PEG6-(γ -Glu)-CO-(CH₂)₁₂-CO₂H,
 -PEG5-(γ -Glu)-CO-(CH₂)₁₂-CO₂H,
 -PEG6-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl),
 -PEG5-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl),
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-Trx-(γ -Glu)-CO-(CH₂)₁₂-CO₂H,
 20 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-Trx-(γ -Glu)-(10-(4-
 carboxyphenoxy)decanoyl),
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Trx-(γ -Glu)-CO-(CH₂)₁₂-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Trx-(γ -Glu)-(10-(4-
 carboxyphenoxy)decanoyl),
 25 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)₂-CO-(CH₂)₁₂-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)₂-(10-(4-
 carboxyphenoxy)decanoyl),
 -(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₂-CO₂H,
 -(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(10-(4-
 30 carboxyphenoxy)decanoyl),

-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H, and

-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl).

5 Provided is a peptide of Formula I, or a pharmaceutically acceptable salt thereof, wherein Z₁ is selected from the group consisting of

-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,

-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₀-CO₂H,

10 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),

-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(4-(4-iodophenyl)butanoyl),

-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(4-(4-*tert*-butylphenyl)butanoyl),

-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₄-CH₃,

15 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₂-CH₃,

-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₀-CH₃,

-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-CO-(CH₂)₁₂-CO₂H,

-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(10-(4-carboxyphenoxy)decanoyl),

-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,

20 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),

-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH₂)₁₄-CH₃,

-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH₂)₁₀-CH₃,

-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₃-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,

25 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₃-(γ-Glu)-CO-(CH₂)₁₄-CH₃,

-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(εK)-CO-(CH₂)₁₂-CO₂H,

-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(εK)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,

-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(εK)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,

-(εK)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,

30 -(εK)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,

-(εK)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 -(εK)-(γ-Glu)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 -(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-CO-(CH₂)₁₂-CO₂H,
 -(εK)-(εK)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 5 -(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO-(CH₂)₁₂-CO₂H
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-
 ethoxy]-acetyl)-CO-(CH₂)₁₂-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(7-(4-
 carboxyphenoxy)heptanoyl),
 10 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(8-(4-
 carboxyphenoxy)octanoyl), and
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(4-(4-*tert*-
 butylphenyl)butanoyl).

Provided is a peptide of Formula I, or a pharmaceutically acceptable salt thereof,

15 wherein Z₁ is selected from the group consisting of

-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₀-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(10-(4-
 carboxyphenoxy)decanoyl),
 20 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(4-(4-iodophenyl)butanoyl),
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(4-(4-*tert*-
 butylphenyl)butanoyl),
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₄-CH₃,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₂-CH₃,
 25 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₀-CH₃,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-CO-(CH₂)₁₂-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(10-(4-carboxyphenoxy)decanoyl),
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(10-(4-
 30 carboxyphenoxy)decanoyl),

- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH₂)₁₄-CH₃,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH₂)₁₀-CH₃,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₃-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₃-(γ-Glu)-CO-(CH₂)₁₄-CH₃,
 5 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(εK)-CO-(CH₂)₁₂-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(εK)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(εK)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 -(εK)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 -(εK)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 10 -(εK)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 -(εK)-(γ-Glu)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 -(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-CO-(CH₂)₁₂-CO₂H,
 -(εK)-(εK)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 -(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO-(CH₂)₁₂-CO₂H,
 15 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-
 ethoxy]-acetyl)-CO-(CH₂)₁₂-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(7-(4-
 carboxyphenoxy)heptanoyl),
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(8-(4-
 20 carboxyphenoxy)octanoyl), and
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(4-(4-*tert*-
 butylphenyl)butanoyl).

Provided is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R₅ is selected from the group consisting of

- 25 -CO-(CH₂)₁₂-CO₂H, -CO-(CH₂)₁₀-CO₂H, -(10-(4-carboxyphenoxy)decanoyl), -(4-(4-
 iodophenyl)butanoyl), -(4-(4-*tert*-butylphenyl)butanoyl), -CO-(CH₂)₁₄-CH₃, -CO-(CH₂)₁₂-
 CH₃, -CO-(CH₂)₁₀-CH₃, -(7-(4-carboxyphenoxy)heptanoyl), -(8-(4-
 carboxyphenoxy)octanoyl), (11-(4-carboxyphenoxy)undecanoyl), -(12-(4-
 carboxyphenoxy)dodecanoyl), and CO-(CH₂)₁₄-CO₂H.

Provided is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R₅ is selected from the group consisting of
 -CO-(CH₂)₁₂-CO₂H, -CO-(CH₂)₁₀-CO₂H, -(10-(4-carboxyphenoxy)decanoyl), -(4-(4-iodophenyl)butanoyl), -(4-(4-*tert*-butylphenyl)butanoyl), -CO-(CH₂)₁₄-CH₃, -CO-(CH₂)₁₂-CH₃,
 5 -CO-(CH₂)₁₀-CH₃, -(7-(4-carboxyphenoxy)heptanoyl), and -(8-(4-carboxyphenoxy)octanoyl).

Provided is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R₄ is selected from the group consisting of

- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-,
- 10 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-,
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-,
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)₂-,
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₃-(γ-Glu)-,
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(εK)-,
- 15 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(εK)-(γ-Glu)-,
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(εK)-(γ-Glu)-,
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Trx-(γ-Glu)-,
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-Trx-(γ-Glu)-,
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-,
- 20 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-(γ-Glu)-,
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Ahx-(γ-Glu)-,
- PEG3-(γ-Glu)-,
- PEG4-(γ-Glu)-,
- PEG5-(γ-Glu)-,
- 25 - PEG6-(γ-Glu)-,
- Ahx-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-,
- Aoc-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-,
- (εK)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-,
- (εK)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-,
- 30 - (εK)-(γ-Glu)-,

-(εK)-(γ-Glu)-(γ-Glu)-,
 -(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-,
 -(εK)-(εK)-(γ-Glu)-,
 -(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-,
 5 -(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-
 ethoxy]-acetyl)-,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-
 ethoxy]-acetyl)-,
 10 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-
 ethoxy]-acetyl)₂-, and
 (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-
 acetyl)-(γ-Glu)-.

Provided is a compound of Formula I, or a pharmaceutically acceptable salt

15 thereof, wherein R₄ is selected from the group consisting of

-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-.
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₃-(γ-Glu)-,
 20 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(εK)-,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(εK)-(γ-Glu)-,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(εK)-(γ-Glu)-,
 -(εK)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-,
 -(εK)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-,
 25 -(εK)-(γ-Glu)-,
 -(εK)-(γ-Glu)-(γ-Glu)-,
 -(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-,
 -(εK)-(εK)-(γ-Glu)-,
 -(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-, and

-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-.

Provided is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein X_{17} and X_{31} are each KZ_1 . Provided is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein X_{17} and X_{24} are each KZ_1 . Provided is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein X_{17} and X_{21} are each KZ_1 . Provided is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein X_{17} and X_{28} are each KZ_1 . Provided is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein X_{17} and X_{40} are each KZ_1 . Provided is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein X_{21} and X_{40} are each KZ_1 . Provided is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein X_{21} and X_{28} are each KZ_1 . Provided is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein X_{24} and X_{28} are each KZ_1 .

Provided is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein X_1 is Y; X_6 is α MeF(2F); X_{10} is selected from the group consisting of 4Pal, Y, and KZ_1 ; X_{11} is selected from the group consisting of S, α MeS, and Aib; X_{12} is I; X_{13} is α MeL; X_{16} is Orn; X_{17} is selected from the group consisting of I and KZ_1 ; X_{20} is Aib; X_{21} is selected from the group consisting of KZ_1 and E; X_{22} is selected from the group consisting of F and α MeF; X_{24} is selected from the group consisting of D-Glu, and KZ_1 ; X_{25} is α MeY; X_{28} is selected from the group consisting of E and KZ_1 ; X_{30} is selected from the group consisting of G and GR_2 ; R_2 is selected from the group consisting of $X_{31}SSGX_{35}PPPX_{39}$ (SEQ ID NO:7), $X_{31}SSGX_{35}PPPX_{39}R_3$ (SEQ ID NO:8), and $X_{31}SSGX_{35}PPPX_{39}X_{40}$ (SEQ ID NO:9), and a modification of the c-terminal group wherein the modification is NH_2 ; X_{31} is selected from the group consisting of P and KZ_1 ; X_{35} is selected from the group consisting of A and Orn; X_{39} is selected from the group consisting of S, Orn; X_{40} is selected from the group consisting of KZ_1 ; R_3 is a modification of the C-terminal group, wherein the modification is NH_2 ; wherein one, and only one, selected from the group consisting of X_{10} , X_{17} , X_{21} , X_{24} , X_{28} , and X_{31} is KZ_1 ; Z_1 is $-R_4R_5$; R_4 is a linker; and R_5 is a fatty acid; or a pharmaceutically acceptable salt thereof.

Provided is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of

- Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₂-CO₂H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₂-CO₂H)SSGAPPPS-NH₂,
- Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))SSGAPPPS-NH₂,
- Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(4-(4-iodophenyl)butanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(4-(4-iodophenyl)butanoyl))SSGAPPPS-NH₂,
- Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(4-(4-*tert*-butylphenyl)butanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(4-(4-*tert*-butylphenyl)butanoyl))SSGAPPPS-NH₂, and
- Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₀-CH₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₀-CH₃)SSGAPPPS-NH₂.

In an embodiment the R₄ linker is one to two amino acids selected from the group consisting of ϵ K and γ -Glu. In an embodiment the R₄ linker comprises from one to three (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) moieties. In an embodiment, the R₅ fatty acid moieties are conjugated to a lysine via an R₄ linker between the lysine and the R₅ fatty acid.

In an embodiment is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the R₄ linker comprises from zero to four amino acids; and from zero to three (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) moieties. In an embodiment, the R₄ linker comprises from one to three amino acids each independently selected from the

group consisting of ϵ K and γ -Glu. In an embodiment, is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the R_4 linker comprises from 1 to 2 amino acids each independently selected from the group consisting of ϵ K and γ -Glu. In an embodiment is a compound of Formula I, or a pharmaceutically acceptable salt thereof, comprising two Z_1 fatty acid moieties wherein each R_5 fatty acid of the Z_1 moiety is conjugated to different lysines of the peptide via an R_4 linker wherein, the R_4 linker comprises from zero to 2 γ -Glu amino acid residues. In an embodiment is a compound of Formula I, or a pharmaceutically acceptable salt thereof, comprising two Z_1 fatty acid moieties wherein each R_5 fatty acid of the Z_1 is conjugated to different lysines of the peptide via an R_4 linker wherein R_4 comprises from one to three amino acids and from one to three (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) moieties. In an embodiment is a compound of Formula I, or a pharmaceutically acceptable salt thereof, comprising two of the same Z_1 fatty acid moieties wherein the R_5 fatty acid of the Z_1 is each conjugated to a different lysine of the peptide via an R_4 linker wherein, R_4 comprises from one to three amino acids each independently selected from the group consisting of ϵ K and γ -Glu; and from one to three (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) moieties attached to the amino acid. In an embodiment is a Formula I compound, or a pharmaceutically acceptable salt thereof, comprising two of the same Z_1 fatty acid moieties wherein the R_5 fatty acid of the Z_1 is each conjugated to different lysines of the peptide via an R_4 linker wherein R_4 comprises up to three amino acids each independently selected from the group consisting of γ -Glu and ϵ K attached to one or two (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) moieties.

In an embodiment is a Formula I compound, or a pharmaceutically acceptable salt thereof, comprising two of the same Z_1 fatty acid moieties wherein the R_5 fatty acid of the Z_1 is each conjugated via an R_4 linker, wherein the R_4 linker has the following formula:

$-(\epsilon K)_{a1}-(\gamma\text{-Glu})_{a2}-(2\text{-}[2\text{-}(2\text{-Amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_{a3}-(\epsilon K)_{b1}-(\gamma\text{-Glu})_{b2}-$;


wherein $a1$ is selected from the group consisting of 0, 1, and 2; $a2$ is selected from the group consisting of 0, 1, and 2; $a3$ is selected from the group consisting of 0, 1, 2, and 3; $b1$ is 0 or 1; and $b2$ is 0 or 1. In an embodiment is a Formula I compound, or a pharmaceutically acceptable salt thereof, comprising two of the same Z_1 fatty acid moieties wherein the R_5 fatty acid of the Z_1 is each conjugated via an R_4 linker wherein Z_1 is of the formula:

$-(\epsilon K)_{a1}-(\gamma\text{-Glu})_{a2}-(2-[2-(2\text{-Amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_{a3}-(\epsilon K)_{b1}-(\gamma\text{-Glu})_{b2}\text{-CO-}$
 $(\text{CH}_2)_q\text{-CO}_2\text{H}$ wherein wherein $a1$ is selected from the group consisting of 0, 1, and 2; $a2$
 is selected from the group consisting of 0, 1, and 2; $a3$ is selected from the group
 consisting of 0, 1, 2, and 3; $b1$ is 0 or 1; $b2$ is 0 or 1; and q is selected from the group
 consisting of 10, 12, 14 and 16.

In an embodiment, $a1$ is 1, $a2$ is 0, $a3$ is 2, $b1$ is 0, $b2$ is 1, and q is 12; and the structure is:

$-(\epsilon K)-(2-[2-(2\text{-Amino-ethoxy})\text{-ethoxy}]\text{-acetyl})_2-(\gamma\text{-Glu})\text{-CO-(CH}_2\text{)}_{12}\text{-CO}_2\text{H}$.

In an embodiment is a Formula I compound, or a pharmaceutically acceptable salt thereof, comprising two of the same Z_1 fatty acid moieties wherein the R_5 fatty acid of the Z_1 is each conjugated via an R_4 linker, wherein the R_4 linker and R_5 fatty acid components have the following formula:



wherein $q2$ is selected from the group consisting of 7, 8, 10, 11, and 12.

In an embodiment is a Formula I compound, or a pharmaceutically acceptable salt thereof, comprising two of the same Z_1 fatty acid moieties wherein the R_5 fatty acid of the Z_1 is each conjugated via an R_4 linker, wherein the R_5 fatty acid is selected from the group consisting of $-(7\text{-(4-carboxyphenoxy)heptanoyl})$ and $-(8\text{-(4-carboxyphenoxy)octanoyl})$. In an embodiment is a Formula I compound, or a pharmaceutically acceptable salt thereof, comprising two of the same Z_1 fatty acid moieties each conjugated via an R_4 linker, wherein the R_5 fatty acid is selected from the group consisting of $-(10\text{-(4-carboxyphenoxy)decanoyl})$, $-(4\text{-(4-iodophenyl)butanoyl})$, and $-(4\text{-(4-tert-butylphenyl)butanoyl})$.

In an embodiment is a Formula I compound, or a pharmaceutically acceptable salt thereof, comprising two of the same Z_1 fatty acid moieties each conjugated via an R_4

linker, wherein the R₅ fatty acid is selected from the group consisting of -CO-(CH₂)₁₄-CH₃, -CO-(CH₂)₁₂-CH₃, and -CO-(CH₂)₁₀-CH₃.

5 In an embodiment is a Formula I compound, or a pharmaceutically acceptable salt thereof, comprising two of the same Z₁ fatty acid moieties each conjugated via an R₄ linker, wherein the R₅ fatty acid is selected from the group consisting of -CO-(CH₂)₁₂-CO₂H and -CO-(CH₂)₁₀-CO₂H. In an embodiment is a Formula I compound, or a pharmaceutically acceptable salt thereof, comprising two of the same Z₁ fatty acid moieties each conjugated via an R₄ linker, wherein the R₅ fatty acid is selected from the group consisting of -CO-(CH₂)₁₀-CH₃ and -CO-(CH₂)₁₂-CH₃.

10 In an embodiment, R₅ fatty acid is selected from the group consisting of -CO-(CH₂)₁₂-CO₂H, -CO-(CH₂)₁₀-CO₂H, -(10-(4-carboxyphenoxy)decanoyl), -(4-(4-iodophenyl)butanoyl), -(4-(4-*tert*-butylphenyl)butanoyl), -CO-(CH₂)₁₄-CH₃, -CO-(CH₂)₁₂-CH₃, -CO-(CH₂)₁₀-CH₃, -(7-(4-carboxyphenoxy)heptanoyl), and -(8-(4-carboxyphenoxy)octanoyl).

15 An embodiment provides a method of treating a condition selected from the group consisting of T2DM, obesity, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), dyslipidemia and metabolic syndrome, comprising administering to a subject in need thereof, an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof. An embodiment provides a method for
20 providing therapeutic weight loss comprising administering to a subject in need thereof, an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof. In one embodiment, the condition is NAFLD. In one embodiment, the condition is NASH.

25 An embodiment provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, for use in therapy. An embodiment provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, for use in the treatment of a condition selected from the group consisting of T2DM, obesity, NAFLD, NASH, dyslipidemia, and metabolic syndrome. In an embodiment, the condition is T2DM. In an embodiment, the condition is obesity. In an embodiment, the condition is NAFLD. In an
30 embodiment, the condition is NASH. In an embodiment, the condition is metabolic syndrome.

The compounds of Formula I, or a pharmaceutically acceptable salt thereof, may be useful in the treatment of a variety of symptoms or disorders. For example, certain embodiments, provide a method for treatment of T2DM in a patient comprising administering to a subject in need of such treatment an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof. In an embodiment, is a method for treatment of obesity in a patient comprising administering to a subject in need of such treatment an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof. In an embodiment, the method is inducing non-therapeutic weight loss in a subject, comprising administering to a subject in need of such treatment an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.

In certain embodiments, the present invention provides a method for treatment of metabolic syndrome in a patient comprising administering to a subject in need of such treatment an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof. In an embodiment, the method is treatment of NASH comprising administering to a subject in need of such treatment an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Also provided herein is a compound of the present invention for use in simultaneous, separate and sequential combinations with one or more agents selected from metformin, a thiazolidinedione, a sulfonylurea, a dipeptidyl peptidase 4 inhibitor, a sodium glucose co-transporter, a SGLT-2 inhibitor, a growth differentiation factor 15 modulator ("GDF15"), a peptide tyrosine tyrosine modulator ("PYY"), a modified insulin, amylin, a dual amylin calcitonin receptor agonist, and oxyntomodulin agonist ("OXM") in the treatment of a condition selected from the group consisting of T2DM, obesity, NAFLD, NASH, dyslipidemia and metabolic syndrome. In an embodiment, a compound of the present invention is provided in a fixed dose combination with one or more agents selected from metformin, a thiazolidinedione, a sulfonylurea, a dipeptidyl peptidase 4 inhibitor, a sodium glucose co-transporter, a SGLT-2 inhibitor, GDF15, PYY, a modified insulin, amylin, a dual amylin calcitonin receptor agonist, and OXM. In an embodiment is a compound of the present invention for use in simultaneous, separate and sequential combinations with one or more agents selected from metformin, a thiazolidinedione, a sulfonylurea, a dipeptidyl peptidase 4 inhibitor, a sodium glucose co-

transporter, a SGLT-2 inhibitor, GDF15, PYY, a modified insulin, amylin, a dual amylin calcitonin receptor agonist, and OXM in the treatment of a condition selected from the group consisting of T2DM and obesity. In an embodiment is a compound of the present invention for use in simultaneous, separate and sequential combinations with one or more agents selected from metformin, a thiazolidinedione, a sulfonylurea, a dipeptidyl peptidase 4 inhibitor, a sodium glucose co-transporter, and a SGLT-2 inhibitor in the treatment of a condition selected from the group consisting of T2DM and obesity.

In other embodiments, the compounds, or a pharmaceutically acceptable salt thereof, may be useful to improve bone strength in subjects in need thereof. The compounds of the present invention, or a pharmaceutically acceptable salt thereof, may be useful in the treatment of other disorders such as Parkinson's disease or Alzheimer's disease. Incretins and incretin analogs having activity at one or more of the GIP, GLP-1 and/or glucagon receptors have been described as having the potential to have therapeutic value in a number of other diseases or conditions, including for example obesity, NAFLD and NASH, dyslipidemia, metabolic syndrome, bone related disorders, Alzheimer's disease, and Parkinson's disease. *See, e.g., Jall S., et. al, Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice, MOL. METAB. 6(5):440-446 (March 2017); Carbone L.J., et. al., Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. J.GASTROENTEROL. HEPATOL., 31(1):23-31 (Jan. 2016); B. Finan, et. al, Reappraisal of GIP Pharmacology for Metabolic Diseases. TRENDS MOL. MED., 22(5):359-76 (May 2016); Choi, I.Y., et al., Potent body weight loss and efficacy in a NASH animal model by a novel long-acting GLP-1/Glucagon/GIP triple-agonist (HM15211), ADA 2017 Poster 1139-P; Ding, K.H., Impact of glucose-dependent insulinotropic peptide on age-induced bone loss, J. BONE MINER. RES., 23(4):536-43 (2008); Tai, J. et. al, Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease, BRAIN RES. 1678, 64-74 (2018); T.D. Müller et al., The New Biology and Pharmacology of Glucagon, PHYSIOL. REV. 97: 721-766 (2017); Finan, B. et. al, Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans, SCI. TRANSL. MED., 5:209 (October 2013); Hölscher C, Insulin, incretins and other growth factors as*

potential novel treatments for Alzheimer's and Parkinson's diseases. BIOCHEM. SOC. TRANS. 42(2):593-0 (Apr. 2014).

Another embodiment provides the use of a compound of the present invention, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition selected from the group consisting of T2DM, obesity, NAFLD, NASH, dyslipidemia and metabolic syndrome. In an embodiment, the medicament is for the treatment of T2DM. In an embodiment, the medicament is for the treatment of obesity. In an embodiment, the medicament is for the treatment of NAFLD. In an embodiment, the medicament is for the treatment of NASH.

Another embodiment provides a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and at least one selected from the group consisting of a carrier, diluent, and excipient.

As used herein, the term “treating” or “to treat” includes restraining, slowing, stopping, or reversing the progression or severity of a symptom, condition, or disorder.

Certain compounds provided herein are generally effective over a wide dosage range. For example, dosages for once weekly parenteral dosing may fall within the range of 0.05 mg to about 30 mg per person per week. Compounds provided herein are orally available and may be dosed using oral formulation techniques. Oral formulations may be formulated for periodic dosing, such as once daily.


The compounds of the present invention include novel amino acid sequences having affinity for the respective GLP-1 and GIP receptors, with desired potency at each of these receptors. GLP-1 is a 36 amino acid peptide, the major biologically active fragment of which is produced as a 30-amino acid, C-terminal amidated peptide (GLP-1₃₀) (SEQ ID NO:2).














GIP is a 42 amino acid peptide (SEQ ID NO:1), which, like GLP-1, is also known as an incretin, and plays a physiological role in glucose homeostasis by stimulating insulin secretion from pancreatic beta cells in the presence of glucose.


The compounds provide desired potency at each of the GIP and GLP-1 receptors. In an embodiment, compounds are suitable for oral administration. In an embodiment, compounds have desirable GIP and GLP receptor extended time action.


As used herein, “linker” means a group conjugating the R₅ fatty acid to a lysine of the peptide. As used herein, “fatty acid” means a hydrocarbon with a carboxyl group. As

used herein “Ac” means acetyl modification. In an embodiment, a fatty acid is an albumin binding group. As used herein the term “amino acid” means both naturally occurring amino acids and unnatural amino acids. The amino acids are typically depicted using standard one letter codes (e.g., L = leucine), as well as alpha-methyl substituted residues of natural amino acids (e.g., α -methyl leucine, or α MeL and α -methyl lysine, or α MeK) and certain other unnatural amino acids, such as alpha amino isobutyric acid, or “Aib,” “4Pal,” “Orn,” and the like. The structures of non-natural amino acids and other abbreviations appear below:



**2Cl-Phe / F(2Cl)****3Cl-Phe / F(3Cl)****2F-Phe / F(2F)****3F-Phe / F(3F)****2-FA****4-TAA****2-TA****3-TA****Ac4c****Tle****ChA****ChG****Bzt**





As used herein “Orn” means ornithine. As used herein “4Pal” means 3-(4-Pyridyl)-L-alanine. As used herein “ α MeF(2F)” means alpha-methyl 2-F-phenylalanine, alpha-methyl-F(2F), and alpha-methyl-Phe(2F). As used herein “ α MeY,” mean alpha methyl tyrosine, alpha methyl-Tyr, and alpha methyl-Y. As used herein, “ α MeL” means alpha methyl leucine, alpha methyl-L, and alpha methyl-Leu. As used herein, “e” and “D-Glu” mean D-glutamic acid. As used herein, “ α MeF”, means alpha-methyl-F and alpha-methyl-Phe. As used herein, “ α MeS”, means alpha-methyl-serine, alpha methyl-S, and alpha-methyl-Ser. As used herein, “AEEA” means (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl); “AEEA2” means (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂; and “AEEA3” means (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₃.

As used herein, “Ahx” is 6-Aminohexanoyl-; “Aoc” is 8-Aminooctanoyl-; “PEG3” is [3-(2-[2-(2-Amino-ethoxy)-ethoxy]-ethoxy)-propanoyl]-; “PEG4” is (3-[2-(2-

[2-(2-Amino-ethoxy)-ethoxy]-ethoxy)-ethoxy]-propanoyl)-; “PEG5” is [3-(2-[2-(2-[2-(2-Amino-ethoxy)-ethoxy]-ethoxy)-ethoxy]-ethoxy)-ethoxy]-propanoyl)-; and “PEG6” is (3-[2-(2-[2-(2-[2-(2-Amino-ethoxy)-ethoxy]-ethoxy)-ethoxy]-ethoxy)-ethoxy]-ethoxy)-ethoxy]-propanoyl)-. “Tle” is tert-Leucine.

5 As shown in the chemical structures of Examples below, in an embodiment the linker-fatty acid moieties (-R₃R₄), described above, link to the epsilon-amino group of a lysine side-chain.

 When used herein in reference to one or more of the GIP or GLP-1 receptors, the terms “activity,” “activate[s]” “activat[ing]” and the like refers to the capacity of a
10 compound, or a pharmaceutically acceptable salt thereof, to bind to and induce a response at the receptor(s), as measured using assays known in the art, such as the in vitro assays described below.

 The affinity of compounds, or a pharmaceutically acceptable salt thereof, of the present invention for each of the GIP and GLP-1 receptors may be measured using
15 techniques known for measuring receptor binding levels in the art, including, for example those described in the examples below, and is commonly expressed as a K_i value. The activity of the compounds of the present invention at each of the receptors may also be measured using techniques known in the art, including for example the in vitro activity assays described below, and is commonly expressed as an EC₅₀ value, which is the
20 concentration of compound causing half-maximal stimulation in a dose response curve.

 In an embodiment, a pharmaceutical composition of a compound of Formula I is suitable for administration by a parenteral route (*e.g.*, subcutaneous, intravenous, intraperitoneal, intramuscular, or transdermal). In an embodiment, a pharmaceutical composition of a compound of Formula I is suitable for oral administration (*e.g.*, tablet,
25 capsule). Some pharmaceutical compositions and processes for preparing same are well known in the art. (*See, e.g.*, Remington: The Science and Practice of Pharmacy (D.B. Troy, Editor, 21st Edition, Lippincott, Williams & Wilkins, 2006).

 Compounds of the provided herein may react with a number of inorganic and organic acids/bases to form pharmaceutically acceptable acid/base addition salts.
30 Pharmaceutically acceptable salts and common methodology for preparing them are well known in the art. (*See, e.g.*, P. Stahl, *et al.* Handbook of Pharmaceutical Salts: Properties, Selection and Use, 2nd Revised Edition (Wiley-VCH, 2011)). Pharmaceutically

acceptable salts of the present invention include, but are not limited to, sodium, trifluoroacetate, hydrochloride, ammonium, and acetate salts. In an embodiment, a pharmaceutically acceptable salt of is selected from the group consisting of sodium, hydrochloride, and acetate salts.

5 The present invention also encompasses novel intermediates and processes useful for the synthesis of compounds of the present invention, or a pharmaceutically acceptable salt thereof. The intermediates and compounds of the present invention may be prepared by a variety of procedures known in the art. In particular, the Examples below describe a process using chemical synthesis. The specific synthetic steps for each of the routes
10 described may be combined in different ways to prepare compounds of the present invention. The reagents and starting materials are readily available to one of ordinary skill in the art.

 When used herein, the term “effective amount” refers to the amount or dose of a compound provided herein, or a pharmaceutically acceptable salt thereof, which, upon
15 single or multiple dose administration to the patient, provides the desired effect in the patient under diagnosis or treatment. An effective amount can be determined by a person of skill in the art using known techniques and by observing results obtained under analogous circumstances. In determining the effective amount for a subject, a number of factors are considered, including, but not limited to: the species of mammal; its size, age,
20 and general health; the specific disease or disorder involved; the degree of or involvement or the severity of the disease or disorder; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.

25 When used herein, the term “subject in need thereof” refers to a mammal, preferably a human, with a disease or condition requiring treatment or therapy, including for example those listed in the preceding paragraphs. As used herein “EDTA” means ethylenediaminetetraacetic acid. As used herein “DMSO” means dimethyl sulfoxide. As used herein “CPM” means counts per minute. As used herein “IBMX” means 3-isobutyl-
30 1-methylxanthine. As used herein “LC/MS” means liquid chromatography/mass spectrometry. As used herein “HTRF” means homogeneous time-resolved fluorescence. As used herein “BSA” mean bovine serum albumin.


The invention is further illustrated by the following examples, which are not to be construed as limiting.

PEPTIDE SYNTHESIS

Example 1

Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₂-CO₂H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₂-CO₂H)SSGAPPS-NH₂ (SEQ ID NO:11).

The structure of SEQ ID NO:11 is depicted below using the standard single letter amino acid codes with the exception of residues Aib2, α MeF(2F)6, 4Pal10, α MeL13, Orn16, K17, Aib20, D-Glu24, α MeY25, K31 and Ser39, where the structures of these amino acid residues have been expanded:



The peptide backbone of Example 1 is synthesized using Fluorenylmethyloxycarbonyl (Fmoc)/tert-Butyl (t-Bu) chemistry on a Symphony multiplex peptide synthesizer (Gyros Protein Technologies, Tucson, AZ).

The resin consists of 1% DVB cross-linked polystyrene (Fmoc-Rink-MBHA Low Loading resin, 100-200 mesh, EMD Millipore) at a substitution of 0.35 mmol/g. Standard side-chain protecting groups were used. Fmoc-Lys(Mtt)-OH is used for the lysine residues at positions 17 and 31, and Boc-Tyr(tBu)-OH was used for the tyrosine residue at position 1. Fmoc groups are removed prior to each coupling step (2 x 7 minutes) using 20% piperidine in DMF. All standard amino acid couplings are performed for 1 hour,

using an equal molar ratio of Fmoc amino acid (0.3 mM in DMF), diisopropylcarbodiimide (0.9 mM in DCM) and Oxyma (0.9 mM in DMF), at a 9-fold molar excess over the theoretical peptide loading. Exceptions are couplings to C α -methylated amino acids, which are coupled for 3 hours. After completion of the synthesis of the peptide backbone, the resin is thoroughly washed with DCM to remove residual DMF. The Mtt protecting groups on the lysine residues at positions 17 and 31 are selectively removed from the peptide resin using 30% hexafluoroisopropanol (Oakwood Chemicals) in DCM (3 x 1 hour treatments), and the resin is thoroughly washed with DCM and DMF.

Subsequent attachment of the linker moieties is accomplished by stepwise coupling of 2-[2-(2-Fmoc-amino-ethoxy)-ethoxy]-acetic acid (Fmoc-AEEA-OH, ChemPep, Inc.) and Fmoc-glutamic acid α -t-butyl ester (Fmoc-Glu-OtBu, Ark Pharm, Inc.), following the procedures described above for standard coupling and deprotection reactions. After removal of the final Fmoc protecting groups, mono-OtBu-tetradecanedioic acid (WuXi AppTec, Shanghai, China) is coupled overnight using a 4-fold excess of the fatty acid, diisopropylcarbodiimide, and Oxyma (1: 1:1 mol/mol/mol) in 1:1 DCM/DMF. After the synthesis is complete, the peptide-resin is washed with DCM and then thoroughly dried under vacuum.


The dry resin is treated with 10 mL of cleavage cocktail (trifluoroacetic acid: water: triisopropylsilane, 95:2.5:2.5 v/v) for 2 hours at room temperature. The resin is filtered off, washed twice each with 2 mL of neat TFA, and the combined filtrates are treated with 5-fold excess volume of cold diethyl ether (-20°C) to precipitate the crude peptide. The peptide/ether suspension is then centrifuged at 3500 rpm for 2 min to form a solid pellet, the supernatant is decanted, and the solid pellet is triturated with ether two additional times and dried in vacuo. The crude peptide is solubilized in 20 mL of 20% acetonitrile/20%acetic acid/60%water and purified by RP- HPLC on a SymmetryPrep 7 μ m C18 preparative column (19 x 300 mm, Waters) with linear gradients of 100% acetonitrile and 0.1% TFA/water buffer system (35-55% acetonitrile in 60 min). The purity of peptide is assessed using analytical RP-HPLC and pooling criteria is >95%. The main pool purity of Example 1 is found to be 96.0%. Subsequent lyophilization of the

final main product pool yielded the lyophilized peptide TFA salt. The molecular weight is determined by LC-MS (obsd: M+3 =1853.9; calc M+3 =1854.1).

Example 2

5 **Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))SSGAPPPS-NH₂ (SEQ ID NO:12)**

10 The structure of SEQ ID NO:12 is depicted below using the standard single letter amino acid codes with the exception of residues Aib2, α MeF(2F)6, 4Pal10, α MeL13, Orn16, K17, Aib20, D-Glu24, α MeY25, K31 and Ser39, where the structures of these amino acid residues have been expanded:



The compound according to SEQ ID NO:12 is prepared substantially as described by the procedures of Example 1, except 4-(9-carboxy-nonyloxy)benzoic acid *tert*-butyl ester (WuXi AppTec, Shanghai, China) was used in the final coupling step. The molecular weight is determined by LC-MS (obsd: M+3 =1887.1; calc M+3 =1887.4).

20


Example 3

Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(4-(4-iodophenyl)butanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(4-(4-iodophenyl)butanoyl))SSGAPPPS-NH₂ (SEQ ID NO:13)

25

The structure of SEQ ID NO:13 is depicted below using the standard single letter amino acid codes with the exception of residues Aib2, α MeF(2F)6, 4Pal10, α MeL13, Orn16, K17, Aib20, D-Glu24, α MeY25, K31 and Ser39, where the structures of these

5 amino acid residues have been expanded:




The compound according to SEQ ID NO:13 is prepared substantially as described

10 by the procedures of Example 1, except 4-(4-Iodophenyl)butyric acid (WuXi AppTec, Shanghai, China) was used in the final coupling step. The molecular weight is determined by LC-MS (obsd: $M+3 = 1875.1$; calc $M+3 = 1875.2$).

Example 4

15 **Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(4-(4-*tert*-butylphenyl)butanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(4-(4-*tert*-butylphenyl)butanoyl))SSGAPPPS-NH₂ (SEQ ID NO:14)**

20 The structure of SEQ ID NO:14 is depicted below using the standard single letter amino acid codes with the exception of residues Aib2, α MeF(2F)6, 4Pal10, α MeL13, Orn16, K17, Aib20, D-Glu24, α MeY25, K31 and Ser39, where the structures of these amino acid residues have been expanded:




The compound according to SEQ ID NO:14 is prepared substantially as described by the procedures of Example 1, except 4-(4-*tert*-Butylphenyl)butyric acid (WuXi AppTec, Shanghai, China) was used in the final coupling step. The molecular weight is determined by LC-MS (obsd: M+3 =1828.3; calc M+3 =1828.7).

Example 5

Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₀-CH₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₀-CH₃)SSGAPPPS-NH₂ (SEQ ID NO:15).

The structure of SEQ ID NO:15 is depicted below using the standard single letter amino acid codes with the exception of residues Aib2, α MeF(2F)6, 4Pal10, α MeL13, Orn16, K17, Aib20, D-Glu24, α MeY25, K31 and Ser39, where the structures of these amino acid residues have been expanded:



The compound according to SEQ ID NO:15 is prepared substantially as described by the procedures of Example 1, except Lauric acid (Sigma Aldrich) was used in the final coupling step. The molecular weight is determined by LC-MS (obsd: M+3 =1815.1; calc M+3 =1815.4).

5

Examples 6 through Example 211

The compounds according to Examples 6 (SEQ ID NO:16) through Example 494 (SEQ ID NO:504) are prepared substantially as described by the procedures of Example 1.

10

Example	Name	SEQ ID NO	MW (g/mol) Calculated
6	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CO ₂ H)SSGAPPPS-NH ₂	16	5503.09
7	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₄ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₄ -CH ₃)SSGAPPPS-NH ₂	17	5555.33
8	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CH ₃)SSGAPPPS-NH ₂	18	5499.23
9	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	19	5300.97
10	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(10-(4-carboxyphenoxy)decanoyl))SSGAPPPS-NH ₂	20	5401

11	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	21	5268.88
12	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))SSGAPPPS-NH ₂	22	5368.91
13	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₄ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₄ -CH ₃)SSGAPPPS-NH ₂	23	5265.02
14	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)SSGAPPPS-NH ₂	24	5152.81
15	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	25	5527.2
16	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	26	5527.2
17	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	27	5527.2
18	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)PSSGAPPPS-NH ₂	28	5599.26

19	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	29	5656.31
20	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	30	5543.24
21	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₄ -CH ₃)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₄ -CH ₃)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	31	5583.3
22	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₄ -CH ₃)AQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₄ -CH ₃)- α MeY-LIEGGPSSGAPPPS-NH ₂	32	5583.3
23	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₄ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₄ -CH ₃)GGPSSGAPPPS-NH ₂	33	5523.34
24	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₄ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₄ -CH ₃)PSSGAPPPS-NH ₂	34	5595.4
25	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₄ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₄ -CH ₃)-NH ₂	35	5652.45
26	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₄ -CH ₃)GGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₄ -CH ₃)SSGAPPPS-NH ₂	36	5539.38
27	Y-Aib-EGT- α MeF(2F)-TSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	37	5508.15

28	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	38	5543.15
29	Y-Aib-EGT- α MeF(2F)-TSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₄ -CH ₃)SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₄ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	39	5504.29
30	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	40	5849.51
31	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₄ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₄ -CH ₃)SSGAPPPS-NH ₂	41	5845.65
32	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₄ -CH ₃)AQ-Aib-EFI-(D-Glu)K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₄ -CH ₃)LIEGGPSSGAPPPS-NH ₂	42	5475.25
33	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(ϵ K)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(ϵ K)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	43	5557.31
34	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(ϵ K)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(ϵ K)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	44	5815.54
35	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(ϵ K)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(ϵ K)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	45	5525.23
36	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((ϵ K)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((ϵ K)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	46	5525.23

37	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((ϵ K)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((ϵ K)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	47	5815.54
38	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((ϵ K)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((ϵ K)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	48	5234.91
39	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((ϵ K)-(γ -Glu)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((ϵ K)-(γ -Glu)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	49	5493.14
40	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((ϵ K)-(ϵ K)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((ϵ K)-(ϵ K)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	50	5491.26
41	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	51	5559.19
42	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	52	5268.88
43	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	53	5559.19
44	Y-Aib-EGT- α MeF-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	54	5541.2
45	Y-Aib-EGT- α MeF-TSD- α MeF-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	55	5554.24

46	Y-Aib-EGT- α MeF-TSD-4Pal-SI- α MeF-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	56	5575.22
47	Y-Aib-EGT- α MeF-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-E- α MeF-I-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	57	5555.23
48	Y-Aib-EGT- α MeF-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeF-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	58	5525.2
49	Y-Aib-EGT- α MeF(2F)-TSDY-aMeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	59	5588.23
50	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	60	5572.23
51	Y-Aib-EGT- α MeF(2F)-TSD- α MeL-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	61	5538.22
52	Y-Aib-EGT- α MeF(2F)-TSD-aMeV-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	62	5524.19
53	Y-Aib-EGT- α MeF(2F)-TSD-Ac5c-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	63	5522.17
54	Y-Aib-EGT- α MeF(2F)-TSD-Ac6c-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	64	5536.2

55	Y-Aib-EGT- α MeF(2F)-TSD-Bip-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	65	5634.3
56	Y-Aib-EGT- α MeF(2F)-TSD-1Nal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	66	5608.26
57	Y-Aib-EGT- α MeF(2F)-TSD-2Nal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	67	5608.26
58	Y-Aib-EGT- α MeF(2F)-TSD-OMeY-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	68	5588.23
59	Y-Aib-EGT- α MeF(2F)-TSD-hTyr-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	69	5588.23
60	Y-Aib-EGT- α MeF(2F)-TSD-Nle-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	70	5524.19
61	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-E-(2ClPhe)-I-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	71	5593.64
62	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-E-(3ClPhe)-I-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	72	5593.64
63	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-E-(2FPhe)-I-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	73	5577.18

64	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-E-3FPhe-I-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	74	5577.18
65	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-E-3,5FPhe-I-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	75	5595.17
66	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-E-1Nal-I-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	76	5609.25
67	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))AQ-Aib-EFI-(D-Glu)-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))LIEGGPSSGAPPPS-NH ₂	77	5403.02
68	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))AQ-Aib-EFIE-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))LIEGGPSSGAPPPS-NH ₂	78	5403.02
69	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	79	5511.24
70	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	80	5511.24
71	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	81	5543.24
72	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	82	5640.35

73	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	83	5511.24
74	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	84	5543.24
75	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	85	5640.35
76	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	86	5236.88
77	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	87	5817.51
78	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	88	5268.97
79	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	89	5236.88
80	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	90	5817.51
81	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	91	5268.97

82	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-E- α MeF-IK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	92	5541.22
83	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeF-LIEGGPSSGAPPPS-NH ₂	93	5511.2
84	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-E- α MeF-IK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeF-LIEGGPSSGAPPPS-NH ₂	94	5525.22
85	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-E- α MeF-IK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)YLIEGGPSSGAPPPS-NH ₂	95	5527.2
86	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-QAQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	96	5558.21
87	Y-Aib-EGT- α MeF(2F)-TSD- α MeF(2F)-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	97	5590.22
88	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-E- α MeF(2F)-I-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	98	5587.25
89	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	99	5557.22
90	Y-Aib-EGT- α MeF(2F)-TSDVSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	100	5510.16

91	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	101	5508.19
92	Y-Aib-EGT- α MeF(2F)-TSDVSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-E- α MeF-I-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	102	5524.19
93	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-E- α MeF-I-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	103	5522.22
94	Y-Aib-EGT- α MeF(2F)-TSD-Ac5c-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-E- α MeF-I-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	104	5536.2
95	Y-Aib-EGT- α MeF(2F)-TSD-Ac4c-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	105	5508.15
96	Y-Aib-EGT- α MeF(2F)-TSD-4CPhe-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	106	5602.22
97	Y-Aib-EGT- α MeF(2F)-TSD-ChG-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	107	5550.23
98	Y-Aib-EGT- α MeF(2F)-TSD-ChA-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	108	5564.25
99	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-E-2Nal-I-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	109	5609.25

100	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-GI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	110	5529.17
101	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	111	5502.1
102	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	112	5545.17
103	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-GFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	113	5487.13
104	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFIG- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	114	5487.13
105	Y-Aib-EGT- α MeF(2F)-TSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	115	5492.19
106	Y-Aib-EGT- α MeF(2F)-TSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SI- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	116	5492.19
107	Y-Aib-EGT- α MeF(2F)-TSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SI- α MeL-LD-Orn-IAQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	117	5492.19
108	Y-Aib-EGT- α MeF(2F)-TSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SI- α MeL-LD-Orn-IAQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	118	5524.19

109	Y-Aib-EGT- α MeF(2F)-TSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeF-I-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	119	5506.22
110	Y-Aib-EGT- α MeF(2F)-TSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SI- α MeL-LD-Orn-IAQ-Aib-E- α MeF-IK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	120	5506.22
111	Y-Aib-EGT- α MeF(2F)-TSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SI- α MeL-LD-Orn-IAQ-Aib-E- α MeF-I-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	121	5506.22
112	Y-Aib-EGT- α MeF(2F)-TSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SI- α MeL-LD-Orn-IAQ-Aib-E- α MeF-I-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	122	5538.22
113	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	123	5525.22
114	Y-Aib-EGT- α MeF(2F)-TSDVSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	124	5478.16
115	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	125	5476.19
116	Y-Aib-EGT- α MeF(2F)-TSD-Ac5c-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	126	5490.18
117	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-E- α MeF-IK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	127	5539.25

118	Y-Aib-EGT- α MeF(2F)-TSDVSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-E- α MeF-IK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	128	5492.19
119	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-E- α MeF-IK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	129	5490.22
120	Y-Aib-EGT- α MeF(2F)-TSD-Ac5c-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-E- α MeF-IK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	130	5504.2
121	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-E- α MeF-IK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeF-LIEGGPSSGAPPPS-NH ₂	131	5523.25
122	Y-Aib-EGT- α MeF(2F)-TSDVSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-E- α MeF-IK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeF-LIEGGPSSGAPPPS-NH ₂	132	5476.19
123	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-E- α MeF-IK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeF-LIEGGPSSGAPPPS-NH ₂	133	5474.22
124	Y-Aib-EGT- α MeF(2F)-TSD-Ac5c-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-E- α MeF-IK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeF-LIEGGPSSGAPPPS-NH ₂	134	5488.2
125	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(7-(4-carboxyphenoxy)heptanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(7-(4-carboxyphenoxy)heptanoyl)))SSGAPPPS-NH ₂	135	5575.07

126	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(8-(4-carboxyphenoxy)octanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(8-(4-carboxyphenoxy)octanoyl))SSGAPPPS-NH ₂	136	5603.12
127	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	137	5643.27
128	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIEGGPSSGAPPPS-NH ₂	138	5627.23
129	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	139	5627.23
130	Y-Aib-EGT- α MeF(2F)-TSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	140	5432.05
131	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	141	5451.1
132	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))AQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))- α MeY-LIEGGPSSGAPPPS-NH ₂	142	5451.1

133	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))GGPSSGAPPPS-NH ₂	143	5451.1
134	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIEGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))PSSGAPPPS-NH ₂	144	5523.17
135	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))-NH ₂	145	5580.22
136	Y-Aib-EGT- α MeF(2F)-TSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	146	5392.08
137	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	147	5411.12
138	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)- α MeY-LIEGGPSSGAPPPS-NH ₂	148	5411.12
139	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)GGPSSGAPPPS-NH ₂	149	5411.12
140	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)PSSGAPPPS-NH ₂	150	5483.19

141	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)-NH ₂	151	5540.24
142	Y-Aib-EGT- α MeF(2F)-TSD-Bzt-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPS-NH ₂	152	5614.29
143	Y-Aib-EGT- α MeF(2F)-TSD-2FA-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPS-NH ₂	153	5548.17
144	Y-Aib-EGT- α MeF(2F)-TSD-4TAA-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPS-NH ₂	154	5565.22
145	Y-Aib-EGT- α MeF(2F)-TSD-2TA-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPS-NH ₂	155	5564.23
146	Y-Aib-EGT- α MeF(2F)-TSD-3TA-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPS-NH ₂	156	5564.23
147	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-E-Bzt-I-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPS-NH ₂	157	5615.28
148	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-E-ChA-I-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPS-NH ₂	158	5565.24
149	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Orn-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPS-NH ₂	159	5588.24

150	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-Orn-FI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	160	5544.23
151	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LI-Orn-GGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	161	5544.23
152	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEG-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	162	5616.29
153	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSG-Orn-PPPS-NH ₂	163	5602.26
154	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPP-Orn-NH ₂	164	5586.26
155	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSG-Orn-PPP-Orn-NH ₂	165	5629.33
156	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-4Pal-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	166	5622.25
157	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-4Pal-FI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	167	5578.24
158	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFIE- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	168	5559.19

159	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFIE- α MeF-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	169	5543.19
160	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(ϵ K)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(ϵ K)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	170	5525.31
161	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K(ϵ K-gE-C14_OH)AQ-Aib-EFIK(ϵ K-gE-C14_OH)- α MeY-LIEGGPSSGAPPPS-NH ₂	171	5202.91
162	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((ϵ K)-(ϵ K)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFIK((ϵ K)-(ϵ K)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	172	5459.26
163	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(ϵ K)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(ϵ K)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	173	5506.31
164	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((ϵ K)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((ϵ K)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	174	5183.91
165	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((ϵ K)-(ϵ K)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((ϵ K)-(ϵ K)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	175	5440.25
166	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(ϵ K)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(ϵ K)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	176	5474.31
167	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((ϵ K)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFIK((ϵ K)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	177	5151.91
168	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((ϵ K)-(ϵ K)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFIK((ϵ K)-(ϵ K)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	178	5408.25

169	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ- α MeF-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	179	5635.29
170	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Ac5c-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	180	5585.23
171	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Ac6c-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	181	5599.26
172	Y-Aib-EGT- α MeF-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)SSGAPPPS-NH ₂	182	5425.13
173	Y-Aib-EGT- α MeF-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-E- α MeF-I-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)SSGAPPPS-NH ₂	183	5439.16
174	Y-Aib-EGT- α MeF-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-E- α MeF-I-(D-Glu)- α MeF-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)SSGAPPPS-NH ₂	184	5423.16
175	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)SSGAPPPS-NH ₂	185	5392.12
176	Y-Aib-EGT- α MeF-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)SSGAPPPS-NH ₂	186	5374.13

177	Y-Aib-EGT- α MeF(2F)-TSD-V-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))SSGAPPPS-NH ₂	187	5432.1
178	Y-Aib-EGT- α MeF-TSD-V-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))SSGAPPPS-NH ₂	188	5414.11
179	Y-Aib-EGT- α MeF-TSDVSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	189	5492.17
180	Y-Aib-EGT- α MeF-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	190	5490.2
181	Y-Aib-EGT- α MeF-TSDVSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	191	5460.17
182	Y-Aib-EGT- α MeF-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	192	5458.2
183	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSG-NH ₂	193	5109.69
184	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	194	4878.49

185	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(ϵ K)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(ϵ K)-CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	195	4876.6
186	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((ϵ K)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((ϵ K)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	196	4554.21
187	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((ϵ K)-(ϵ K)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((ϵ K)-(ϵ K)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	197	4810.55
188	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSG-NH ₂	198	5077.69
189	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGG-NH ₂	199	4749.37
190	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEG-Orn-NH ₂	200	4806.47
191	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	201	5253.01
192	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	202	5253.01
193	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	203	5285.01

194	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	204	5382.13
195	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	205	5285.01
196	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	206	5382.13
197	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-EFIK((ϵ K)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGK((ϵ K)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	207	5218.96
198	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-EFIK((ϵ K)-(ϵ K)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGK((ϵ K)-(ϵ K)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	208	5475.3
199	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Dap-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	209	5558.21
200	Y-Aib-EGT- α MeF(2F)-TSDY-Dap-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	210	5573.22
201	Y-Aib-EGT- α MeF(2F)-TSDV-Dap-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFIe- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	211	5509.18
202	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-TIe-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	212	5585.27

203	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))GGPSSGAPPPS-NH ₂	213	5435.15
204	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))GGPSSGAPPPS-NH ₂	214	5435.15
205	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))FI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))-NH ₂	215	5564.26
206	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))GGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))-NH ₂	216	5564.26
207	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	217	5160.79
208	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))GGPSSGAPPPS-NH ₂	218	5160.79
209	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(4-(4-tert-butylphenyl)butanoyl))-NH ₂	219	5289.9

210	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	220	5398.12
211	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Ac5c-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	221	5583.26
212	Y-Aib-EGT- α MeF(2F)-TSDV- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	222	5524.19
213	Y-Aib-EGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)SSGAPPPS-NH ₂	223	5573.22
214	Y-Aib-EGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	224	5541.22
215	Y-Aib-EGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	225	5525.27
216	Y-Aib-EGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	226	5525.27
217	Y-Aib-EGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	227	5525.27
218	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIEGGPSSGAPPPS-NH ₂	228	5509.27

219	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	229	5509.27
220	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	230	5509.27
221	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	231	5398.08
222	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	232	5253.01
223	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	233	5382.13
224	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	234	5817.51
225	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	235	5946.62
226	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	236	5801.55
227	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	237	5801.55

228	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	238	5930.67
229	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	239	5930.67
230	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	240	5540.23
231	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	241	5540.23
232	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	242	5669.35
233	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	243	5524.28
234	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	244	5524.28
235	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	245	5653.39
236	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	246	5640.27

237	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	247	5640.27
238	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))-NH ₂	248	5769.38
239	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	249	5624.31
240	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	250	5624.31
241	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))-NH ₂	251	5753.42
242	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(11-(4-carboxyphenoxy)undecanoyl))FI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(11-(4-carboxyphenoxy)undecanoyl))-NH ₂	252	5766.46
243	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	253	5625.25

244	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	254	5625.25
245	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))-NH ₂	255	5754.37
246	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	256	5609.3
247	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	257	5609.3
248	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))-NH ₂	258	5738.41
249	Y-Aib-EGT- α MeF(2F)-TSD-2Nal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	259	5576.27
250	Y-Aib-EGT- α MeF(2F)-TSD-2Nal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	260	5576.27
251	Y-Aib-EGT- α MeF(2F)-TSD-2Nal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H))-NH ₂	261	5705.38

252	Y-Aib-EGT- α MeF(2F)-TSD-2Nal-SI- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	262	5560.31
253	Y-Aib-EGT- α MeF(2F)-TSD-2Nal-SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	263	5560.31
254	Y-Aib-EGT- α MeF(2F)-TSD-2Nal-SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	264	5689.42
255	Y-Aib-EGT- α MeF(2F)-TSD-2Nal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	265	5318.04
256	Y-Aib-EGT- α MeF(2F)-TSD-2Nal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	266	5318.04
257	Y-Aib-EGT- α MeF(2F)-TSD-2Nal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	267	5302.08
258	Y-Aib-EGT- α MeF(2F)-TSD-2Nal-SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	268	5431.2
259	Y-Aib-EGT- α MeF(2F)-TSD-OMeY-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	269	5556.23
260	Y-Aib-EGT- α MeF(2F)-TSD-OMeY-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	270	5556.23

261	Y-Aib-EGT- α MeF(2F)-TSD-OMeY-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	271	5685.35
262	Y-Aib-EGT- α MeF(2F)-TSD-OMeY-SI- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	272	5540.28
263	Y-Aib-EGT- α MeF(2F)-TSD-OMeY-SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	273	5540.28
264	Y-Aib-EGT- α MeF(2F)-TSD-OMeY-SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	274	5669.39
265	Y-Aib-EGT- α MeF(2F)-TSD-OMeY-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	275	5298.01
266	Y-Aib-EGT- α MeF(2F)-TSD-OMeY-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	276	5298.01
267	Y-Aib-EGT- α MeF(2F)-TSD-OMeY-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	277	5427.12
268	Y-Aib-EGT- α MeF(2F)-TSD-OMeY-SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	278	5411.16
269	Y-Aib-EGT- α MeF(2F)-TSD-Nle-SI- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	279	5476.23

270	Y-Aib-EGT- α MeF(2F)-TSD-hTyr-SI- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	280	5540.28
271	Y-Aib-EGT- α MeF(2F)-TSD-Nle-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	281	5233.96
272	Y-Aib-EGT- α MeF(2F)-TSD-hTyr-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	282	5298.01
273	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))-NH ₂	283	5756.34
274	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	284	5611.27
275	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	285	5611.27
276	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))-NH ₂	286	5740.38
277	Y-Aib-EGT- α MeF(2F)-TSD-OMeY-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	287	5656.26

278	Y-Aib-EGT- α MeF(2F)-TSD-OMeY-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	288	5656.26
279	Y-Aib-EGT- α MeF(2F)-TSD-OMeY-SI- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	289	5640.31
280	Y-Aib-EGT- α MeF(2F)-TSD-OMeY-SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	290	5640.31
281	Y-Aib-EGT- α MeF(2F)-TSD-2Nal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	291	5676.3
282	Y-Aib-EGT- α MeF(2F)-TSD-2Nal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	292	5676.3
283	Y-Aib-EGT- α MeF(2F)-TSD-2Nal-SI- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	293	5660.34
284	Y-Aib-EGT- α MeF(2F)-TSD-2Nal-SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	294	5660.34

285	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(11-(4-carboxyphenoxy)undecanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(11-(4-carboxyphenoxy)undecanoyl))-NH ₂	295	5784.39
286	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(11-(4-carboxyphenoxy)undecanoyl)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(11-(4-carboxyphenoxy)undecanoyl))GGPSSGAPPPS-NH ₂	296	5639.32
287	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(11-(4-carboxyphenoxy)undecanoyl)FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(11-(4-carboxyphenoxy)undecanoyl))GGPSSGAPPPS-NH ₂	297	5639.32
288	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(11-(4-carboxyphenoxy)undecanoyl)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(11-(4-carboxyphenoxy)undecanoyl))-NH ₂	298	5768.44
289	Y-Aib-EGT- α MeF(2F)-TSD-OMeY-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	299	5440.16
290	Y-Aib-EGT- α MeF(2F)-TSD-OMeY-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)GGPSSGAPPPS-NH ₂	300	5440.16
291	Y-Aib-EGT- α MeF(2F)-TSD-OMeY-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)-NH ₂	301	5569.27
292	Y-Aib-EGT- α MeF(2F)-TSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	302	5390.1

293	Y-Aib-EGT- α MeF(2F)-TSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-E- α MeF-I-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	303	5406.1
294	Y-Aib-EGT- α MeF(2F)-TSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGG-NH ₂	304	4614.25
295	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)FI-(D-Glu)- α MeY-LIEGG-NH ₂	305	4633.3
296	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)GG-NH ₂	306	4633.3
297	Y-Aib-EGT- α MeF(2F)-TSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-E- α MeF-I-(D-Glu)- α MeY-LIEGG-NH ₂	307	4628.28
298	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)FI-(D-Glu)- α MeY-LI-Orn-GGPSSGAPPPS-NH ₂	308	5396.15
299	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-Orn-FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)GGPSSGAPPPS-NH ₂	309	5396.15
300	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	310	5424.16
301	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)GGPSSGAPPPS-NH ₂	311	5424.16

302	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)-NH ₂	312	5553.28
303	Y-Aib-EGT- α MeF(2F)-TSDY- α MeS-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	313	5540.28
304	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	314	5460.24
305	Y-Aib-EGT- α MeF(2F)-TSDV- α MeS-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	315	5476.23
306	Y-Aib-EGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	316	5625.3
307	Y-Aib-EGT- α MeF(2F)-TSDY- α MeS-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	317	5640.31
308	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	318	5560.27
309	Y-Aib-EGT- α MeF(2F)-TSDV- α MeS-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	319	5576.27

310	Y-Aib-EGT- α MeF(2F)-TSD-hTyr-SI- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	320	5640.31
311	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(11-(4-carboxyphenoxy)undecanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(11-(4-carboxyphenoxy)undecanoyl))GGPSSGAPPPS-NH ₂	321	5637.35
312	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(11-(4-carboxyphenoxy)undecanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(11-(4-carboxyphenoxy)undecanoyl))GGPSSGAPPPS-NH ₂	322	5652.36
313	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(11-(4-carboxyphenoxy)undecanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(11-(4-carboxyphenoxy)undecanoyl))GGPSSGAPPPS-NH ₂	323	5588.32
314	Y-Aib-EGT- α MeF(2F)-TSD-Nle-SI- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	324	5576.27
315	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-IAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H))GGPSSGAPPPS-NH ₂	325	5494.3
316	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-IAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H))GGPSSGAPPPS-NH ₂	326	5509.31
317	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-IAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H))GGPSSGAPPPS-NH ₂	327	5445.27

318	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	328	5476.19
319	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	329	5576.22
320	Y-Aib-EGT- α MeF(2F)-TSD-hTyr-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	330	5656.26
321	Y-Aib-EGT- α MeF(2F)-TSD-Nle-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	331	5592.22
322	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	332	5409.15
323	Y-Aib-EGT- α MeF(2F)-TSD-hTyr-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	333	5440.16
324	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)-NH ₂	334	5538.26
325	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	335	5476.19

326	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	336	5576.22
327	Y-Aib-EGT- α MeF(2F)-TSD-hTyr-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	337	5656.26
328	Y-Aib-EGT- α MeF(2F)-TSD-Nle-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	338	5592.22
329	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	339	5460.24
330	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	340	5560.27
331	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(11-(4-carboxyphenoxy)undecanoyl)FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(11-(4-carboxyphenoxy)undecanoyl))GGPSSGAPPPS-NH ₂	341	5637.35
332	Y-Aib-EGT- α MeF(2F)-TSD-hTyr-SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	342	5640.31

333	Y-Aib-EGT- α MeF(2F)-TSD-Nle-SI- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	343	5576.27
334	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)GGPSSGAPPPS-NH ₂	344	5409.15
335	Y-Aib-EGT- α MeF(2F)-TSD-hTyr-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)GGPSSGAPPPS-NH ₂	345	5440.16
336	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	346	5234.91
337	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	347	5234.91
338	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	348	5364.02
339	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	349	5218.95
340	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	350	5218.95
341	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	351	5348.07

342	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	352	5799.58
343	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	353	5814.59
344	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	354	5750.55
345	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	355	5899.61
346	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	356	5914.62
347	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	357	5850.58
348	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-Orn-FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	358	5510.25
349	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-Orn-FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	359	5525.27

350	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-Orn-FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	360	5461.22
351	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-Orn-FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	361	5610.29
352	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-Orn-FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	362	5625.3
353	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-Orn-FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	363	5561.25
354	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-IAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	364	5594.33
355	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-IAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	365	5609.34
356	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-IAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	366	5545.3
357	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	367	5525.22

358	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	368	5525.22
359	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	369	5654.34
360	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	370	5334.94
361	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFIe- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	371	5334.94
362	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))-NH ₂	372	5464.05
363	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	373	5814.59
364	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	374	5814.59

365	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	375	5524.28
366	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	376	5249.92
367	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	377	5249.92
368	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	378	5379.03
369	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	379	5233.96
370	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	380	5233.96
371	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	381	5363.08
372	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	382	5349.95

373	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	383	5349.95
374	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))-NH ₂	384	5479.07
375	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	385	5334
376	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	386	5334
377	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))-NH ₂	387	5463.11
378	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	388	5285.91
379	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	389	5285.91

380	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))-NH ₂	390	5705.34
381	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	391	5269.95
382	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	392	5269.95
383	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-IAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))-NH ₂	393	5689.38
384	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	394	5266.99
385	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	395	5282.01
386	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	396	5217.96
387	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	397	5266.99

388	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	398	5282.01
389	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	399	5217.96
390	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-QAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	400	5475.21
391	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	401	5509.27
392	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	402	5367.03
393	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	403	5382.04
394	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	404	5318
395	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	405	5367.03

396	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	406	5382.04
397	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	407	5318
398	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	408	5185.88
399	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	409	5185.88
400	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-IAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	410	5169.92
401	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	411	5524.28
402	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-QAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	412	5639.28
403	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	413	5624.27

404	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K(PEG3-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-K(PEG3-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	414	5351.07
405	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K(PEG4-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-K(PEG4-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	415	5439.17
406	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LI-Orn-GGPSSGAPPPS-NH ₂	416	5510.25
407	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LI-Orn-GGPSSGAPPPS-NH ₂	417	5461.22
408	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LI-Orn-GGPSSGAPPPS-NH ₂	418	5610.29
409	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LI-Orn-GGPSSGAPPPS-NH ₂	419	5625.3
410	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))FI-(D-Glu)- α MeY-LI-Orn-GGPSSGAPPPS-NH ₂	420	5561.25
411	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	421	5524.24
412	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-QAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	422	5539.25

413	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)FI-(D-Glu)- α MeY-LI-Orn-GGPSSGAPPPS-NH ₂	423	5394.18
414	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-Orn-FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)GGPSSGAPPPS-NH ₂	424	5394.18
415	Y-Aib-EGT- α MeF(2F)-TSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-4Pal-FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	425	5409.15
416	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-4Pal-FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)GGPSSGAPPPS-NH ₂	426	5428.2
417	Y-Aib-EGT- α MeF(2F)-TSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-Orn-FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	427	5375.13
418	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-Orn-FI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)-NH ₂	428	5523.3
419	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-TFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)GGPSSGAPPPS-NH ₂	429	5381.14
420	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-4Pal-FI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)-NH ₂	430	5557.31
421	Y-Aib-EGT- α MeF(2F)-TSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	431	5680.42

422	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	432	5699.46
423	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)GGPSSGAPPPS-NH ₂	433	5699.46
424	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)-NH ₂	434	5828.58
425	Y-Aib-EGT- α MeF(2F)-TSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	435	5099.79
426	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	436	5118.84
427	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)GGPSSGAPPPS-NH ₂	437	5118.84
428	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)-NH ₂	438	5247.95
429	Y-Aib-EGT- α MeF(2F)-TSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-E- α MeF-I-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	439	5404.13
430	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)- α MeF-I-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	440	5423.18

431	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-E- α MeF-I-(D-Glu)- α MeY-LIEGGPSSGAPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)-NH ₂	441	5552.29
432	Y-Aib-EGT- α MeF(2F)-TSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-Orn-FI-(D-Glu)- α MeY-LIEGGPSSGAPPS-NH ₂	442	5665.45
433	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)FI-(D-Glu)- α MeY-LI-Orn-GGPSSGAPPS-NH ₂	443	5599.39
434	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-Orn-FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)GGPSSGAPPS-NH ₂	444	5684.5
435	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-Orn-FI-(D-Glu)- α MeY-LIEGGPSSGAPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)-NH ₂	445	5813.61
436	Y-Aib-EGT- α MeF(2F)-TSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-E- α MeF-I-(D-Glu)- α MeY-LIEGGPSSGAPPS-NH ₂	446	5694.44
437	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)- α MeF-I-(D-Glu)- α MeY-LIEGGPSSGAPPS-NH ₂	447	5729.53
438	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-E- α MeF-I-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)GGPSSGAPPS-NH ₂	448	5713.49
439	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-E- α MeF-I-(D-Glu)- α MeY-LIEGGPSSGAPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)-NH ₂	449	5842.6

440	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	450	5609.3
441	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-G- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H))GGPSSGAPPPS-NH ₂	451	5453.16
442	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(11-(4-carboxyphenoxy)undecanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(11-(4-carboxyphenoxy)undecanoyl))GGPSSGAPPPS-NH ₂	452	5637.35
443	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₄ -CO ₂))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₄ -CO ₂))GGPSSGAPPPS-NH ₂	453	5565.38
444	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-4Pal-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H))GGPSSGAPPPS-NH ₂	454	5543.29
445	Y-Aib-EGT- α MeF(2F)-TSDK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)-Aib-I- α MeL-LDGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃))AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGPSSGAPPPS-NH ₂	455	5333.01
446	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-QAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	456	5575.24
447	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	457	5560.27

448	Y-Aib-EGT- α MeF(2F)-TSDV-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	458	5460.24
449	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Ahx-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Ahx-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂)GGPSSGAPPPS-NH ₂	459	5445.27
450	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂)GGPSSGAPPPS-NH ₂	460	5501.38
451	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK(Ahx-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂)- α MeY-LIK(Ahx-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂)GGPSSGAPPPS-NH ₂	461	5445.27
452	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK(Aoc-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂)- α MeY-LIK(Aoc-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂)GGPSSGAPPPS-NH ₂	462	5501.38
453	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Ahx-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Ahx-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	463	5545.3
454	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	464	5601.41
455	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK(Ahx-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK(Ahx-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	465	5545.3

456	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK(Aoc-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK(Aoc-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	466	5601.41
457	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK(PEG4-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK(PEG4-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	467	5423.22
458	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK(PEG3-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK(PEG3-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	468	5335.11
459	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	469	5218.96
460	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	470	5814.55
461	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK(PEG4-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK(PEG4-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	471	5523.25
462	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK(PEG3-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK(PEG3-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	472	5435.15
463	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	473	5318.99
464	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-EFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	474	5914.58

465	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K(((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-CO-(CH ₂) ₁₂ -CO ₂ H)AQ-Aib-EFI-(D-Glu)- α MeY-LIK(((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	475	5259.1
466	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK(PEG6-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK(PEG6-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	476	5599.43
467	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK(PEG5-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK(PEG5-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	477	5511.33
468	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK(PEG6-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK(PEG6-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	478	5699.46
469	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK(PEG5-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK(PEG5-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	479	5611.36
470	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK(((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ --Trx-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK(((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ --Trx-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	480	5787.66
471	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK(((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ --Trx-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK(((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ --Trx-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	481	5887.69
472	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK(((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Trx-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK(((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Trx-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	482	5497.35
473	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK(((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Trx-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK(((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Trx-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	483	5597.38

474	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	484	5767.5
475	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu) ₂ --(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu) ₂ --(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	485	5867.53
476	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	486	5799.58
477	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)--(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)--(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	487	5899.61
478	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-IAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	488	5799.62
479	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	489	5814.59
480	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu) ₂ -CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	490	5782.51
481	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-IAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)--(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₃ -(γ -Glu)--(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	491	5899.65

482	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	492	5767.5
483	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	493	5867.53
484	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	494	5767.5
485	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	495	5867.53
486	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu) ₃ -CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu) ₃ -CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	496	5735.41
487	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu) ₃ -(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu) ₃ -(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	497	5835.44
488	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	498	5524.24

489	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)FI-(D-Glu)- α MeY-LIEGGPSSGAPPPSK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)-NH ₂	499	5653.35
490	Y-Aib-EGT- α MeF(2F)-TSD-Nle-SI- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	500	5474.27
491	Y-Aib-EGT- α MeF(2F)-TSD-hY-SI- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₂ -CO ₂ H)GGPSSGAPPPS-NH ₂	501	5538.31
492	Y-Aib-EGT- α MeF(2F)-TSDY-Aib-I- α MeL-LD-Orn-QAQ-Aib-Orn-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)--C10_4CP)- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)--C10_4CP)GGPSSGAPPPS-NH ₂	502	5624.31
493	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-QAQ-Aib-4Pal-FIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))GGPSSGAPPPS-NH ₂	503	5643.32
494	Y-Aib-EGT- α MeF(2F)-TSD-4Pal-Aib-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)AQ-Aib-GFIe- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₀ -CH ₃)GGPSSGAPPPS-NH ₂	504	5337.09

Binding Assays

Glucagon (referred to as Gcg) is a Reference Standard prepared at Eli Lilly and Company. GLP-1, 7-36-NH₂ (referred to as GLP-1) is obtained from CPC Scientific (Sunnyvale, CA, 97.2% purity, 100 μ M aliquots in 100% DMSO). GIP 1-42 (referred to as GIP) is prepared at Lilly Research Laboratories using peptide synthesis and HPLC chromatography as described above (>80% purity, 100 μ M aliquots in 100% DMSO). [¹²⁵I]-radiolabeled Gcg, GLP-1, or GIP is prepared using [¹²⁵I]-lactoperoxidase and obtained from Perkin Elmer (Boston, MA).

Stably transfected cell lines are prepared by subcloning receptor cDNA into a pcDNA3 expression plasmid and transfected into human embryonic kidney (HEK) 293 (hGcgR and hGLP-1R) or Chinese Hamster Ovary (CHO) (hGIPR) cells followed by selection with Geneticin (hGLP-1R and hGIPR) or hygromycin B (hGcgR).

5 Two methods are used for the preparation of crude cell membranes.

Method 1: Frozen cell pellets are lysed on ice in hypotonic buffer containing 50 mM Tris HCl, pH 7.5, and Roche Complete™ Protease Inhibitors with EDTA. The cell suspension is disrupted using a glass Potter-Elvehjem homogenizer fitted with a Teflon® pestle for 25 strokes. The homogenate is centrifuged at 4°C at 1100 x g for 10 minutes.

10 The supernatant is collected and stored on ice while the pellets are resuspended in homogenization buffer and rehomogenized as described above. The homogenate is centrifuged at 1100 x g for 10 minutes. The second supernatant is combined with the first supernatant and centrifuged at 35000 x g for 1 hour at 4°C. The resulting membrane pellet is resuspended in homogenization buffer containing protease inhibitors at
15 approximately 1 to 3 mg/mL, quick frozen in liquid nitrogen and stored as aliquots in a -80°C freezer until use.

Method 2: Frozen cell pellets are lysed on ice in hypotonic buffer containing 50 mM Tris HCl, pH 7.5, 1 mM MgCl₂, Roche Complete™ EDTA-free Protease Inhibitors and 25 units/ml DNase I (Invitrogen). The cell suspension is disrupted using a glass
20 Potter-Elvehjem homogenizer fitted with a Teflon® pestle for 20 to 25 strokes. The homogenate is centrifuged at 4°C at 1800 x g for 15 minutes. The supernatant is collected and stored on ice while the pellets are resuspended in homogenization buffer (without DNase I) and rehomogenized as described above. The homogenate is centrifuged at 1800 x g for 15 minutes. The second supernatant is combined with the first supernatant
25 and centrifuged an additional time at 1800 x g for 15 minutes. The overall supernatant is then centrifuged at 25000 x g for 30 minutes at 4°C. The resulting membrane pellet is resuspended in homogenization buffer (without DNase I) containing protease inhibitors at approximately 1 to 3 mg/mL and stored as aliquots in a -80°C freezer until use.

Binding Determination Methods

30 The equilibrium binding dissociation constants (K_d) for the various receptor/radioligand interactions are determined from homologous competition binding

analysis instead of saturation binding due to high propanol content in the [^{125} I] stock material. The K_d values determined for the receptor preparations were as follows: hGcgR (3.9 nM), hGLP-1R (1.2 nM) and hGIPR (0.14 nM).

[^{125} I]-Glucagon Binding

5 The human Gcg receptor binding assays are performed using a Scintillation Proximity Assay (SPA) format with wheat germ agglutinin (WGA) beads (Perkin Elmer). The binding buffer contains 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.4, 2.5 mM CaCl_2 , 1 mM MgCl_2 , 0.1% (w/v) bacitracin (Research Products), 0.003% (w/v) Polyoxyethylenesorbitan monolaurate (TWEEN[®]-20), and
10 Roche Complete[™] Protease Inhibitors without EDTA. Peptides and Gcg are thawed and 3-fold serially diluted in 100% DMSO (10 point concentration response curves). Next, 5 μL serially diluted compound or DMSO is transferred into Corning[®] 3632 clear bottom assay plates containing 45 μL assay binding buffer or unlabeled Gcg control (non-specific binding or NSB, at 1 μM final). Then, 50 μL [^{125} I]-Gcg (0.15 nM final), 50 μL human
15 GcgR membranes (1.5 $\mu\text{g}/\text{well}$) and 50 μL of WGA SPA beads (80 to 150 $\mu\text{g}/\text{well}$) are added with a Biotek Multiflo dispenser. Plates are sealed and mixed on a plate shaker (setting 6) for 1 minute and read with a PerkinElmer Trilux MicroBeta[®] scintillation counter after 12 hours of incubation/settling time at room temperature. Final assay concentration ranges for peptides tested in response curves is typically 1150 nM to 0.058
20 nM and for the control Gcg from 1000 nM to 0.05 nM.

[^{125} I]-GLP-1 Binding

 The human GLP-1 receptor binding assay is performed using an SPA format with WGA beads. The binding buffer contains 25 mM HEPES, pH 7.4, 2.5 mM CaCl_2 , 1 mM
25 MgCl_2 , 0.1% (w/v) bacitracin, 0.003% (w/v) TWEEN[®]-20, and Roche Complete[™] Protease Inhibitors without EDTA. Peptides and GLP-1 are thawed and 3-fold serially diluted in 100% DMSO (10 point concentration response curves). Next, 5 μL serially diluted compound or DMSO is transferred into Corning[®] 3632 clear bottom assay plates containing 45 μL assay binding buffer or unlabeled GLP-1 control (non-specific binding
30 or NSB, at 0.25 μM final). Then, 50 μL [^{125} I]-GLP-1 (0.15 nM final), 50 μL human GLP-1R membranes (0.5 $\mu\text{g}/\text{well}$ and 50 μL of WGA SPA beads (100 to 150 $\mu\text{g}/\text{well}$) are added with a Biotek Multiflo dispenser. Plates are sealed and mixed on a plate shaker

(setting 6) for 1 minute and read with a PerkinElmer Trilux MicroBeta[®] scintillation counter after 5 to 12 hours of incubation/settling time at room temperature. Final assay concentration ranges for peptides tested in response curves are typically 1150 nM to 0.058 nM and for the control GLP-1, 250 nM to 0.013 nM.

5

[125I]-GIP Binding

The human GIP receptor binding assay is performed using an SPA format with WGA beads. The binding buffer contains 25 mM HEPES, pH 7.4, 2.5 mM CaCl₂, 1 mM MgCl₂, 0.1% (w/v) bacitracin, 0.003% (w/v) TWEEN[®]-20, and Roche Complete[™] Protease Inhibitors without EDTA. Peptides and GIP are thawed and 3 fold serially diluted in 100% DMSO (10 point concentration response curves). Next, 5 µL serially diluted compound or DMSO is transferred into Corning[®] 3632 clear bottom assay plates containing 45 µL assay binding buffer or unlabeled GIP control (non-specific binding or NSB, at 0.25 µM final). Then, 50 µL [¹²⁵I]-GIP (0.075-0.15 nM final), 50 µL human GIPR membranes (3 µg/well) and 50 µL of WGA SPA beads (100 to 150 µg/well) are added with a Biotek Multiflo dispenser. Plates are sealed and mixed on a plate shaker (setting 6) for 1 minute and read with a PerkinElmer Trilux MicroBeta[®] scintillation counter after 2.5 to 12 hours of incubation/settling time at room temperature. Final assay concentration ranges for peptides tested in response curves is typically 1150 to 0.058 nM or 115 nM to 0.0058 nM and for the control GIP, 250 nM to 0.013 nM.

20

Binding Assay Data Analysis

Raw CPM data for concentration curves of peptides, Gcg, GLP-1, or GIP are converted to percent inhibition by subtracting nonspecific binding (binding in the presence of excess unlabeled Gcg, GLP-1, or GIP, respectively) from the individual CPM values and dividing by the total binding signal, also corrected by subtracting nonspecific binding. Data are analyzed using four-parameter (curve maximum, curve minimum, IC₅₀, Hill slope) nonlinear regression routines (Genedata Screener, version 12.0.4, Genedata AG, Basel, Switzerland). The affinity constant (K_i) is calculated from the absolute IC₅₀ value based upon the equation $K_i = IC_{50}/(1 + D/K_d)$ where D is the concentration of radioligand used in the experiment, IC₅₀ is the concentration causing 50% inhibition of binding and K_d is the equilibrium binding dissociation constant of the radioligand

30

(described above). Values for K_i are reported as the geometric mean, with error expressed as the standard error of the mean (SEM) and n is equal to the number of independent replicates (determined in assays performed on different days). Geometric Means are calculated as follows:

$$5 \quad \text{Geometric Mean} = 10(\text{Arithmetic Mean of Log } K_i \text{ Values})$$

The K_i Ratio (K_i for native control peptide/ K_i for test compound) at each receptor and each species is calculated. The K_i Ratio is a rapid indication of the apparent affinity of a peptide compared to the native control peptide. A K_i Ratio < 1 indicates that the test peptide has a lower affinity (higher K_i value) for the receptor than the native peptide, whereas a K_i Ratio > 1 indicates that the test peptide has a higher affinity (lower K_i value) for the receptor than the native peptide.

n=1/x means that only one value out of the total number of replicates (x) is used to express the mean. SEM is only calculated when n=2 or greater non-qualified results exist. Means are expressed as GeoMetric means with the standard error of the mean (SEM) and the number of replicates (n) indicated in parenthesis.

Table 1. *In vitro* Binding Affinity (K_i) of indicated Examples and comparator molecules for human GLP-1R, GcgR and GIPR.

20 Binding Affinity

	K_i , nM (SEM, n)		
Molecule or Example	hGIPR	hGLP-1R	hGCGR
hGIP(1-42)NH ₂	0.135 (0.00585, 378/380)		
hGLP-1(7-36)NH ₂		0.791 (0.0236, 545)	
hGCCG			3.07 (0.115, 510/511)
1	0.0880 (0.0147, 3)	2.33 (0.341, 3)	>969 (1/3)
2	0.0446	1.04	>958
3	0.0629	0.471	711
4	0.0528 (0.0149, 2)	0.413 (0.0153, 2)	637 (12.3, 2)

5	0.0309 (0.00250, 3)	0.154 (0.0391, 3)	44.8 (53.4, 3)
6	0.145	2.99	>969
7	0.0501 (0.00636, 3)	0.362 (0.101, 3)	1.46 (0.930, 3)
8	0.0240 (0.00569, 3)	0.139 (0.0154, 3)	4.29 (4.32, 3)
9	0.0557 (0.00698, 3)	1.05 (0.0625, 3)	209 (1/3)
10	0.0489 (0.00825, 2)	0.681 (0.0423, 2)	424 (214, 2)
11	0.0508 (0.00450, 2)	1.06 (0.222, 2)	660 (24.3, 2)
12	0.0575 (0.00224, 2)	0.638 (0.249, 2)	213 (27.9, 2)
13	0.0575 (0.0351, 2)	0.691 (0.304, 2)	0.987 (0.0552, 2)
14	0.0360 (0.00828, 2)	0.286 (0.170, 2)	17.6 (0.912, 2)
15	0.0629 (0.00467, 3)	2.11 (0.383, 3)	>966 (1/3)
16	0.0540 (0.0165, 3)	1.40 (0.275, 3)	707 (53.3, 2/3)
17	0.0649 (0.0248, 3)	3.18 (0.127, 3)	>966 (1/3)
18	0.0769 (0.0200, 2)	8.41 (2.71, 2)	>958 (1/2)
19	0.0807 (0.00750, 3)	3.13 (0.185, 3)	>966 (1/3)
20	0.0722 (0.00347, 4)	1.96 (0.319, 4)	139 (27.5, 4)
21	0.0231 (0.00290, 3)	0.246 (0.0413, 3)	0.293 (0.0186, 3)
22	0.0217 (0.00493, 3)	0.301 (0.0914, 3)	0.596 (0.0330, 3)
23	0.0238 (0.00306, 3)	0.251 (0.0187, 3)	1.18 (0.130, 3)
24	0.0361 (0.00975, 3)	0.520 (0.0555, 3)	0.646 (0.0169, 3)
25	0.0293 (0.0105, 3)	0.483 (0.0966, 3)	0.283 (0.0162, 3)
26	0.0863 (0.00997, 3)	0.867 (0.300, 3)	3.82 (0.560, 3)
27	0.378 (0.140, 2)	6.48 (1.80, 2)	>958 (1/2)
28	0.0972 (0.00197, 2)	3.01 (0.442, 2)	>966 (1/2)
29	0.0505	0.412	0.923
30	0.0653 (0.0190, 2)	2.66 (0.303, 2)	>966 (1/2)
31	0.0308	0.315	0.62
33	0.117	1.34	264
34	0.131	2.81	>957
35	0.077	1.38	868
36	0.103	1.47	611
37	0.171	2.22	>957
38	0.0608	0.803	174
39	0.234	1.69	412
40	0.163	1.6	223

41	0.108	2.06	>957
42	0.0759	2.02	458
43	0.092	2.5	>957
44	0.0595	3.08	>966
45	0.0891	6.9	>966
46	0.0683	6.1	>966
47	0.0761	29	217
48	0.0621	3.67	>966
49	0.0573	1.21	196
50	0.0296	0.876	42
51	0.0741	1.64	51.7
52	0.0832	1.16	>966
53	0.085	1.46	274
55	0.252	5.17	299
56	0.152	2.85	137
57	0.297	4.35	114
58	0.208	1.15	1920
59	0.171	0.789	2000
60	0.11	0.872	737
62	0.132	1.59	>4780
64	0.161	1.52	>4780
65	0.121	1.05	4290
66	0.263	1.55	4150
70	0.120 (0.0470, 2)	1.67 (0.736, 4)	151
73	0.0454	3.38	53.9
75	0.107	2.8	206
78	0.0627	0.881 (0.349, 4)	625
91	0.126	1.26 (0.316, 4)	>955
128	0.0314	0.777 (0.202, 4)	>955
137	0.0403	0.250 (0.0518, 4)	8.29
139	0.0415 (0.00520, 2)	0.268 (0.0773, 4)	109
141	0.0291 (0.00776, 2)	0.194 (0.0837, 4)	13.9
212	0.161	1.17 (0.333, 4)	>955
216	0.0491	0.863 (0.505, 4)	328
219	0.114	0.939 (0.627, 4)	135
246	0.0432 (0.00892, 2)	0.557	44.6
292	0.0161 (0.00313, 5)	0.289 (0.0849, 5)	132 (25.5, 5)
293	0.022	0.211	23.1
298	0.0131	0.119	14.3

299	0.0215	0.101	93.3
302	0.0228	0.137	2.84
322	0.0162 (0.00203, 5)	0.234 (0.0542, 5)	2.91 (0.693, 5)
324	0.0163 (0.00117, 5)	0.168 (0.0289, 5)	6.28 (0.938, 5)
334	0.0195 (0.00139, 5)	0.325 (0.0497, 5)	75.5 (12.7, 5)
336	0.0782	1.85	230
337	0.0747	2.17	>957
338	0.091	2.07	>957
360	0.046	0.673	118
361	0.0578	1.22	238
362	0.053	0.765	360
391	0.0279 (0.00204, 4)	0.346 (0.0663, 3)	289 (41.4, 3)
403	0.0375	0.424	134
411	0.0375 (0.00780, 2)	1.33	>957
414	0.0229 (0.000330, 3)	0.194 (0.0265, 3)	33.7 (5.31, 3)
415	0.0152 (0.00797, 2)	0.156 (0.109, 2)	51.8 (18.2, 2)
417	0.0214 (0.00497, 3)	0.167 (0.0783, 3)	58.4 (7.11, 3)
418	0.0174 (0.00276, 2)	0.0684	3.59 (1.87, 2)
419	0.0166	0.265	60.6
421	0.0245 (0.00418, 3)	0.198 (0.0413, 3)	345 (101, 3)
422	0.0218 (0.00310, 3)	0.194 (0.0162, 3)	12.2 (1.63, 3)
423	0.0207 (0.00795, 3)	0.275 (0.0192, 3)	85.9 (10.6, 3)
424	0.0206 (0.00786, 3)	0.219 (0.0306, 3)	16.0 (1.93, 3)
432	0.0134 (0.00295, 2)	0.134 (0.00717, 2)	356 (72.8, 2)
433	0.0175	0.187	28.3
434	0.00965 (0.00495, 2)	0.150 (0.0253, 2)	81.2 (12.2, 2)
435	0.00910 (0.000766, 2)	0.122 (0.00471, 2)	14.4 (1.56, 2)
436	0.0372	0.412	64.9
440	0.0312 (0.00264, 3)	0.373 (0.118, 3)	131 (27.8, 3)
441	0.0539 (0.0323, 2)	0.386 (0.0706, 2)	592 (1/2)
442	0.0507	0.164	130

446	0.0369 (0.00841, 2)	0.382 (0.116, 2)	109 (11.0, 2)
448	0.0314 (0.00845, 2)	0.367 (0.103, 2)	116 (13.5, 2)
449	0.0133	0.201	243
451	0.0239	0.234	258
453	0.013	0.123	71.8
455	0.0143	0.243	60.1
457	0.0419 (0.0217, 2)	0.252 (0.0198, 2)	351 (0.454, 2)
458	0.0232	0.266	170
459	0.023	0.224	108
460	0.0528 (0.0151, 2)	0.433 (0.0173, 2)	>959 (1/2)
461	0.0100 (0.00141, 2)	0.140 (0.0483, 2)	101 (26.9, 2)
462	0.0102	0.125	87.5
463	0.0183	0.143	54.5
464	0.0261 (0.00416, 2)	0.352 (0.0418, 2)	753 (58.6, 2)
465	0.0464	1.29	304
466	0.0199 (0.00474, 2)	0.200 (0.0377, 2)	342 (223, 2)
467	0.0486	0.381	208
468	0.0291	0.0943	269
469	0.0387	0.0847	144
470	0.0346	0.121	945
471	0.0493	0.197	452
472	0.0376	0.254	258
473	0.0319	0.169	162
474	0.0427	0.343	382
475	0.0294	0.189	139
476	0.0351	0.226	605
477	0.0279	0.143	268
478	0.0406	0.407	49.7
479	0.0249	0.246	213
480	0.0368	0.307	88.5
481	0.0266	0.326	20.1
482	0.0277	0.254	273
483	0.0236	0.263	151
484	0.0296	0.268	305
485	0.0548	0.3	121
486	0.046	0.299	115
487	0.0714	0.217	73.3
488	0.064	0.964	>958

489	0.0912	0.947	>957
490	0.0288	0.27	37.8
491	0.0301	0.182	94.4
492	0.0264	0.233	28.6
493	0.0345	0.25	70.1
494	0.0197 (0.00489, 2)	0.188 (0.0462, 2)	135 (26.5, 2)

Functional Activity

Functional hGIP-R, hGLP-1R and hGCGR Assays

- 5 Methods: Functional activity is determined using cAMP formation in HEK-293 clonal cell lines expressing hGIPR, hGLP-1R or hGCGR. hGIPR, hGLP-1R or hGCGR receptor-expressing cells are treated with a control polypeptide or one of Examples 1 to 3 (20 point concentration-response curve in DMSO, 2.75-fold Labcyte Echo direct dilution, 384 well plate Corning Cat# 3570) in DMEM (Gibco Cat# 31053) supplemented with 1X GlutaMAX™ (Gibco Cat# 35050), 0.1% bovine casein (Sigma C4765-10ML), 250 μ M IBMX (3-Isobutyl-1-methylxanthine, Acros Cat# 228420010) and 20 mM HEPES (Gibco Cat# 15630) in a 20 μ L assay volume (final DMSO concentration was 0.5%). Experiments also are performed under identical assay conditions with the addition of 1.0 % fatty acid free, globulin free human serum albumin (Sigma Cat# A3782).
- 15 After a 30-min incubation at 37°C, the resulting increase in intracellular cAMP is quantitatively determined using a CisBio cAMP Dynamic 2 HTRF Assay Kit (62AM4PEJ). Briefly, cAMP levels within the cell are detected by adding the cAMP-d2 conjugate in cell lysis buffer (10 μ L) followed by the antibody anti-cAMP-Eu³⁺-Cryptate, also in cell lysis buffer (10 μ L). The resulting competitive assay is incubated for at least
- 20 60 min at room temperature, and then is detected using a PerkinElmer Envision® instrument with excitation at 320 nm and emission at 665 nm and 620 nm. Envision units (emission at 665nm/620nm*10,000) are inversely proportional to the amount of cAMP present and are converted to nM cAMP per well using a cAMP standard curve. The amount of cAMP generated (nM) in each well is converted to a percent of the maximal response observed with human GIP(1-42)NH₂, hGLP-1(7-36)NH₂ or hGCG. A relative EC₅₀ value and percent top (E_{max}) are derived by non-linear regression analysis using the
- 25 percent maximal response vs. the concentration of peptide added, fitted to a four-parameter logistic equation.

Results: Functional data for hGIP(1-42)NH₂, hGLP-1(7-36)NH₂, hGCG and the Example compounds are provided below in Table 2 (0.1% bovine casein) and Table 3 (0.1% bovine casein, 1.0% human serum albumin).

Table 2: Functional cAMP Potency (EC₅₀) and Efficacy (E_{max}) for Peptides

5

Incubated at 37°C (in the presence of 0.1% bovine casein).

	hGIPR ^a		hGLP-1R ^a		hGCGR ^a	
Example	EC ₅₀ , nM (SEM, n) ^b	E _{max} , % ± SEM ^c	EC ₅₀ , nM (SEM, n) ^b	E _{max} , % ± SEM ^c	EC ₅₀ , nM (SEM, n) ^b	E _{max} , % ± SEM ^c
hGIP(1-42)NH ₂	0.988 (0.0675, 244/246)	100 ± 0.863				
hGLP-1(7-36)NH ₂			0.315 (0.00999, 400)	106 ± 0.687		
hGCG					1.95 (0.0802, 301)	101 (se=1.13, n=301)
1	0.0145 (0.00159, 5)	90.2 ± 2.82	0.925 (0.101, 5)	97.0 ± 4.47	>9950 (n=1/5)	ND
6	0.0477 (0.00717, 3)	101 ± 3.61	2.30 (0.212, 3)	105 ± 1.05	>9950 (n=1/3)	ND
2	0.0154 (0.000643, 5)	93.0 ± 0.813	1.14 (0.0827, 5)	93.1 ± 5.83	>9950 (n=1/5)	ND
3	0.0133 (0.00186, 3)	95.9 ± 2.95	0.223 (0.0583, 3)	107 ± 2.51	>9950 (n=1/3)	ND
4	0.00962 (0.000822, 6)	92.9 ± 0.381	0.137 (0.0117, 6)	99.2 ± 1.24	>9950 (n=1/6)	ND
7	0.00327 (0.000331, 8)	99.5 ± 2.88	0.00676 (0.00104, 8)	95.4 ± 5.03	>9950 (n=1/8)	ND
8	0.00307 (0.000291, 5)	103 ± 3.48	0.0157 (0.00381, 5)	103 ± 2.63	>9950 (n=1/5)	ND
5	0.00585 (0.000683, 6)	99.9 ± 0.649	0.0570 (0.0122, 6)	103 ± 4.79	>9150 (n=1/6)	ND

9	0.0102 (0.000680, 5)	93.6 ± 2.36	0.421 (0.0704, 5)	98.0 ± 4.97	>9950 (n=1/5)	ND
10	0.0106 (0.00115, 4)	97.9 ± 1.99	0.329 (0.0311, 4)	99.1 ± 4.04	>9950 (n=1/4)	ND
11	0.0135 (0.00157, 5)	97.7 ± 2.82	0.511 (0.0355, 5)	102 ± 2.11	>9950 (n=1/5)	ND
12	0.0127 (0.000647, 5)	100.0 ± 3.09	0.423 (0.0365, 5)	105 ± 5.32	>9950 (n=1/5)	ND
13	0.00597 (0.000599, 6)	99.0 ± 1.77	0.0214 (0.00421, 6)	104 ± 4.07	>9950 (n=1/6)	ND
14	0.00802 (0.00123, 6)	95.0 ± 2.32	0.0884 (0.00658, 6)	100 ± 3.78	>9950 (n=1/6)	ND
15	0.0133 (0.00177, 6)	95.9 ± 2.34	0.995 (0.149, 6)	94.3 ± 4.44	>9950 (n=1/6)	ND
16	0.0113 (0.00240, 6)	101 ± 4.45	0.245 (0.0192, 6)	104 ± 1.61	>9950 (n=1/6)	ND
17	0.0129 (0.00209, 5)	97.5 ± 5.04	1.57 (0.314, 5)	106 ± 4.38	>9950 (n=1/5)	ND
18	0.0226 (0.00161, 4)	97.1 ± 3.28	5.06 (0.710, 4)	104 ± 4.11	>9950 (n=1/4)	ND
19	0.0158 (0.00198, 4)	96.6 ± 2.70	1.34 (0.201, 4)	104 ± 1.72	>9950 (n=1/4)	ND
20	0.00985 (0.000468, 3)	98.8 ± 3.19	0.552 (0.0748, 3)	103 ± 3.37	>9950 (n=1/3)	ND
21	0.00347 (0.000301, 4)	102 ± 2.44	0.00655 (0.000594, 4)	106 ± 2.32	>9950 (n=1/4)	ND
22	0.00656 (0.00118, 4)	102 ± 3.06	0.0153 (0.00165, 4)	98.6 ± 2.87	>9950 (n=1/4)	ND
23	0.00299 (0.000153, 4)	101 ± 3.70	0.00722 (0.00106, 4)	102 ± 3.01	>9950 (n=1/4)	ND

24	0.00266 (0.000185, 5)	104 ± 2.75	0.00630 (0.000480, 5)	104 ± 3.48	>9950 (n=1/5)	ND
25	0.00243 (0.000195, 5)	101 ± 4.03	0.00426 (0.000485, 5)	102 ± 5.06	>9950 (n=1/5)	ND
26	0.0218 (0.00198, 5)	99.1 ± 0.793	0.0711 (0.00713, 5)	106 ± 4.85	>9950 (n=1/5)	ND
27	0.116	88.8	2.77	102	>9950	ND
28	0.0554 (0.0177, 3)	95.4 ± 1.58	2.65 (0.180, 3)	99.2 ± 4.11	>9950 (n=1/3)	ND
29	0.00252 (0.000214, 3)	101 ± 3.24	0.00468 (0.000882, 3)	100 ± 6.65	>9950 (n=1/3)	ND
30	0.0175 (0.00401, 3)	99.3 ± 4.47	2.27 (0.367, 3)	97.8 ± 10.7	>9950 (n=1/3)	ND
31	0.00157 (0.000662, 2)	100.0 ± 5.25	0.00342 (0.00136, 2)	91.3 ± 16.1	>9950 (n=1/2)	ND
32	0.002	98.4	0.0063	119	>9950	ND
33	0.00957 (0.00110, 3)	97.6 ± 2.45	0.370 (0.0515, 3)	102 ± 4.78	>9950 (n=1/3)	ND
34	0.0148 (0.00105, 2)	97.4 ± 2.34	1.00 (0.141, 2)	99.6 ± 4.28	>9950 (n=1/2)	ND
35	0.0162 (0.00309, 3)	97.0 ± 2.32	0.612 (0.125, 3)	107 ± 4.76	>9950 (n=1/3)	ND
36	0.0185 (0.00551, 3)	95.4 ± 2.02	0.536 (0.0920, 3)	100 ± 3.79	>9950 (n=1/3)	ND
37	0.0211 (0.0115, 2)	91.2 ± 3.67	0.909 (0.0795, 3)	105 ± 3.13	>9950 (n=1/3)	ND
38	0.0155 (0.00104, 3)	99.7 ± 1.92	0.225 (0.0142, 3)	106 ± 1.38	>9950 (n=1/3)	ND
39	0.0238 (0.00641, 3)	96.5 ± 1.44	0.358 (0.0311, 3)	105 ± 6.57	>9950 (n=1/3)	ND
40	0.0116 (0.00653, 2)	99.7 ± 2.94	0.279 (0.0725, 2)	101 ± 5.30	>9950 (n=1/2)	ND

41	0.0108 (0.000456, 2)	101 ± 3.16	0.691 (0.0736, 2)	102 ± 3.70	>9950 (n=1/2)	ND
42	0.0103 (0.00133, 2)	97.8 ± 7.18	0.429 (0.0612, 2)	104 ± 1.38	>9950 (n=1/2)	ND
43	0.0123 (0.00510, 2)	92.6 ± 5.56	0.821 (0.00670, 2)	106 ± 2.02	>9950 (n=1/2)	ND
44	0.0637 (0.0744, 2)	92.2 ± 6.17	4.77 (0.859, 2)	90.9 ± 10.4	>9950 (n=1/2)	ND
45	0.0517 (0.0654, 2)	91.3 ± 1.04	9.18 (5.30, 2)	85.7 ± 8.37	>9950 (n=1/2)	ND
46	0.0801 (0.0992, 2)	89.5 ± 2.64	3.29 (1.49, 2)	79.2 ± 1.23	>9950 (n=1/2)	ND
47	0.0138 (0.00357, 2)	89.8 ± 1.20	1.94 (4.03, 2)	87.1 ± 14.1	>9950 (n=1/2)	ND
48	0.0182 (0.00262, 2)	91.6 ± 3.38	1.000 (1.43, 2)	87.8 ± 6.25	>9950 (n=1/2)	ND
49	0.0205 (0.00423, 5)	91.0 ± 1.70	0.398 (0.0572, 5)	97.3 ± 5.46	>9950 (n=1/5)	ND
50	0.0168 (0.00162, 4)	94.7 ± 1.77	0.273 (0.0222, 4)	101 ± 6.20	>9950 (n=1/4)	ND
51	0.110 (0.0153, 2)	101 ± 0.990	0.890 (0.0286, 2)	85.7 ± 9.80	>9950 (n=1/2)	ND
52	0.258 (0.00726, 2)	104 ± 1.25	0.384 (0.116, 2)	84.3 ± 6.96	>9950 (n=1/2)	ND
53	0.0841 (0.0165, 4)	99.6 ± 2.21	0.180 (0.0157, 4)	89.9 ± 9.41	>9950 (n=1/4)	ND
54	0.0675	113	0.538	101	>9950	ND
55	0.0207 (0.00345, 4)	97.1 ± 2.16	0.154 (0.0278, 4)	108 ± 1.94	>9950 (n=1/4)	ND
56	0.0138 (0.00215, 4)	90.3 ± 2.57	0.205 (0.0208, 4)	106 ± 4.02	>9950 (n=1/4)	ND
57	0.0135 (0.00176, 3)	91.5 ± 4.94	0.140 (0.0119, 3)	102 ± 2.52	>9950 (n=1/3)	ND

58	0.0158 (0.00284, 3)	89.2 ± 5.96	0.194 (0.0220, 3)	101 ± 5.94	>9950 (n=1/3)	ND
59	0.0240 (0.00529, 3)	89.2 ± 4.62	0.202 (0.0167, 3)	107 ± 4.27	>9950 (n=1/3)	ND
60	0.0126 (0.00263, 3)	94.0 ± 6.07	0.190 (0.0132, 3)	97.2 ± 4.28	>9950 (n=1/3)	ND
61	0.012	88.2	1.35	82.9	>9950	ND
62	0.0211 (0.00397, 3)	96.1 ± 2.64	0.480 (0.0200, 3)	99.4 ± 5.83	>9950 (n=1/3)	ND
63	0.0176	92.7	1.86	90.6	>9950	ND
64	0.0158 (0.00140, 3)	92.9 ± 3.06	0.557 (0.0434, 3)	97.3 ± 4.13	>9950 (n=1/3)	ND
65	0.0139 (0.00208, 3)	95.2 ± 2.93	0.300 (0.0590, 3)	103 ± 0.751	>9950 (n=1/3)	ND
66	0.0168 (0.00351, 3)	93.5 ± 1.39	0.355 (0.0103, 3)	104 ± 1.78	>9950 (n=1/3)	ND
67	0.00795	95	2.63	91.7	>9950	ND
68	0.0105	106	0.668	95.9	>9950	ND
69	0.0265 (0.00500, 3)	99.0 ± 2.43	0.276 (0.00951, 4)	103 ± 1.65	>9950 (n=1/4)	ND
70	0.0182 (0.00101, 4)	89.1 ± 2.30	0.283 (0.0345, 5)	100.0 ± 3.11	>9950 (n=1/5)	ND
71	0.0171 (0.00174, 3)	93.8 ± 3.59	0.246 (0.0242, 4)	106 ± 1.60	>9950 (n=1/4)	ND
72	0.0160 (0.00172, 3)	96.5 ± 3.71	0.245 (0.0271, 4)	103 ± 3.06	>9950 (n=1/4)	ND
73	0.0207 (0.00350, 4)	97.1 ± 2.70	0.437 (0.0687, 4)	99.2 ± 1.69	>9950 (n=1/4)	ND
74	0.0156 (0.00216, 3)	93.3 ± 2.89	0.334 (0.0383, 4)	105 ± 3.28	>9950 (n=1/4)	ND
75	0.0182 (0.00258, 4)	92.3 ± 0.780	0.411 (0.0467, 5)	104 ± 4.00	>9950 (n=1/5)	ND

76	0.0205 (0.00391, 4)	102 ± 3.22	0.527 (0.0914, 4)	93.5 ± 1.85	>9950 (n=1/4)	ND
77	0.0288 (0.00467, 3)	94.8 ± 2.69	3.03 (0.922, 3)	87.0 ± 1.71	>9950 (n=1/3)	ND
78	0.0145 (0.00447, 4)	101 ± 2.27	0.286 (0.0619, 4)	100 ± 2.19	>9950 (n=1/4)	ND
79	0.0130 (0.00567, 2)	101 ± 0.395	0.223 (0.0242, 2)	102 ± 1.09	>9950 (n=1/2)	ND
80	0.0245 (0.00347, 4)	92.4 ± 1.14	0.718 (0.155, 4)	102 ± 4.87	>9950 (n=1/4)	ND
81	0.0114 (0.00273, 2)	98.6 ± 6.19	0.176 (0.0351, 2)	102 ± 3.94	>9950 (n=1/2)	ND
82	0.0206 (0.00375, 2)	81.4 ± 6.09	4.78 (1.32, 2)	103 ± 1.82	>9950 (n=1/2)	ND
83	0.0223 (0.00261, 2)	89.6 ± 7.35	0.451 (0.0979, 2)	103 ± 4.98	>9950 (n=1/2)	ND
84	0.0315	98.5	5.27	94	>9950	ND
85	0.0312	91.7	7.69	95.3	>9950	ND
86	0.0184 (0.00461, 2)	94.2 ± 1.16	0.359 (0.0267, 2)	103 ± 1.21	>9950 (n=1/2)	ND
87	0.029	84.7	1.34	106	>9950	ND
88	0.00884	85.1	6.08	97.1	>9950	ND
89	0.0301 (0.00853, 2)	88.9 ± 3.76	1.03 (0.293, 2)	105 ± 2.00	>9950 (n=1/2)	ND
90	0.0436 (0.0112, 3)	93.0 ± 3.31	0.221 (0.0317, 3)	96.2 ± 1.50	>9950 (n=1/3)	ND
91	0.0739 (0.0337, 3)	92.8 ± 4.69	0.153 (0.0297, 3)	94.0 ± 5.44	>9950 (n=1/3)	ND
92	0.0251 (0.0114, 2)	104 ± 4.05	0.942 (0.0878, 2)	105 ± 2.61	>9950 (n=1/2)	ND
93	0.0448 (0.0197, 2)	99.4 ± 6.93	0.575 (0.0808, 2)	106 ± 1.59	>9950 (n=1/2)	ND
94	0.0132	91	2.1	97.4	>9950	ND
95	0.0748	97.3	0.181	86.9	>9950	ND
96	0.0484	107	6.81	103	>9950	ND

97	0.0276 (0.00391, 3)	97.0 ± 1.53	0.683 (0.124, 3)	96.6 ± 1.60	>9950 (n=1/3)	ND
98	0.0148 (0.00572, 3)	97.7 ± 2.54	0.227 (0.0401, 3)	98.6 ± 4.62	>9950 (n=1/3)	ND
99	0.0235 (0.00111, 2)	93.4 ± 1.02	0.349 (0.114, 3)	99.1 ± 4.31	>9950 (n=1/3)	ND
100			11.4	111	>9950	ND
101	0.0297	92.1	2.94	106	>9950	ND
102			19.1	93.7	>9950	ND
103	0.0305	92.8	2.10 (0.127, 2)	106 ± 0.389	>9950 (n=1/2)	ND
104	0.0361	94.9	0.417 (0.00529, 2)	107 ± 1.35	>9950 (n=1/2)	ND
105	0.0366 (0.00225, 3)	103 ± 4.03	0.520 (0.0485, 3)	105 ± 1.91	>9950 (n=1/3)	ND
106	0.0385 (0.00452, 3)	98.7 ± 3.32	0.296 (0.0390, 3)	103 ± 2.32	>9950 (n=1/3)	ND
107	0.0473	94.3	1.01	93.4	>9950	ND
108	0.0249	85.2	0.701	97.6	>9950	ND
109	0.0236	84.8	0.846	102	>9950	ND
110	0.0417	106	1.43	98.8	>9950	ND
111	0.0202	76.1	2.28	121	>9950	ND
112	0.0229	93.6	2.26	107	>9950	ND
113	0.0331 (0.00385, 3)	97.9 ± 3.21	0.291 (0.0242, 3)	101 ± 0.880	>9950 (n=1/3)	ND
114	0.0613	93.8	0.176	91.7	>9950	ND
115	0.103	105	0.16	91.6	>9950	ND
116	0.137	115	0.197	99.3	>9950	ND
117	0.0352	96.4	5.6	98.2	>9950	ND
118	0.0547	94.7	0.437	103	>9950	ND
119	0.0863	103	0.351	99.4	>9950	ND
120	0.0866	105	1.43	102	>9950	ND
121	0.0271	92.8	8.95	106	>9950	ND
122	0.064	105	0.41	94.3	>9950	ND
123	0.101	94.9	0.508	96.3	>9950	ND
124	0.1	102	1.24	93.3	>9950	ND
125	0.0547	94.4	2.78	103	>9950	ND

126	0.0472	91.8	1.69	101	>9950	ND
127	0.027	99.3	0.762	98.5	>9950	ND
128	0.0232 (0.000862, 3)	98.5 ± 2.47	0.293 (0.0278, 3)	98.4 ± 4.78	>9950 (n=1/3)	ND
129	0.0248	100	1.28	97.9	>9950	ND
130	0.0266 (0.00252, 3)	94.7 ± 4.51	0.204 (0.0158, 3)	100 ± 1.69	>9950 (n=1/3)	ND
131	0.0156 (0.000742, 5)	96.4 ± 1.95	0.190 (0.0152, 6)	101 ± 2.01	>9950 (n=1/6)	ND
132	0.0208 (0.00119, 4)	98.3 ± 1.68	0.182 (0.0131, 4)	102 ± 3.32	>9950 (n=1/4)	ND
133	0.0180 (0.00101, 5)	92.7 ± 2.84	0.258 (0.0246, 6)	101 ± 0.993	>9950 (n=1/5)	ND
134	0.0238 (0.00167, 3)	99.2 ± 3.29	0.577 (0.0669, 3)	106 ± 6.27	>9950 (n=1/3)	ND
135	0.0184 (0.00169, 4)	92.3 ± 2.64	0.271 (0.00688, 5)	98.4 ± 1.80	>9950 (n=1/4)	ND
136	0.00690 (0.000974, 3)	97.4 ± 4.23	0.0918 (0.0102, 3)	107 ± 4.14	>9950 (n=1/3)	ND
137	0.0116 (0.00151, 3)	105 ± 3.73	0.134 (0.0126, 4)	99.0 ± 4.03	>9950 (n=1/4)	ND
138	0.0197 (0.00311, 3)	104 ± 2.12	0.267 (0.0474, 3)	101 ± 2.93	>9950 (n=1/3)	ND
139	0.0108	99.3	0.141	111	>9950	ND
140	0.0121 (0.000610, 3)	98.5 ± 1.71	0.131 (0.00335, 3)	106 ± 5.31	>9950 (n=1/3)	ND
141	0.00723 (0.000819, 3)	98.8 ± 1.09	0.0693 (0.00248, 4)	102 ± 2.84	>9950 (n=1/4)	ND
142	0.0317 (0.00486, 2)	98.6 ± 5.71	0.322 (0.0246, 2)	103 ± 6.70	>9950 (n=1/2)	ND
143	0.022	95	0.512	103	>9950	ND
144	0.0193	90	3.47	97	>9950	ND
145	0.0286	74.8	0.555	95.1	>9950	ND

146	0.0198	76.5	0.688	108	>9950	ND
147	0.0229	98.6	0.338	93.5	>9950	ND
148	0.0209	98.4	1.77	94.5	>9950	ND
149	0.0791 (0.00155, 2)	104 ± 0.229	1.50 (0.0754, 2)	98.3 ± 0.579	>9950 (n=1/2)	ND
150	0.0268 (0.00212, 3)	104 ± 6.96	0.455 (0.0582, 4)	99.8 ± 3.10	>9950 (n=1/4)	ND
151	0.0197 (0.00252, 3)	99.9 ± 4.41	0.546 (0.0892, 4)	102 ± 4.57	>9950 (n=1/4)	ND
152	0.0416 (0.000338, 2)	97.9 ± 3.25	3.91 (0.457, 2)	102 ± 7.89	>9950 (n=1/2)	ND
153	0.0277 (0.00197, 2)	97.8 ± 2.74	1.10 (0.248, 3)	91.8 ± 4.63	>9950 (n=1/3)	ND
154	0.0299 (0.00189, 2)	96.6 ± 3.26	1.69 (0.354, 3)	102 ± 4.07	>9950 (n=1/2)	ND
155	0.0309 (0.00849, 2)	96.6 ± 7.55	0.912 (0.163, 3)	99.0 ± 5.16	>9950 (n=1/2)	ND
156	0.0422	89.9	4.6	110	>9950	ND
157	0.0286 (0.000896, 2)	98.8 ± 1.33	0.940 (0.206, 3)	98.5 ± 4.73	>9950 (n=1/3)	ND
158	0.0204	93.4	0.448	87.2	>9950	ND
159	0.0198	95.3	0.558	89.4	>9950	ND
160	0.0197	101	0.228	93.6	>9950	ND
161	0.0207 (0.00167, 3)	94.6 ± 1.21	0.203 (0.00545, 3)	107 ± 5.29	>9950 (n=1/3)	ND
162	0.022	89.7	0.327	99	>9950	ND
163	0.0427	98.2	0.199	86.3	>9950	ND
164	0.0464 (0.00253, 2)	95.8 ± 5.48	0.236 (0.00998, 2)	93.8 ± 0.298	>9950 (n=1/2)	ND
165	0.0442	96.1	0.291	94.3	>9950	ND
166	0.0774	97	0.192	90.3	>9950	ND
167	0.0534 (0.0163, 2)	99.5 ± 6.17	0.217 (0.00420, 2)	91.4 ± 3.21	>9950 (n=1/2)	ND
168	0.0482	93	0.312	93.3	>9950	ND

169	0.0381	96.1	1.23	100	>9950	ND
170	0.0244	93.9	1.03	104	>9950	ND
171	0.0389	95.3	1.7	99.7	>9950	ND
172	0.0149 (0.000516, 2)	89.9 ± 1.05	0.141 (0.0138, 3)	99.8 ± 2.93	>9950 (n=1/3)	ND
173	0.0155 (0.00731, 2)	87.8 ± 6.22	0.343 (0.0897, 3)	89.9 ± 2.72	>9950 (n=1/3)	ND
174	0.0284	92.2	0.33	98.2	>9950	ND
175	0.0337	100	0.227	91.1	>9950	ND
176	0.0485	89.3	0.298	98.9	>9950	ND
177	0.0433	113	0.178	101	>9950	ND
178	0.11	105	0.22	102	>9950	ND
179	0.15	91	0.461	99	>9950	ND
180	0.224	86.8	0.26	99.5	>9950	ND
181	0.154	94.6	0.182	101	>9950	ND
182	0.368	89	0.185	96.9	>9950	ND
183	0.0326 (0.000430, 2)	93.5 ± 1.46	1.37 (0.273, 2)	93.9 ± 4.99	>9950 (n=1/2)	ND
184	0.0354 (0.00396, 2)	95.2 ± 1.13	1.82 (0.135, 2)	96.8 ± 12.0	>9950 (n=1/2)	ND
185	0.0180 (0.00136, 2)	94.5 ± 0.288	0.419 (0.0758, 2)	95.1 ± 1.74	>9950 (n=1/2)	ND
186	0.0274 (0.00339, 2)	92.7 ± 0.689	0.371 (0.0267, 2)	102 ± 5.53	>9950 (n=1/2)	ND
187	0.0260 (0.00396, 3)	101 ± 2.77	0.386 (0.0467, 3)	102 ± 7.10	>9950 (n=1/3)	ND
188	0.0228 (0.00116, 2)	94.9 ± 1.49	0.332 (0.0557, 2)	96.6 ± 4.28	>9950 (n=1/2)	ND
189	0.0202 (0.00407, 2)	96.6 ± 4.38	0.280 (0.0253, 2)	100 ± 3.68	>9950 (n=1/2)	ND
190	0.0240 (0.00181, 2)	94.5 ± 0.611	0.303 (0.0624, 3)	98.9 ± 4.64	>9950 (n=1/3)	ND
191	0.0601 (0.00698, 2)	90.0 ± 3.29	0.926 (0.0435, 3)	98.6 ± 5.09	>9950 (n=1/3)	ND

192	0.0375 (0.00284, 4)	96.5 ± 4.86	0.518 (0.0340, 5)	100 ± 2.34	>9950 (n=1/5)	ND
193	0.0201 (0.0000166, 2)	97.2 ± 4.63	0.382 (0.0862, 3)	104 ± 3.84	>9950 (n=1/3)	ND
194	0.0233 (0.00272, 2)	93.1 ± 1.05	0.317 (0.0737, 3)	103 ± 2.96	>9950 (n=1/2)	ND
195	0.0219 (0.000744, 2)	88.5 ± 4.32	0.343 (0.0430, 3)	101 ± 5.39	>9950 (n=1/3)	ND
196	0.0232 (0.00120, 4)	96.0 ± 2.10	0.356 (0.0387, 5)	96.8 ± 2.59	>9950 (n=1/5)	ND
197	0.0338 (0.00123, 3)	102 ± 1.85	0.336 (0.0398, 4)	103 ± 3.66	>9950 (n=1/4)	ND
198	0.0269 (0.000614, 3)	94.0 ± 1.17	0.362 (0.0292, 4)	102 ± 2.25	>9950 (n=1/4)	ND
199	0.0587 (0.00741, 2)	96.9 ± 1.48	3.20 (1.31, 2)	96.7 ± 6.69	>9950 (n=1/2)	ND
200	0.0503 (0.00678, 2)	96.3 ± 2.76	0.834 (0.287, 2)	93.7 ± 2.72	>9950 (n=1/2)	ND
201	0.188 (0.0191, 2)	92.2 ± 3.26	0.487 (0.143, 2)	105 ± 4.51	>9950 (n=1/2)	ND
202	0.057	86	0.944	92.2	>9950	ND
203	0.0721	106	0.535	119	>9950	ND
204	0.0304	99.3	0.47	126	>9950	ND
205	0.0264	101	0.287	99.6	>9950	ND
206	0.0204	96.4	0.299	100	>9950	ND
207	0.019	96.2	0.209	95.1	>9950	ND
208	0.018	94.9	0.238	101	>9950	ND
209	0.0133	92.7	0.235	100	>9950	ND
210	0.02	92.1	0.57	102	>9950	ND
211	0.0465	91.6	3.55	93.1	>9950	ND
212	0.0385	100	0.265	94.7	>9950	ND
213	0.0275	92	2.14	94.8	>9950	ND
214	0.0351	93.7	0.618	93.2	>9950	ND
215	0.0437	85	0.44	89.8	>9950	ND
216	0.0287	88.5	0.384	93.6	>9950	ND
217	0.0309	95.5	0.436	88	>9950	ND

218	0.0515	90.2	0.714	92.6	>9950	ND
219	0.0227 (0.00409, 3)	96.7 (2.65, 3)	0.376 (0.0133, 3)	103 (6.04, 3)	>9950 (n=1/3)	ND
220	0.0237	91.6	0.535	87.6	>9950	ND
221	0.0279	81.8	1.83	83	>9950	ND
222	0.0195	98.7	0.518	91.6	>9950	ND
223	0.0252	103	1.43	94	>9950	ND
224	0.0374	109	7.51	88.4	>9950	ND
225	0.0466	105	9.62	92.1	>9950	ND
226	0.0232	101	0.611	101	>9950	ND
227	0.0224	103	1.22	96.1	>9950	ND
228	0.0232	110	1.34	91.1	>9950	ND
229	0.0253	103	2.25	94.3	>9950	ND
230	0.0199 (0.00457, 2)	105 (4.33, 2)	0.726 (0.336, 2)	90.3 (7.27, 2)	>9950 (n=1/2)	ND
231	0.0184 (0.000100, 2)	102 (3.90, 2)	1.22 (0.624, 2)	107 (0.639, 2)	>9950 (n=1/2)	ND
232	0.0192	101	0.565	103	>9950	ND
233	0.0269 (0.00700, 2)	105 (2.26, 2)	0.604 (0.378, 2)	111 (1.51, 2)	>9950 (n=1/2)	ND
234	0.0182	107	0.319	112	>9950	ND
235	0.0168	99.3	0.295	104	>9950	ND
236	0.0154 (0.000744, 2)	104 (0.0421, 2)	0.336 (0.103, 2)	96.5 (2.64, 2)	>9950 (n=1/2)	ND
237	0.0186 (0.00115, 2)	102 (0.313, 2)	0.633 (0.0615, 2)	102 (2.05, 2)	>9950 (n=1/2)	ND
238	0.0214 (0.00134, 2)	104 (0.833, 2)	1.03 (0.378, 2)	107 (1.17, 2)	>9950 (n=1/2)	ND
239	0.0328 (0.00506, 2)	104 (5.23, 2)	0.546 (0.0853, 2)	101 (4.97, 2)	>9950 (n=1/2)	ND
240	0.0237 (0.000808, 2)	99.1 (1.18, 2)	0.508 (0.151, 2)	98.5 (11.5, 2)	>9950 (n=1/2)	ND
241	0.0213 (0.0000794, 2)	105 (0.357, 2)	0.362 (0.0106, 2)	91.0 (16.3, 2)	>9950 (n=1/2)	ND

242	0.0197 (0.00163, 2)	100 (8.54, 2)	0.584 (0.134, 2)	96.3 (3.81, 2)	>9950 (n=1/2)	ND
243	0.0154 (0.00300, 3)	101 (6.26, 3)	0.860 (0.294, 3)	93.2 (4.52, 3)	>9950 (n=1/3)	ND
244	0.0218 (0.00545, 3)	101 (3.95, 3)	2.25 (1.04, 3)	104 (3.83, 3)	>9950 (n=1/3)	ND
245	0.0195 (0.00407, 3)	96.7 (3.74, 3)	1.88 (0.824, 3)	88.9 (8.09, 3)	>9950 (n=1/3)	ND
246	0.0223 (0.00101, 4)	96.9 (2.89, 4)	0.441 (0.0598, 4)	102 (1.52, 4)	>9950 (n=1/4)	ND
247	0.0220 (0.000585, 2)	103 (1.70, 2)	1.00 (0.641, 2)	108 (0.981, 2)	>9950 (n=1/2)	ND
248	0.0176 (0.00189, 2)	99.2 (1.51, 2)	0.537 (0.130, 2)	89.1 (7.08, 2)	>9950 (n=1/2)	ND
249	0.0201	108	0.300 (0.0349, 2)	101 (6.23, 2)	>9950	ND
250	0.021	102	0.414 (0.126, 2)	114 (4.93, 2)	>9950	ND
251	0.0305	107	0.338 (0.0109, 2)	99.0 (7.31, 2)	>9950	ND
252	0.049	109	0.555 (0.102, 2)	115 (4.34, 2)	>9950	ND
253	0.0295 (0.00329, 2)	101 (3.43, 2)	0.430 (0.0422, 2)	113 (3.67, 2)	>9950 (n=1/2)	ND
254	0.0273 (0.000844, 2)	98.2 (5.88, 2)	0.507 (0.101, 2)	103 (4.62, 2)	>9950 (n=1/2)	ND
255	0.0213	103	0.357	103	>9950	ND
256	0.0175	97.7	0.249	95.4	>9950	ND
257	0.148	90.3	2.03	82	>9950	ND
258	0.0473	90.3	0.653	94.9	>9950	ND
259	0.0198	111	0.362 (0.0362, 2)	99.5 (5.41, 2)	>9950	ND
260	0.0239	113	0.547 (0.0453, 2)	108 (2.42, 2)	>9950	ND
261	0.025	105	0.531 (0.00408, 2)	97.9 (1.27, 2)	>9950	ND

262	0.0327	89.8	0.472 (0.00490, 2)	105 (5.10, 2)	>9950	ND
263	0.0214	88.6	0.294 (0.000357, 2)	98.5 (5.68, 2)	>9950	ND
264	0.0208	114	0.413 (0.0548, 2)	113 (1.32, 2)	>9950	ND
265	0.0145 (0.000696, 2)	100 (1.69, 2)	0.262 (0.0581, 2)	99.8 (5.27, 2)	>9950 (n=1/2)	ND
266	0.0136 (0.0000240, 2)	93.2 (8.75, 2)	0.282 (0.0352, 2)	90.5 (17.9, 2)	>9950 (n=1/2)	ND
267	0.0162 (0.000222, 2)	104 (6.11, 2)	0.271 (0.0367, 2)	103 (0.674, 2)	>9950 (n=1/2)	ND
268	0.0265	102	0.613	112	>9950	ND
269	0.0335 (0.00245, 2)	95.3 (4.18, 2)	1.72 (1.17, 2)	96.5 (7.69, 2)	>9950 (n=1/2)	ND
270	0.0567	91.7	0.551	97	>9950	ND
271	0.0186	98.6	0.494	101	>9950	ND
272	0.0264	86	0.388	99.9	>9950	ND
273	0.0166	100	2.08	103	>9950	ND
274	0.0226	103	0.406	114	>9950	ND
275	0.0152	104	0.737	110	>9950	ND
276	0.0134	102	0.49	103	>9950	ND
277	0.0176 (0.000579, 2)	107 (2.27, 2)	0.225 (0.0241, 2)	97.1 (0.819, 2)	>9950 (n=1/2)	ND
278	0.0173 (0.000584, 2)	105 (0.0609, 2)	0.290 (0.0314, 2)	109 (3.42, 2)	>9950 (n=1/2)	ND
279	0.0305	103	0.406	112	>9950	ND
280	0.0229	105	0.346	106	>9950	ND
281	0.0187	110	0.252	100	>9950	ND
282	0.0193	100	0.216	97.1	>9950	ND
283	0.073	107	1.14	108	>9950	ND
284	0.0389	98.3	0.505	110	>9950	ND
285	0.0115	101	1.21	102	>9950	ND
286	0.0344	108	0.678	110	>9950	ND
287	0.0189	93	0.563	97.2	>9950	ND
288	0.0219	110	0.354	103	>9950	ND

289	0.017	111	0.731	96.7	>9950	ND
290	0.0188	103	0.324	101	>9950	ND
291	0.012	99.6	0.207	97.6	>9950	ND
292	0.00620 (0.000221, 5)	101 (2.00, 5)	0.0758 (0.00345, 5)	104 (1.25, 5)	>9950 (n=1/5)	ND
293	0.00915 (0.00192, 3)	102 (0.983, 3)	0.102 (0.00688, 3)	102 (1.78, 3)	>9950 (se=20.5, n=2/3)	ND
294	0.00615	105	0.0665	106	>9950	ND
295	0.0141	104	0.167	109	>9950	ND
296	0.0121	100	0.108	109	>9950	ND
297	0.0112	103	0.125	108	>9950	ND
298	0.0107 (0.00103, 3)	97.4 (2.75, 3)	0.190 (0.0493, 3)	106 (2.35, 3)	>9950 (n=1/3)	ND
299	0.0104 (0.00202, 3)	101 (4.84, 3)	0.126 (0.0217, 3)	103 (3.15, 3)	>9950 (n=1/3)	ND
300	0.0128 (0.000753, 3)	102 (1.14, 3)	0.194 (0.00146, 3)	107 (2.29, 3)	>9950 (n=1/3)	ND
301	0.0128 (0.000550, 2)	97.4 (2.71, 2)	0.175 (0.0218, 2)	99.2 (3.94, 2)	>9950 (n=1/2)	ND
302	0.00916 (0.00192, 2)	100 (2.39, 2)	0.0917 (0.00850, 2)	103 (0.561, 2)	>9950 (n=1/2)	ND
303	0.0178	100	0.389	102	>9950	ND
304	0.047	110	0.474	101	>9950	ND
305	0.0289	105	0.629	92.7	>9950	ND
306	0.0227	102	0.414	105	>9950	ND
307	0.0292	105	0.376	101	>9950	ND
308	0.0551	117	0.689	98	>9950	ND
309	0.0212	107	0.527	104	>9950	ND
310	0.0250 (0.00750, 2)	99.9 (0.909, 2)	0.347 (0.00203, 2)	105 (1.16, 2)	>9950 (n=1/2)	ND
311	0.0243	105	0.791	110	>9950	ND
312	0.00757	105	0.663	104	>9950	ND
313	0.00781	101	1.13	98.6	>9950	ND
314	0.0216	100	0.673	104	>9950	ND
315	0.0245 (0.000567, 2)	108 (2.95, 2)	0.376 (0.0331, 2)	98.9 (6.60, 2)	>9950 (n=1/2)	ND

316	0.0316 (0.00498, 2)	103 (2.75, 2)	0.571 (0.0402, 2)	109 (0.715, 2)	>9950 (n=1/2)	ND
317	0.0587	112	1.34	101	>9950 (n=1/2)	ND
318	0.0402 (0.0122, 3)	106 (5.44, 3)	0.219 (0.00541, 3)	99.9 (2.22, 3)	>9950 (n=1/3)	ND
319	0.0196 (0.00610, 3)	98.1 (2.58, 3)	0.180 (0.00678, 2)	100 (4.36, 2)	>9950 (n=1/3)	ND
320	0.0144 (0.00517, 2)	94.2 (0.879, 2)	0.246 (0.0335, 2)	101 (5.01, 2)	>9950 (n=1/2)	ND
321	0.0107 (0.00388, 2)	108 (0.116, 2)	0.295 (0.0332, 2)	102 (1.81, 2)	>9950 (n=1/2)	ND
322	0.00937 (0.00109, 6)	101 (1.47, 6)	0.144 (0.0108, 6)	100 (1.87, 6)	>9950 (n=1/6)	ND
323	0.00793	101	0.203	92.6	>9950	ND
324	0.00632 (0.000630, 6)	101 (2.01, 6)	0.0647 (0.00427, 6)	97.6 (3.15, 6)	>9950 (n=1/6)	ND
325	0.0485 (0.0145, 3)	104 (1.22, 3)	0.225 (0.0687, 3)	97.8 (1.80, 3)	>9950 (n=1/3)	ND
326	0.0338 (0.0137, 3)	102 (3.35, 3)	0.186 (0.00851, 3)	94.4 (4.49, 3)	>9950 (n=1/3)	ND
327	0.0180 (0.00855, 2)	105 (2.94, 2)	0.211 (0.0578, 2)	105 (1.05, 2)	>9950 (n=1/2)	ND
328	0.00973	106	0.405	99.6	>9950	ND
329	0.015	109	0.353	104	>9950	ND
330	0.0185	112	0.477	103	>9950	ND
331	0.0113	101	0.436	99.6	>9950	ND
332	0.0109	107	0.263	114	>9950	ND
333	0.0062	109	0.388	107	>9950	ND
334	0.00987 (0.00114, 6)	103 (2.09, 6)	0.131 (0.0111, 6)	104 (2.98, 6)	>9950 (n=1/6)	ND
335	0.00871	107	0.175	113	>9950	ND
336	0.0136 (0.00163, 4)	109 (3.29, 4)	0.338 (0.0360, 4)	107 (4.12, 4)	>10100 (n=1/4)	ND

337	0.0151 (0.00142, 4)	103 (4.79, 4)	0.444 (0.0734, 4)	107 (3.72, 4)	>10100 (n=1/4)	ND
338	0.0157 (0.000927, 4)	104 (2.93, 4)	0.468 (0.0280, 4)	109 (4.09, 4)	>10100 (n=1/4)	ND
339	0.0190 (0.00238, 4)	106 (3.70, 4)	0.308 (0.0377, 4)	113 (6.21, 4)	>10100 (n=1/4)	ND
340	0.0206	95.2	0.409	105	>9950	ND
341	0.0127 (0.00156, 2)	91.4 (2.36, 2)	0.329 (0.00763, 2)	99.9 (1.08, 2)	>9950 (n=1/2)	ND
342	0.0105 (0.000707, 4)	106 (4.47, 4)	0.191 (0.0245, 4)	113 (5.23, 4)	>10100 (n=1/4)	ND
343	0.0111	98.8	0.275	104	>9950	ND
344	0.0174	97.9	0.336	100	>9950	ND
345	0.0147 (0.000586, 2)	98.9 (1.25, 2)	0.285 (0.0205, 2)	105 (3.05, 2)	>9950 (n=1/2)	ND
346	0.0194	96.6	0.329	107	>9950	ND
347	0.0259	98	0.356	103	>9950	ND
348	0.0228	95.9	0.805	99.9	>9950	ND
349	0.015	95.9	0.334	99	>9950	ND
350	0.0288	101	0.202	95.9	>9950	ND
351	0.0185	102	0.397	100	>9950	ND
352	0.0106	98.3	0.262	99.5	>9950	ND
353	0.0249	98.2	0.203	98	>9950	ND
354	0.0249	95.4	0.505	99.9	>9950	ND
355	0.0365	101	0.574	105	>9950	ND
356	0.0488	96.2	0.936	101	>9950	ND
357	0.0110 (0.00125, 4)	99.9 (5.05, 4)	0.649 (0.130, 4)	107 (2.67, 4)	>10100 (n=1/4)	ND
358	0.0137 (0.000651, 4)	99.6 (4.03, 4)	0.773 (0.119, 4)	107 (3.82, 4)	>10100 (n=1/4)	ND
359	0.0261 (0.00304, 4)	103 (4.28, 4)	1.18 (0.164, 4)	104 (5.15, 4)	>10100 (n=1/4)	ND
360	0.0121 (0.00106, 2)	106 (1.70, 2)	0.301 (0.0234, 2)	89.8 (0.316, 2)	>9950 (n=1/2)	ND

361	0.0121 (0.00279, 2)	107 (0.508, 2)	0.580 (0.0801, 2)	98.2 (2.23, 2)	>9950 (n=1/2)	ND
362	0.0131 (0.000845, 4)	107 (1.67, 4)	0.340 (0.0419, 4)	109 (2.00, 4)	>10100 (n=1/4)	ND
363	0.0183	111	0.34	108	>9950	ND
364	0.0111	101	0.347	107	>9950	ND
365	0.00809	105	0.362	98.5	>9950	ND
366	0.0162 (0.00214, 2)	108 (3.61, 2)	0.279 (0.0415, 2)	89.6 (8.49, 2)	>9950 (n=1/2)	ND
367	0.019	112	0.366	93.9	>9950	ND
368	0.0271	105	0.411	103	>9950	ND
369	0.037	102	0.555	99.1	>9950	ND
370	0.0282	105	0.402	112	>9950	ND
371	0.0209	102	0.363	112	>9950	ND
372	0.0112	97.3	0.291	108	>9950	ND
373	0.0152	101	0.329	101	>9950	ND
374	0.0135	96.2	0.269	106	>9950	ND
375	0.0566	100	1.11	106	>9950	ND
376	0.0281	99.8	0.539	104	>9950	ND
377	0.0205	92.8	0.356	100	>9950	ND
378	0.0132 (0.00169, 2)	93.5 (2.41, 2)	0.166 (0.00187, 2)	98.9 (2.96, 2)	>9950 (n=1/2)	ND
379	0.0167 (0.00194, 2)	97.5 (1.50, 2)	0.171 (0.0104, 2)	104 (5.78, 2)	>9950 (n=1/2)	ND
380	0.0209 (0.00237, 2)	100 (3.53, 2)	0.176 (0.0372, 2)	96.2 (1.96, 2)	>9950 (n=1/2)	ND
381	0.0784	101	1.1	105	>9950	ND
382	0.0302	97.6	0.619	101	>9950	ND
383	0.0147 (0.00111, 2)	100 (1.51, 2)	0.306 (0.0408, 2)	105 (4.16, 2)	>9950 (n=1/2)	ND
384	0.0124 (0.000559, 2)	94.5 (3.49, 2)	0.308 (0.0612, 2)	98.2 (1.53, 2)	>9950 (n=1/2)	ND
385	0.0154 (0.00229, 2)	95.2 (1.73, 2)	0.189 (0.0226, 2)	100 (4.42, 2)	>9950 (n=1/2)	ND

386	0.0174 (0.00148, 2)	95.7 (4.77, 2)	0.194 (0.00360, 2)	98.9 (5.82, 2)	>9950 (n=1/2)	ND
387	0.0137 (0.0000708, 2)	102 (3.23, 2)	0.320 (0.125, 2)	101 (1.61, 2)	>9950 (n=1/2)	ND
388	0.0103	98.3	0.292	95.4	>9950	ND
389	0.0178 (0.000953, 2)	94.6 (0.800, 2)	0.190 (0.00883, 2)	92.4 (0.872, 2)	>9950 (n=1/2)	ND
390	0.0187 (0.00223, 3)	103 (1.73, 3)	0.209 (0.00349, 3)	97.7 (0.126, 3)	>9950 (n=1/3)	ND
391	0.0101 (0.000893, 4)	101 (2.26, 4)	0.167 (0.0161, 4)	109 (0.750, 4)	>9950 (n=1/4)	ND
392	0.0107	94.4	0.521	97.9	>9950	ND
393	0.0115	94.3	0.372	96.8	>9950	ND
394	0.0179 (0.00421, 2)	97.7 (4.16, 2)	0.223 (0.0106, 2)	101 (2.99, 2)	>9950 (n=1/2)	ND
395	0.0127	93.1	0.377	90.8	>9950	ND
396	0.0113	96.2	0.291	107	>9950	ND
397	0.0293 (0.0179, 2)	94.6 (2.83, 2)	0.166 (0.0101, 2)	95.8 (4.65, 2)	>9950 (n=1/2)	ND
398	0.0166 (0.000570, 2)	97.4 (0.108, 2)	0.215 (0.0107, 2)	101 (5.97, 2)	>9950 (n=1/2)	ND
399	0.0186	98.4	0.259	91.9	>9950	ND
400	0.0821	98.1	0.708	108	>9950	ND
401	0.0112 (0.00138, 3)	98.9 (1.97, 3)	0.235 (0.00554, 3)	104 (7.95, 3)	>9950 (n=1/3)	ND
402	0.0132 (0.00118, 3)	98.9 (2.45, 3)	0.221 (0.0238, 3)	107 (4.31, 3)	>9950 (n=1/3)	ND
403	0.00939 (0.000448, 3)	98.1 (1.21, 3)	0.175 (0.00248, 2)	108 (0.362, 2)	>9950 (n=1/3)	ND
404	0.014	101	0.632	94.3	>9950	ND
405	0.0209	100	1.26	93.3	>9950	ND
406	0.00896 (0.000684, 2)	101 (2.15, 2)	0.351 (0.0303, 2)	98.5 (5.32, 2)	>9950 (n=1/2)	ND

407	0.0114 (0.00120, 3)	99.2 (1.86, 3)	0.156 (0.00731, 3)	100 (2.08, 3)	>9950 (n=1/3)	ND
408	0.00888 (0.000279, 3)	99.7 (1.81, 3)	0.227 (0.0140, 3)	102 (2.46, 3)	>9950 (n=1/3)	ND
409	0.00928 (0.000716, 3)	99.2 (0.111, 3)	0.188 (0.0149, 3)	103 (0.304, 3)	>9950 (n=1/3)	ND
410	0.0118 (0.000492, 2)	99.1 (1.74, 2)	0.251 (0.147, 2)	94.0 (4.37, 2)	>9950 (n=1/2)	ND
411	0.0102 (0.00112, 3)	101 (0.677, 3)	0.167 (0.00866, 3)	110 (5.40, 3)	>9950 (n=1/3)	ND
412	0.0108 (0.00119, 3)	95.4 (0.413, 3)	0.160 (0.00954, 3)	108 (2.23, 3)	>9950 (n=1/3)	ND
413	0.0146 (0.00126, 3)	101 (1.34, 3)	0.234 (0.0297, 3)	96.9 (5.28, 3)	>9950 (n=1/3)	ND
414	0.00961 (0.000457, 4)	98.4 (1.10, 4)	0.119 (0.00178, 4)	103 (1.77, 4)	>9950 (n=1/4)	ND
415	0.00991 (0.000319, 4)	101 (0.864, 4)	0.122 (0.00605, 4)	109 (0.830, 4)	>9950 (n=1/4)	ND
416	0.0214 (0.000620, 3)	99.0 (2.74, 3)	0.332 (0.0140, 3)	104 (1.88, 3)	>9950 (n=1/3)	ND
417	0.00651 (0.000543, 4)	101 (3.45, 4)	0.0675 (0.00545, 4)	109 (2.32, 4)	>9950 (n=1/4)	ND
418	0.00599 (0.000221, 3)	91.0 (4.24, 3)	0.0603 (0.00801, 3)	93.7 (3.72, 3)	>9950 (n=1/3)	ND
419	0.00958 (0.00102, 3)	101 (2.60, 3)	0.132 (0.0105, 3)	113 (4.86, 3)	>9950 (n=1/3)	ND
420	0.00964 (0.000804, 2)	101 (0.422, 2)	0.123 (0.0177, 2)	99.7 (2.76, 2)	>9950 (n=1/2)	ND
421	0.00618 (0.000456, 5)	100 (4.89, 5)	0.0570 (0.00402, 5)	101 (4.19, 5)	>9950 (n=1/5)	ND

422	0.00655 (0.000179, 5)	104 (3.27, 5)	0.0729 (0.00508, 5)	106 (4.97, 5)	>9950 (n=1/5)	ND
423	0.00658 (0.000673, 5)	104 (2.28, 5)	0.0721 (0.00530, 5)	105 (3.34, 5)	>9950 (n=1/5)	ND
424	0.00502 (0.000436, 5)	101 (3.60, 5)	0.0427 (0.00649, 5)	102 (4.22, 5)	>9950 (n=1/5)	ND
425	0.00943 (0.000670, 2)	97.6 (2.09, 2)	0.0965 (0.000509, 2)	108 (1.41, 2)	>9950 (n=1/2)	ND
426	0.0191	93.3	0.206	97.2	>9950 (n=1/2)	ND
427	0.0132 (0.000467, 2)	95.9 (0.131, 2)	0.206 (0.000352, 2)	109 (1.69, 2)	>9950 (n=1/2)	ND
428	0.00797 (0.000657, 2)	95.5 (1.18, 2)	0.102 (0.00942, 2)	106 (2.33, 2)	>9950 (n=1/2)	ND
429	0.00799 (0.000619, 2)	108 (1.47, 2)	0.116 (0.0211, 2)	116 (8.54, 2)	>9950 (n=1/2)	ND
430	0.0175 (0.00305, 2)	107 (3.65, 2)	0.342 (0.0582, 2)	93.1 (9.40, 2)	>9950 (n=1/2)	ND
431	0.00970 (0.000165, 2)	104 (2.51, 2)	0.134 (0.0264, 2)	99.2 (5.72, 2)	>9950 (n=1/2)	ND
432	0.00602 (0.000709, 5)	103 (4.98, 5)	0.0549 (0.00308, 5)	106 (5.75, 5)	>9950 (n=1/5)	ND
433	0.00972 (0.000248, 3)	94.0 (6.04, 3)	0.128 (0.00910, 3)	102 (3.73, 3)	>9950 (n=1/3)	ND
434	0.00704 (0.000555, 5)	98.3 (4.47, 5)	0.0837 (0.00431, 5)	104 (4.56, 5)	>9950 (n=1/5)	ND
435	0.00517 (0.000107, 5)	104 (5.02, 5)	0.0527 (0.00123, 5)	111 (2.21, 5)	>9950 (n=1/5)	ND
436	0.00714 (0.000579, 3)	102 (0.413, 3)	0.102 (0.00751, 3)	98.9 (3.69, 3)	>9950 (n=1/3)	ND
437	0.0146 (0.000707, 2)	94.8 (7.99, 2)	0.249 (0.0290, 2)	89.2 (2.76, 2)	>9950 (n=1/2)	ND

438	0.0157 (0.00257, 2)	98.9 (3.64, 2)	0.471 (0.0582, 2)	88.5 (0.533, 2)	>9950 (n=1/2)	ND
439	0.00799 (0.000558, 3)	96.0 (3.26, 3)	0.110 (0.0145, 3)	95.7 (2.01, 3)	>9950 (n=1/3)	ND
440	0.0104 (0.000447, 6)	102 (1.92, 6)	0.180 (0.0111, 6)	107 (2.68, 6)	>10100 (n=1/6)	ND
441	0.0174 (0.00153, 4)	97.2 (0.594, 4)	0.134 (0.0135, 4)	110 (4.43, 4)	>9950 (n=1/4)	ND
442	0.0129 (0.000387, 3)	101 (1.37, 3)	0.285 (0.0824, 3)	113 (7.08, 3)	>9950 (n=1/3)	ND
443	0.0178 (0.00241, 2)	102 (1.04, 2)	0.294 (0.00644, 2)	114 (3.48, 2)	>9950 (n=1/2)	ND
444	0.0157 (0.00115, 2)	93.6 (7.04, 2)	0.289 (0.00144, 2)	106 (8.34, 2)	>9950 (n=1/2)	ND
445	0.00728 (0.000110, 2)	102 (1.47, 2)	0.0781 (0.00635, 2)	103 (1.23, 2)	>9950 (n=1/2)	ND
446	0.0164 (0.000887, 3)	105 (4.26, 3)	0.162 (0.00890, 3)	103 (5.00, 3)	>9950 (n=1/3)	ND
447	0.0170 (0.00248, 3)	102 (7.41, 3)	0.219 (0.0213, 3)	105 (4.10, 3)	>9950 (n=1/3)	ND
448	0.0164 (0.00151, 3)	105 (3.52, 3)	0.157 (0.0114, 3)	104 (1.69, 3)	>9950 (n=1/3)	ND
449	0.0102 (0.000548, 5)	101 (1.21, 5)	0.160 (0.0159, 5)	112 (2.67, 5)	>9950 (n=1/5)	ND
450	0.0138 (0.000576, 5)	103 (1.18, 5)	0.201 (0.0102, 5)	120 (3.81, 5)	>9950 (n=1/5)	ND
451	0.0113 (0.000589, 5)	101 (2.33, 5)	0.172 (0.00777, 5)	118 (3.25, 5)	>9950 (n=1/5)	ND
452	0.0192 (0.00110, 3)	102 (1.68, 3)	0.259 (0.0104, 3)	117 (1.07, 3)	>9950 (n=1/3)	ND

453	0.0139 (0.00141, 5)	101 (1.94, 5)	0.200 (0.00941, 5)	116 (3.41, 5)	>9950 (n=1/5)	ND
454	0.0202 (0.00176, 4)	101 (1.53, 4)	0.266 (0.00975, 4)	114 (3.68, 4)	>9950 (n=1/4)	ND
455	0.0146 (0.00112, 5)	104 (1.34, 5)	0.219 (0.0123, 5)	117 (2.80, 5)	>9950 (n=1/5)	ND
456	0.0236 (0.00188, 3)	101 (2.59, 3)	0.341 (0.0277, 3)	116 (0.822, 3)	>9950 (n=1/3)	ND
457	0.0106 (0.00217, 4)	106 (3.22, 4)	0.185 (0.0580, 4)	119 (4.53, 4)	>9950 (n=1/4)	ND
458	0.0121 (0.000899, 4)	101 (3.63, 4)	0.179 (0.0147, 4)	111 (4.25, 4)	>9950 (n=1/4)	ND
459	0.0130 (0.00287, 4)	106 (3.71, 4)	0.180 (0.0192, 4)	120 (4.73, 4)	>9950 (n=1/4)	ND
460	0.0108 (0.00140, 4)	102 (2.05, 4)	0.187 (0.0213, 4)	111 (2.78, 4)	>9950 (n=1/4)	ND
461	0.0103 (0.000757, 4)	100 (3.07, 4)	0.173 (0.0146, 4)	108 (0.909, 4)	>10100 (n=1/4)	ND
462	0.0128 (0.00203, 3)	99.3 (3.59, 3)	0.189 (0.00876, 3)	113 (7.43, 3)	>9950 (n=1/3)	ND
463	0.0124 (0.00111, 3)	91.4 (3.32, 3)	0.267 (0.0917, 3)	111 (4.12, 3)	>9950 (n=1/3)	ND
464	0.00955 (0.000825, 4)	99.7 (1.97, 4)	0.161 (0.00664, 4)	114 (4.40, 4)	>10100 (n=1/4)	ND
465	0.0174 (0.00309, 3)	94.9 (2.15, 3)	0.413 (0.0329, 3)	98.6 (1.80, 3)	>9950 (n=1/3)	ND
466	0.00971 (0.000114, 2)	98.8 (0.994, 2)	0.156 (0.00268, 2)	105 (1.96, 2)	>10100 (n=1/2)	ND
467	0.0113 (0.00170, 2)	102 (4.24, 2)	0.131 (0.00641, 2)	110 (3.61, 2)	>10100 (n=1/2)	ND

468	0.00991 (0.000823, 2)	97.1 (2.96, 2)	0.168 (0.00905, 2)	109 (3.35, 2)	>10100 (n=1/2)	ND
469	0.0121 (0.00130, 2)	102 (1.70, 2)	0.161 (0.00141, 2)	111 (1.47, 2)	>9950 (n=1/2)	ND
470	0.0103 (0.00167, 2)	104 (7.15, 2)	0.127 (0.00754, 2)	112 (1.75, 2)	>9950 (n=1/2)	ND
471	0.0107 (0.000902, 2)	101 (5.62, 2)	0.143 (0.0220, 2)	112 (0.242, 2)	>9950 (n=1/2)	ND
472	0.0131 (0.00159, 2)	108 (3.90, 2)	0.154 (0.0130, 2)	118 (0.770, 2)	>9950 (n=1/2)	ND
473	0.0163 (0.00190, 2)	106 (3.37, 2)	0.192 (0.0132, 2)	118 (4.95, 2)	>9950 (n=1/2)	ND
474	0.0106 (0.00162, 2)	107 (1.06, 2)	0.123 (0.0104, 2)	113 (3.38, 2)	>9950 (n=1/2)	ND
475	0.0120 (0.000617, 2)	106 (2.22, 2)	0.143 (0.0302, 2)	116 (1.92, 2)	>9950 (n=1/2)	ND
476	0.00886 (0.00204, 2)	103 (0.456, 2)	0.117 (0.0135, 2)	114 (1.14, 2)	>9950 (n=1/2)	ND
477	0.00861 (0.00132, 2)	102 (1.19, 2)	0.143 (0.0278, 2)	110 (1.47, 2)	>9950 (n=1/2)	ND
478	0.0139	93.9	0.322	109	>9950	ND
479	0.00718	107	0.115	101	>9950	ND
480	0.00955	102	0.124	120	>9950	ND
481	0.0181	97.9	0.279	111	>9950	ND
482	0.0158 (0.00283, 2)	103 (2.04, 2)	0.169 (0.00139, 2)	118 (0.635, 2)	>9950 (n=1/2)	ND
483	0.0138 (0.0000352, 2)	97.4 (1.31, 2)	0.169 (0.0278, 2)	118 (4.57, 2)	>9950 (n=1/2)	ND
484	0.0136 (0.00267, 2)	102 (2.16, 2)	0.170 (0.00710, 2)	118 (0.624, 2)	>9950 (n=1/2)	ND
485	0.0113 (0.000946, 2)	106 (6.69, 2)	0.153 (0.00444, 2)	115 (0.806, 2)	>10100 (n=1/2)	ND

486	0.0143 (0.00116, 2)	94.1 (4.47, 2)	0.166 (0.00560, 2)	108 (0.513, 2)	>9950 (n=1/2)	ND
487	0.0161 (0.00374, 2)	103 (4.77, 2)	0.199 (0.0396, 2)	116 (5.51, 2)	>9950 (n=1/2)	ND
488	0.0115 (0.00121, 5)	104 (2.35, 5)	0.207 (0.0233, 5)	113 (2.17, 5)	>10100 (n=1/5)	ND
489	0.0131 (0.000283, 3)	103 (2.46, 3)	0.257 (0.0330, 3)	112 (5.59, 3)	>10100 (n=1/3)	ND
490	0.0122 (0.00221, 2)	110 (0.557, 2)	0.143 (0.0153, 2)	115 (3.29, 2)	>9950 (n=1/2)	ND
491	0.0148 (0.00265, 2)	100 (2.79, 2)	0.148 (0.00935, 2)	119 (2.42, 2)	>9950 (n=1/2)	ND
492	0.0125 (0.00109, 4)	101 (4.03, 4)	0.143 (0.0174, 4)	117 (2.36, 4)	>9950 (n=1/4)	ND
493	0.0155 (0.000342, 2)	105 (1.97, 2)	0.184 (0.0219, 2)	126 (3.27, 2)	>9950 (n=1/2)	ND
494	0.0123 (0.000792, 4)	101 (2.14, 4)	0.150 (0.00983, 4)	104 (3.60, 4)	>9950 (n=1/4)	ND

ND = Not Determined

^a Expression density is determined using homologous competition binding of [¹²⁵I]GLP-1(7-36)NH₂ at hGLP-1R (112 fmol/mg protein), [¹²⁵I]GCG at hGCGR (98 fmol/mg protein) and [¹²⁵I]GIP(1-42) at hGIPR (124 fmol/mg protein).

5 ^b EC₅₀, nM = the Geometric Mean, followed by the Standard Error of the Mean and the number of observations in parenthesis.

^c E_{max}, % = the Arithmetic Mean ± the Standard Error of the Mean for the percent of maximal response to GLP-1(7-36)NH₂ at hGLP-1R, GCG at hGCGR or GIP(1-42)NH₂ at hGIPR.

All values shown are to three (3) significant digits.

Table 3: Functional cAMP Potency (EC₅₀) and Efficacy (E_{max}) for Peptides

Incubated at 37°C (in the presence of 0.1% bovine casein and 1.0% human serum albumin).

	hGIPR ^a		hGLP-1R ^a		hGCGR ^a	
Example	EC ₅₀ , nM (SEM, n) ^b	E _{max} , % ± SEM ^c	EC ₅₀ , nM (SEM, n) ^b	E _{max} , % ± SEM ^c	EC ₅₀ , nM (SEM, n) ^b	E _{max} , % ± SEM ^c

hGIP(1-42)NH ₂	0.597 (0.0522, 132)	98.0 ± 1.16				
hGLP-1(7-36)NH ₂			0.340 (0.0195, 133)	105 ± 1.39		
hGCG					2.37 (0.153, 135)	102 (se=1.49, n=135)
1	0.696 (0.0329, 3)	87.5 ± 3.24	30.7 (3.51, 3)	94.3 ± 4.39	>9950 (n=1/3)	ND
6	0.0823 (0.00389, 3)	89.4 ± 1.74	4.19 (0.479, 3)	99.2 ± 5.54	>9950 (n=1/3)	ND
2	0.659 (0.150, 2)	87.8 ± 5.11	32.1 (0.134, 2)	105 ± 3.87	>9950 (n=1/2)	ND
3	0.0971	80	1.05	107	>9950	ND
4	0.0296 (0.00275, 4)	88.3 ± 2.17	0.584 (0.0543, 4)	98.2 ± 1.60	>9950 (n=1/4)	ND
7	0.566 (0.0700, 5)	94.1 ± 2.10	2.74 (0.284, 5)	105 ± 2.62	>9950 (n=1/5)	ND
8	0.635 (0.120, 3)	91.3 ± 3.11	8.00 (1.46, 3)	106 ± 3.25	>9950 (n=1/3)	ND
5	0.372 (0.0352, 5)	91.2 ± 3.65	4.78 (0.559, 5)	103 ± 4.77	>9950 (n=1/5)	ND
9	0.211 (0.0411, 3)	91.6 ± 4.63	8.82 (1.34, 3)	105 ± 3.71	>9950 (n=1/3)	ND
10	0.121 (0.0130, 4)	84.9 ± 1.84	4.38 (0.399, 4)	99.8 ± 1.37	>9950 (n=1/4)	ND
11	1.22 (0.0617, 4)	90.0 ± 2.71	34.5 (1.60, 4)	102 ± 0.940	>9950 (n=1/4)	ND
12	0.745 (0.0971, 4)	93.0 ± 2.25	20.3 (2.83, 4)	103 ± 5.98	>9950 (n=1/4)	ND
13	1.45 (0.180, 4)	95.1 ± 3.55	6.79 (0.450, 4)	95.9 ± 1.76	>9950 (n=1/4)	ND
14	0.769 (0.0465, 4)	89.5 ± 1.02	9.19 (0.283, 4)	101 ± 2.00	>9950 (n=1/4)	ND
15	0.573 (0.0563, 4)	94.4 ± 1.01	24.8 (0.964, 4)	93.2 ± 3.68	>9950 (n=1/4)	ND
16	0.625 (0.0549, 4)	91.5 ± 1.01	9.06 (0.814, 4)	98.3 ± 0.735	>9950 (n=1/4)	ND
17	0.605 (0.0691, 3)	88.9 ± 2.36	48.9 (6.33, 3)	99.3 ± 0.621	>9950 (n=1/3)	ND
18	1.12 (0.150, 3)	86.9 ± 3.59	164 (42.5, 3)	103 ± 5.83	>9950 (n=1/3)	ND

19	0.438 (0.0168, 3)	89.7 ± 2.13	24.4 (3.41, 3)	102 ± 2.33	>9950 (n=1/3)	ND
20	1.66 (0.433, 2)	90.6 ± 0.878	62.4 (20.7, 2)	101 ± 4.72	>9950 (n=1/2)	ND
21	0.302 (0.0443, 3)	94.2 ± 3.12	0.806 (0.119, 3)	107 ± 4.52	>9950 (n=1/3)	ND
22	0.533 (0.0909, 3)	93.4 ± 0.775	1.50 (0.0680, 3)	101 ± 1.14	>9950 (n=1/3)	ND
23	0.623 (0.0883, 3)	95.3 ± 0.863	1.98 (0.220, 3)	106 ± 1.77	>9950 (n=1/3)	ND
24	0.444 (0.0309, 3)	92.4 ± 5.97	2.04 (0.143, 3)	103 ± 5.84	>9950 (n=1/3)	ND
25	0.274 (0.0482, 3)	94.3 ± 1.73	1.11 (0.0768, 3)	103 ± 1.65	>9950 (n=1/3)	ND
26	1.20 (0.0936, 3)	95.4 ± 2.54	3.93 (0.133, 3)	105 ± 3.59	>9950 (n=1/3)	ND
27	6.78 (1.82, 2)	82.8 ± 1.14	70.2 (2.19, 2)	110 ± 3.03	>9950 (n=1/2)	ND
28	2.08 (0.820, 2)	93.0 ± 7.02	60.4 (15.0, 2)	101 ± 2.12	>9950 (n=1/2)	ND
29	0.472 (0.0549, 2)	96.9 ± 5.32	0.876 (0.104, 2)	107 ± 2.92	>9950 (n=1/2)	ND
30	0.337 (0.252, 2)	91.8 ± 0.797	18.3 (3.71, 2)	96.5 ± 0.219	>9950 (n=1/2)	ND
31	0.147	88.9	0.545 (0.128, 2)	109 ± 7.91	>9950 (n=1/2)	ND
32	0.148	98.2	1.73	102	>9950	ND
33	0.0941 (0.0207, 2)	92.0 ± 1.02	4.35 (0.0139, 2)	109 ± 0.0920	>9950 (n=1/2)	ND
34	0.213 (0.0165, 2)	89.1 ± 2.00	19.8 (3.06, 2)	107 ± 1.76	>9950 (n=1/2)	ND
35	0.350 (0.00250, 2)	91.7 ± 1.28	16.4 (2.30, 2)	109 ± 0.873	>9950 (n=1/2)	ND
36	0.408 (0.0282, 2)	91.4 ± 0.667	10.9 (1.38, 2)	101 ± 0.511	>9950 (n=1/2)	ND
37	0.306 (0.0256, 2)	88.5 ± 0.188	17.0 (2.86, 2)	99.9 ± 4.41	>9950 (n=1/2)	ND
38	0.539 (0.0934, 2)	88.8 ± 0.590	12.5 (1.43, 2)	115 ± 2.53	>9950 (n=1/2)	ND
39	0.342 (0.00832, 2)	86.8 ± 3.27	7.98 (1.61, 2)	111 ± 1.02	>9950 (n=1/2)	ND
40	0.301 (0.00465, 2)	92.2 ± 6.05	6.69 (2.15, 2)	103 ± 2.62	>9950 (n=1/2)	ND

41	0.405 (0.0540, 2)	88.5 ± 0.638	27.2 (1.30, 2)	104 ± 3.41	>9950 (n=1/2)	ND
42	1.000 (0.00288, 2)	91.1 ± 0.670	26.7 (4.92, 2)	105 ± 10.9	>9950 (n=1/2)	ND
43	0.375	100	35.6	98.7	>9950	ND
44	1.68	87	125	94.5	>9950	ND
45	13.7	72.5	387	109	>9950	ND
46	12.8	73.3	261	117	>9950	ND
47	0.777	85.6	1670	134	>9950	ND
48	2.12	90.8	118	111	>9950	ND
49	1.51 (0.110, 3)	92.4 ± 4.07	20.1 (2.77, 3)	104 ± 0.273	>9950 (n=1/3)	ND
50	1.81 (0.416, 3)	91.4 ± 4.20	27.8 (3.38, 3)	106 ± 0.713	>9950 (n=1/3)	ND
51	15.8	90.7	100	92.9	>9950	ND
52	18.6	87.6	37.8	101	>9950	ND
53	3.53 (1.25, 3)	91.7 ± 1.16	13.2 (2.18, 3)	89.3 ± 6.12	>9950 (n=1/3)	ND
54	0.865	85.6	20.3	103	>9950	ND
55	6.62 (0.645, 3)	85.7 ± 0.885	70.5 (4.49, 3)	112 ± 0.840	>9950 (n=1/3)	ND
56	6.75 (0.962, 3)	91.4 ± 1.04	123 (8.75, 3)	123 ± 6.57	>9950 (n=1/3)	ND
57	4.55 (0.383, 2)	92.1 ± 5.54	39.3 (0.445, 2)	114 ± 7.39	>9950 (n=1/2)	ND
58	1.12 (0.134, 2)	92.2 ± 7.40	21.6 (2.74, 2)	106 ± 3.99	>9950 (n=1/2)	ND
59	1.52 (0.323, 2)	90.3 ± 3.64	16.2 (2.88, 2)	108 ± 9.04	>9950 (n=1/2)	ND
60	1.20 (0.0303, 2)	89.4 ± 4.57	28.5 (3.31, 2)	111 ± 3.97	>9950 (n=1/2)	ND
61	0.744	92.8	36.9	89.7	>9950	ND
62	1.27 (0.343, 2)	94.3 ± 0.785	34.0 (10.3, 2)	85.8 ± 3.31	>9950 (n=1/2)	ND
63	0.771	101	47.6	98	>9950	ND
64	0.986 (0.230, 2)	90.5 ± 3.44	27.0 (4.48, 2)	87.8 ± 0.301	>9950 (n=1/2)	ND
65	1.05 (0.102, 2)	93.8 ± 6.73	25.5 (5.32, 2)	104 ± 2.15	>9950 (n=1/2)	ND
66	0.787 (0.0298, 2)	90.6 ± 3.37	27.0 (8.48, 2)	93.0 ± 2.36	>9950 (n=1/2)	ND
67	0.0417	91.9	12	104	>9950	ND
68	0.0831	92.4	5.79	102	>9950	ND
69	2.32	86.8	18.9	102	>9950	ND

70	1.73 (0.0380, 2)	89.9 ± 0.987	27.0 (3.69, 2)	106 ± 4.82	>9950 (n=1/2)	ND
71	3.07	99.1	43.7	100	>9950	ND
72	3.55	95.9	40.1	98.8	>9950	ND
73	2.16	80.2	56.2	109	>9950	ND
74	2.19	86.7	59.5	110	>9950	ND
75	2.18 (0.153, 2)	87.8 ± 3.33	41.3 (8.02, 2)	97.0 ± 8.30	>9950 (n=1/2)	ND
76	1.40 (0.683, 2)	89.9 ± 2.11	28.9 (1.46, 2)	100 ± 13.5	>9950 (n=1/2)	ND
78	0.242 (0.0493, 2)	89.7 ± 2.65	4.29 (0.505, 2)	99.2 ± 0.361	>9950 (n=1/2)	ND
79	2.31	95	15.1	109	>9950	ND
81	0.531	97.4	3.47	95	>9950	ND
87	4.84	89.2	80	101	>9950	ND
88	0.591	80.3	209	102	>9950	ND
89	1.49	94.2	27.7	108	>9950	ND
90	3.81	104	23.4	96.6	>9950	ND
91	7.05	91.9	20.4	89.8	>9950	ND
92	2.64	102	76.8	108	>9950	ND
93	5.58	92	66	90.2	>9950	ND
94	2.81	97.1	145	113	>9950	ND
95	4.68	86.9	8.84	84	>9950	ND
97	5.49	93.1	227	103	>9950	ND
98	4.97	95	58.1	97.5	>9950	ND
99	2.49	102	20	81.1	>9950	ND
100	2.61	98.3	402	123	>9950	ND
102	2.36	96.9	367	106	>9950	ND
103	0.515	94.2	35.5	96.9	>9950	ND
104	0.52	95.9	12.3	95.8	>9950	ND
131	0.0581 (0.00374, 2)	90.4 ± 1.62	1.04 (0.0207, 2)	112 ± 1.76	>9950 (n=1/2)	ND
133	0.0695 (0.0139, 2)	89.1 ± 4.64	1.17 (0.0663, 2)	105 ± 5.52	>9950 (n=1/2)	ND
135	0.0609 (0.0105, 2)	91.2 ± 4.78	0.936 (0.160, 2)	101 ± 1.98	>9950 (n=1/2)	ND
137	0.728 (0.0218, 2)	90.3 ± 0.387	5.02 (0.348, 2)	103 ± 3.88	>9950 (n=1/2)	ND
141	0.379 (0.0143, 2)	96.0 ± 7.42	5.78 (1.57, 2)	115 ± 2.04	>9950 (n=1/2)	ND
150	0.350 (0.0449, 2)	81.3 ± 3.18	11.0 (2.84, 2)	100 ± 3.80	>9950 (n=1/2)	ND

151	0.306 (0.0354, 2)	87.5 ± 3.78	17.3 (6.93, 2)	112 ± 8.42	>9950 (n=1/2)	ND
153	1.15 (0.0744, 2)	94.1 ± 3.21	40.8 (6.36, 2)	98.2 ± 5.40	>9950 (n=1/2)	ND
154	1.34 (0.0132, 2)	93.0 ± 4.96	70.5 (3.34, 2)	103 ± 3.93	>9950 (n=1/2)	ND
155	1.25 (0.0855, 2)	96.5 ± 1.04	34.6 (4.78, 2)	102 ± 2.27	>9950 (n=1/2)	ND
157	0.718 (0.0184, 2)	89.6 ± 3.39	36.0 (2.81, 2)	101 ± 4.27	>9950 (n=1/2)	ND
164	3.62	93	26.6	95.4	>9950	ND
172	0.385 (0.0503, 2)	80.1 ± 2.06	7.70 (0.104, 2)	112 ± 10.3	>9950 (n=1/2)	ND
173	1.24 (0.0219, 2)	92.9 ± 6.91	29.7 (4.49, 2)	99.5 ± 1.80	>9950 (n=1/2)	ND
183	1.22	75.5	66.6	97.3	>9950	ND
184	2.46	81.2	119	87.8	>9950	ND
185	0.335	86.2	11.3	103	>9950	ND
186	2.19	85.6	24.3	107	>9950	ND
187	0.939	79.3	18	109	>9950	ND
188	1.37	89	19.1	106	>9950	ND
190	1.55 (0.169, 2)	82.8 ± 3.36	28.9 (0.482, 2)	112 ± 8.50	>9950 (n=1/2)	ND
191	0.866 (0.0257, 2)	86.2 ± 5.50	13.1 (2.25, 2)	105 ± 7.98	>9950 (n=1/2)	ND
192	0.832 (0.0527, 2)	93.6 ± 3.98	11.2 (3.64, 2)	121 ± 2.56	>9950 (n=1/2)	ND
193	1.47 (0.124, 2)	92.2 ± 0.240	24.3 (4.18, 2)	104 ± 8.64	>9950 (n=1/2)	ND
194	1.24 (0.0572, 2)	80.7 ± 7.81	21.2 (4.53, 2)	109 ± 10.5	>9950 (n=1/2)	ND
195	0.771 (0.268, 2)	87.0 ± 12.2	14.0 (3.17, 2)	106 ± 2.61	>9950 (n=1/2)	ND
196	0.712 (0.191, 2)	80.8 ± 0.269	21.4 (1.40, 2)	112 ± 4.62	>9950 (n=1/2)	ND
197	2.06 (0.255, 2)	84.5 ± 4.08	26.2 (3.64, 2)	102 ± 2.64	>9950 (n=1/2)	ND
198	1.06 (0.264, 2)	83.1 ± 3.45	14.5 (3.33, 2)	108 ± 0.518	>9950 (n=1/2)	ND
199	2.45	77.1	70	100	>9950	ND
200	2.7	83.7	26.6	97.4	>9950	ND
201	13.2	80.5	25.1	104	>9950	ND
202	6.09	75.3	62.2	109	>9950	ND
203	0.682	87.2	3.38	105	>9950	ND
204	0.341	83.3	2.44	104	>9950	ND

205	0.261 (0.0684, 2)	72.1 (10.2, 2)	2.18 (0.439, 2)	106 (1.66, 2)	>9950 (n=1/2)	ND
206	0.242 (0.107, 2)	77.6 (6.91, 2)	3.03 (0.792, 2)	98.1 (0.421, 2)	>9950 (n=1/2)	ND
207	0.591 (0.0545, 2)	97.9 (9.30, 2)	2.98 (0.814, 2)	112 (10.5, 2)	>9950 (n=1/2)	ND
208	0.126 (0.0370, 2)	64.1 (0.979, 2)	1.58 (0.664, 2)	105 (8.90, 2)	>9950 (n=1/2)	ND
209	0.173 (0.0236, 2)	90.8 (2.77, 2)	1.16 (0.312, 2)	109 (4.47, 2)	>9950 (n=1/2)	ND
210	0.440 (0.0195, 2)	68.1 (7.17, 2)	8.86 (0.573, 2)	110 (7.68, 2)	>9950 (n=1/2)	ND
211	2.16	64.5	94.2	99	>9950	ND
212	16.6	81	33.7	91	>9950	ND
213	4.38	95.6	40.3	102	>9950	ND
214	2.03	80.4	17.9	108	>9950	ND
215	0.925	91.3	14.8	107	>9950	ND
216	5.31	63.4	32.3	117	>9950	ND
217	7.84	62.7	87.8	118	>9950	ND
218	3.27	95.9	36.6	121	>9950	ND
219	2.86 (1.19, 2)	82.9 (17.7, 2)	25.9 (3.30, 2)	101 (2.32, 2)	>9950 (n=1/2)	ND
220	11.6	83.5	150	110	>9950	ND
221	0.838	67.4	17.9	92.3	>9950	ND
222	2.1	77.9	13.8	117	>9950	ND
223	7.84	79.2	90.5	115	>9950	ND
224	2.92	90.6	71	102	>9950	ND
225	1.81	67.5	51.6	106	>9950	ND
226	4.86	92.1	11.3	118	>9950	ND
227	1.59	76.1	41.8	111	>9950	ND
228	3.37	83.3	42	119	>9950	ND
229	7.35	80.5	135	99	>9950	ND
230	2.57 (0.207, 3)	85.8 (2.02, 3)	49.7 (3.88, 3)	103 (3.29, 3)	>9950 (n=1/3)	ND
231	2.46 (0.528, 2)	85.4 (1.66, 2)	51.8 (5.87, 2)	109 (2.34, 2)	>9950 (n=1/2)	ND
232	1.86	91.5	33.6	95.4	>9950	ND
233	6.08 (0.278, 2)	91.4 (1.15, 2)	56.7 (19.2, 2)	116 (15.0, 2)	>9950 (n=1/2)	ND
234	7.58	84.4	156	102	>9950	ND
235	10.1	92.2	598	152	>9950	ND
236	0.641 (0.0940, 2)	80.5 (3.87, 2)	32.6 (4.16, 2)	125 (2.87, 2)	>9950 (n=1/2)	ND

237	0.889 (0.480, 2)	93.1 (3.84, 2)	38.1 (0.788, 2)	113 (2.42, 2)	>9950 (n=1/2)	ND
238	1.31 (0.644, 2)	90.5 (11.3, 2)	27.2 (1.11, 2)	103 (2.10, 2)	>9950 (n=1/2)	ND
239	5.46 (2.04, 2)	89.1 (0.575, 2)	25.2 (9.76, 2)	109 (1.64, 2)	>9950 (n=1/2)	ND
240	11.7 (0.555, 2)	87.2 (11.8, 2)	150 (5.84, 2)	107 (1.18, 2)	>9950 (n=1/2)	ND
241	8.02 (3.37, 2)	84.9 (9.74, 2)	103 (8.35, 2)	105 (4.79, 2)	>9950 (n=1/2)	ND
242	11.0 (5.42, 2)	83.9 (8.92, 2)	214 (35.7, 2)	102 (0.239, 2)	>9950 (n=1/2)	ND
243	0.728 (0.185, 3)	90.5 (0.658, 3)	34.7 (7.58, 3)	114 (12.1, 3)	>9950 (n=1/3)	ND
244	0.983 (0.411, 3)	89.5 (3.16, 3)	30.8 (6.22, 3)	96.3 (3.54, 3)	>9950 (n=1/3)	ND
245	0.552 (0.0557, 3)	81.9 (4.90, 3)	27.0 (1.02, 3)	93.8 (2.93, 3)	>9950 (n=1/3)	ND
246	1.63 (0.495, 3)	91.0 (3.43, 3)	22.9 (6.17, 3)	108 (9.08, 3)	>9950 (n=1/3)	ND
247	4.24 (0.948, 2)	90.2 (4.32, 2)	77.7 (0.558, 2)	109 (1.12, 2)	>9950 (n=1/2)	ND
248	4.10 (1.68, 2)	91.8 (0.258, 2)	56.7 (2.29, 2)	92.7 (4.61, 2)	>9950 (n=1/2)	ND
249	5.88	88.9	51.6	105	>9950	ND
250	38.8	101	63	105	>9950	ND
251	14.3	71.2	51	104	>9950	ND
252	29.9	87.2	131	115	>9950	ND
253	21.7 (1.79, 3)	78.9 (6.58, 3)	192 (28.9, 3)	114 (7.97, 3)	>9950 (n=1/3)	ND
254	16.8 (1.47, 3)	68.5 (4.32, 3)	211 (49.2, 3)	122 (16.8, 3)	>9950 (n=1/3)	ND
255	2.27	93.4	13.7	106	>9950	ND
256	1.5	75.3	12.6	95.5	>9950	ND
257	5.61	72.2	46.3	102	>9950	ND
258	5.28	84.3	41.5	103	>9950	ND
259	2.34	66.4	28.9	99.2	>9950	ND
260	3.27	83	32	107	>9950	ND
261	2.28	75.7	15.6	104	>9950	ND
262	8.15	79.7	69.8	115	>9950	ND
263	5.91	72.7	56.7	95.8	>9950	ND
264	7.12	84.4	75.2	105	>9950	ND
265	0.775 (0.0602, 2)	96.0 (0.960, 2)	5.14 (1.17, 2)	102 (2.46, 2)	>9950 (n=1/2)	ND
266	0.575	82.7	5.83	97.6	>9950	ND

267	0.808	88.1	8.46	104	>9950	ND
268	5.06	92.3	26.5	104	>9950	ND
269	2.65 (3.59, 3)	87.3 (0.702, 3)	46.5 (16.2, 3)	105 (4.56, 3)	>9950 (n=1/3)	ND
270	3.8	80.9	32.6	111	>9950	ND
271	0.767	97.3	10.2	122	>9950	ND
272	0.561	81.2	4.72	102	>9950	ND
273	0.318	88.4	40.9	90.5	>9950	ND
274	1.16	93.5	32.9	121	>9950	ND
275	0.926	101	33.5	103	>9950	ND
276	1.97	91.4	63.6	104	>9950	ND
277	0.962	99.3	12.2	93.1	>9950	ND
278	1.41	91.1	27	121	>9950	ND
279	3.21	88.6	36.6	114	>9950	ND
280	4.84	88.5	49.9	105	>9950	ND
281	1.87	97.9	22.4	91.7	>9950	ND
282	1.44	84.4	31.8	102	>9950	ND
283	4.88	114	49.5	96.6	>9950	ND
284	8.38	101	137	112	>9950	ND
285	1.28	84.7	136	105	>9950	ND
286	2.18	104	35	90.3	>9950	ND
287	3.76	98.9	83.8	106	>9950	ND
288	0.48	85.2	17.1	123	>9950	ND
289	3.11	94.9	627	170	>9950	ND
290	0.878	93.4	12.1	109	>9950	ND
291	0.833	92.9	7.43	100	>9950	ND
292	0.416 (0.0297, 5)	88.4 (4.96, 5)	4.35 (0.151, 5)	101 (2.62, 5)	>9950 (n=1/5)	ND
293	0.987 (0.168, 3)	96.6 (2.52, 3)	10.7 (0.553, 3)	99.4 (3.13, 3)	>9950 (n=1/3)	ND
294	0.833	107	6.26	104	>9950	ND
295	1.09	99.6	10.4	101	>9950	ND
296	0.823	91.9	13	109	>9950	ND
297	1.54	93.7	19.1	108	>9950	ND
298	0.237 (0.0133, 3)	95.0 (3.55, 3)	3.64 (1.18, 3)	107 (10.3, 3)	>9950 (n=1/3)	ND
299	0.204 (0.0143, 3)	99.8 (4.40, 3)	2.58 (0.211, 3)	102 (1.94, 3)	>9950 (n=1/3)	ND
300	1.25 (0.0915, 3)	91.5 (6.45, 3)	19.6 (2.89, 3)	109 (2.14, 3)	>9950 (n=1/3)	ND
301	0.919 (0.0935, 2)	85.5 (3.43, 2)	12.9 (0.666, 2)	106 (7.59, 2)	>9950 (n=1/2)	ND

302	0.453 (0.00185, 2)	86.3 (0.816, 2)	6.55 (0.397, 2)	99.4 (1.04, 2)	>9950 (n=1/2)	ND
303	2	89.8	50.4	111	>9950	ND
304	4.83	99.3	64.2	98.3	>9950	ND
305	4.34	95.4	80.3	125	>9950	ND
306	1.12	102	18.2	102	>9950	ND
307	1.66	81.8	33	109	>9950	ND
308	10.5	98.4	67.3	92.2	>9950	ND
309	6.08	95.3	64.6	106	>9950	ND
310	2.4	83.9	22	106	>9950	ND
311	2.16	98.3	33.8	104	>9950	ND
312	4.48	89.5	50.8	112	>9950	ND
313	21.9	101	98.8	95	>9950	ND
314	3.51	101	38.6	102	>9950	ND
315	0.393	89.2	5.38	93.5	>9950	ND
316	1.11	102	19.2	113	>9950	ND
317	2.03 (0.0584, 2)	84.4 (8.11, 2)	29.5 (4.64, 2)	98.1 (5.04, 2)	>9950 (n=1/2)	ND
318	5.42 (0.737, 2)	91.4 (2.19, 2)	28.7 (1.02, 2)	101 (1.14, 2)	>9950 (n=1/2)	ND
319	3.35 (1.04, 2)	92.5 (5.28, 2)	28.1 (3.97, 2)	114 (17.1, 2)	>9950 (n=1/2)	ND
320	0.338	84.1	6.22	99.2	>9950	ND
321	0.631	94.5	13.9	96.6	>9950	ND
322	0.617 (0.107, 5)	89.7 (3.98, 5)	8.09 (0.489, 5)	94.5 (2.57, 5)	>9950 (n=1/5)	ND
323	0.694	92.9	9.52	104	>9950	ND
324	0.321 (0.0210, 5)	85.4 (4.62, 5)	4.38 (0.281, 5)	99.4 (4.29, 5)	>9950 (n=1/5)	ND
325	3.96 (0.456, 2)	94.7 (5.70, 2)	23.5 (6.01, 2)	98.4 (2.48, 2)	>9950 (n=1/2)	ND
326	4.62 (0.384, 2)	88.7 (7.81, 2)	26.1 (0.140, 2)	96.1 (2.59, 2)	>9950 (n=1/2)	ND
327	0.751	90.2	13.6	97.6	>9950	ND
328	0.75	85.5	23.3	102	>9950	ND
329	5.44	100	74.7	88.3	>9950	ND
330	6.26	103	85.2	85	>9950	ND
331	8.31	108	223	114	>9950	ND
332	4.59	96.5	33.3	116	>9950	ND
333	6.74	100	70.4	93.3	>9950	ND
334	0.618 (0.0980, 5)	89.0 (3.96, 5)	8.67 (0.430, 5)	105 (3.28, 5)	>9950 (n=1/5)	ND
335	1.04	85.2	12.3	101	>9950	ND

336	2.92 (0.0217, 2)	94.6 (4.74, 2)	47.0 (6.26, 2)	103 (8.40, 2)	>10100 (n=1/2)	ND
337	2.65 (0.235, 2)	86.8 (4.14, 2)	53.6 (8.71, 2)	100 (1.63, 2)	>10100 (n=1/2)	ND
338	1.24 (0.0430, 2)	83.9 (2.56, 2)	36.6 (6.57, 2)	103 (1.43, 2)	>10100 (n=1/2)	ND
339	4.35 (0.915, 2)	87.3 (9.37, 2)	68.2 (10.6, 2)	115 (6.65, 2)	>10100 (n=1/2)	ND
340	9.91	87.9	122	112	>9950	ND
341	5.74 (0.563, 2)	83.6 (3.95, 2)	95.8 (1.69, 2)	113 (8.64, 2)	>9950 (n=1/2)	ND
342	1.04 (0.0681, 2)	89.3 (1.18, 2)	13.6 (0.635, 2)	101 (2.94, 2)	>9950 (n=1/2)	ND
343	2.38	90.2	20.2	98.2	>9950	ND
344	6.78	87.3	48.3	96.5	>9950	ND
345	0.731 (0.0103, 2)	86.8 (8.74, 2)	11.8 (1.13, 2)	110 (2.77, 2)	>9950 (n=1/2)	ND
346	1.83	83.9	19	97.7	>9950	ND
347	7.27	84.6	51.7	99.5	>9950	ND
348	1.79	79.3	8.95	98	>9950	ND
349	0.606	79.3	5.15	94.3	>9950	ND
350	5.82	73.5	6.4	91.4	>9950	ND
351	0.722	67.9	5.8	91	>9950	ND
352	0.277	71.3	5.46	93.5	>9950	ND
353	5.35	84.8	7.12	92.5	>9950	ND
354	0.857	67.5	7.25	95.9	>9950	ND
355	1.81	86	11.3	109	>9950	ND
356	2.47	82.7	23.4	93	>9950	ND
357	1.19 (0.250, 2)	78.2 (14.7, 2)	36.2 (2.98, 2)	92.8 (1.82, 2)	>9950 (n=1/2)	ND
358	2.06 (0.735, 2)	86.2 (0.397, 2)	65.3 (2.90, 2)	102 (4.28, 2)	>9950 (n=1/2)	ND
359	1.58 (0.643, 2)	81.0 (10.1, 2)	40.5 (4.21, 2)	95.1 (1.93, 2)	>9950 (n=1/2)	ND
360	1.91 (0.0821, 2)	84.3 (10.5, 2)	28.2 (0.0380, 2)	97.1 (5.05, 2)	>9950 (n=1/2)	ND
361	1.44 (0.180, 2)	88.8 (5.34, 2)	43.0 (0.650, 2)	98.8 (3.89, 2)	>9950 (n=1/2)	ND
362	0.936 (0.0457, 2)	86.7 (0.254, 2)	29.9 (0.294, 2)	107 (6.56, 2)	>9950 (n=1/2)	ND
363	0.976	91.1	14.3	111	>9950	ND
364	0.895	89.1	13	102	>9950	ND
365	1.93	93.5	22.3	91	>9950	ND
366	3.14	95.9	96.2	98.3	>9950	ND

372	3.75	90.6	38	101	>9950	ND
373	2.84	82.4	37.4	112	>9950	ND
374	1.96	88.8	39.7	108	>9950	ND
375	4.68	85.4	56.1	113	>9950	ND
376	39.6	88.3	419	121	>9950	ND
377	17.5	79.4	178	110	>9950	ND
378	7.46 (0.401, 2)	81.2 (0.297, 2)	47.7 (5.86, 2)	104 (2.97, 2)	>9950 (n=1/2)	ND
379	11.6 (3.09, 2)	90.0 (2.40, 2)	48.5 (1.05, 2)	101 (1.65, 2)	>9950 (n=1/2)	ND
380	9.23 (1.41, 2)	93.5 (4.71, 2)	28.0 (2.79, 2)	94.5 (0.549, 2)	>9950 (n=1/2)	ND
381	28	90.3	153	106	>9950	ND
382	18.7	87.2	204	118	>9950	ND
383	10.7 (0.361, 2)	82.8 (0.0145, 2)	92.2 (7.22, 2)	102 (1.72, 2)	>9950 (n=1/2)	ND
384	0.457 (0.0717, 2)	83.5 (7.50, 2)	5.32 (0.0375, 2)	99.5 (3.98, 2)	>9950 (n=1/2)	ND
385	0.558 (0.0738, 2)	83.5 (1.48, 2)	10.6 (0.719, 2)	112 (4.74, 2)	>9950 (n=1/2)	ND
386	2.08 (0.338, 2)	81.3 (1.47, 2)	17.7 (0.911, 2)	96.8 (3.81, 2)	>9950 (n=1/2)	ND
387	0.278 (0.00115, 2)	93.0 (6.92, 2)	4.40 (1.07, 2)	103 (1.08, 2)	>9950 (n=1/2)	ND
388	0.463	82.1	6.31	104	>9950	ND
389	1.50 (0.343, 2)	82.0 (2.14, 2)	9.58 (1.62, 2)	106 (0.535, 2)	>9950 (n=1/2)	ND
390	3.85 (0.361, 3)	89.3 (3.58, 3)	24.3 (1.05, 3)	94.6 (2.35, 3)	>9950 (n=1/3)	ND
391	0.266 (0.0311, 4)	88.3 (1.76, 4)	2.62 (0.437, 4)	105 (2.45, 4)	>9950 (n=1/4)	ND
392	0.797	85.7	3.14	93.7	>9950	ND
393	0.547	66.7	9.18	103	>9950	ND
394	1.38 (0.437, 2)	84.6 (11.0, 2)	5.83 (1.31, 2)	96.8 (7.02, 2)	>9950 (n=1/2)	ND
395	0.327	57.8	6.26	96.1	>9950	ND
396	0.595	67.1	6.49	94.4	>9950	ND
397	1.92 (0.780, 2)	84.5 (11.6, 2)	7.17 (0.884, 2)	103 (8.65, 2)	>9950 (n=1/2)	ND
398	5.40 (1.52, 2)	91.9 (0.357, 2)	41.3 (4.18, 2)	106 (4.28, 2)	>9950 (n=1/2)	ND
399	16.2	86.8	43.6	89.7	>9950	ND
400	16.7	83.2	107	109	>9950	ND

401	0.434 (0.0341, 3)	83.0 (7.25, 3)	5.39 (0.0937, 3)	107 (3.32, 3)	>9950 (n=1/3)	ND
402	1.11 (0.0989, 3)	84.5 (0.945, 3)	13.5 (2.55, 3)	110 (5.84, 3)	>9950 (n=1/3)	ND
403	0.711 (0.103, 3)	91.7 (6.87, 3)	7.31 (0.446, 3)	107 (2.08, 3)	>9950 (n=1/3)	ND
404	1.74	77.3	49.1	99.3	>9950	ND
405	1.23	74.3	37.5	78.1	>9950	ND
406	0.527 (0.130, 2)	87.3 (2.48, 2)	9.21 (0.435, 2)	96.0 (2.59, 2)	>9950 (n=1/2)	ND
407	1.87 (0.139, 3)	95.4 (4.35, 3)	12.4 (1.15, 3)	97.2 (2.74, 3)	>9950 (n=1/3)	ND
408	0.299 (0.0439, 3)	84.4 (2.26, 3)	5.92 (0.553, 3)	99.5 (3.91, 3)	>9950 (n=1/3)	ND
409	0.537 (0.0122, 3)	84.0 (0.901, 3)	8.05 (0.761, 3)	97.7 (3.00, 3)	>9950 (n=1/3)	ND
410	1.28 (0.255, 2)	86.4 (5.77, 2)	11.0 (0.428, 2)	93.1 (0.997, 2)	>9950 (n=1/2)	ND
411	1.09 (0.153, 3)	84.6 (2.63, 3)	11.4 (1.88, 3)	101 (2.54, 3)	>9950 (n=1/3)	ND
412	1.57 (0.136, 3)	87.5 (2.85, 3)	18.3 (1.35, 3)	106 (3.38, 3)	>9950 (n=1/3)	ND
413	0.422 (0.0398, 3)	91.8 (3.88, 3)	5.47 (0.460, 3)	107 (4.11, 3)	>9950 (n=1/3)	ND
414	0.274 (0.0130, 5)	92.2 (1.90, 5)	3.24 (0.450, 5)	103 (3.30, 5)	>9950 (n=1/5)	ND
415	0.492 (0.0557, 4)	93.9 (2.34, 4)	5.72 (0.324, 4)	104 (3.90, 4)	>9950 (n=1/4)	ND
416	0.723 (0.0458, 3)	83.0 (5.25, 3)	10.1 (0.689, 3)	109 (2.55, 3)	>9950 (n=1/3)	ND
417	0.201 (0.0212, 4)	96.4 (1.41, 4)	2.66 (0.254, 4)	104 (2.88, 4)	>9950 (n=1/4)	ND
418	0.126 (0.0101, 3)	87.2 (4.56, 3)	1.72 (0.202, 3)	98.8 (3.48, 3)	>9950 (n=1/3)	ND
419	0.440 (0.0108, 3)	88.2 (0.828, 3)	7.19 (1.28, 3)	97.3 (3.90, 3)	>9950 (n=1/3)	ND
420	0.351 (0.0281, 2)	89.7 (1.93, 2)	10.0 (1.52, 2)	109 (14.4, 2)	>9950 (n=1/2)	ND
421	0.164 (0.0176, 5)	98.0 (2.76, 5)	2.01 (0.326, 5)	105 (3.71, 5)	>9950 (n=1/5)	ND
422	0.199 (0.0226, 5)	97.5 (1.55, 5)	3.84 (0.645, 4)	102 (6.38, 4)	>9950 (n=1/5)	ND
423	0.294 (0.0208, 5)	89.7 (3.15, 5)	4.74 (0.644, 5)	99.5 (3.90, 5)	>9950 (n=1/5)	ND
424	0.159 (0.0110, 5)	89.5 (1.11, 5)	3.07 (0.179, 5)	98.1 (3.03, 5)	>9950 (n=1/5)	ND

425	0.875 (0.138, 2)	89.9 (1.77, 2)	10.3 (0.951, 2)	103 (0.221, 2)	>9950 (n=1/2)	ND
426	3.88 (0.200, 2)	91.2 (3.07, 2)	29.7 (2.34, 2)	106 (11.5, 2)	>9950 (n=1/2)	ND
427	2.04 (0.124, 2)	92.4 (2.27, 2)	25.1 (5.36, 2)	109 (1.53, 2)	>9950 (n=1/2)	ND
428	0.748 (0.0265, 2)	93.6 (1.01, 2)	10.2 (0.217, 2)	105 (7.48, 2)	>9950 (n=1/2)	ND
429	1.03 (0.0757, 2)	93.3 (2.97, 2)	17.3 (0.623, 2)	101 (1.10, 2)	>9950 (n=1/2)	ND
430	1.09 (0.108, 2)	91.5 (4.62, 2)	26.8 (3.10, 2)	88.5 (3.34, 2)	>9950 (n=1/2)	ND
431	0.645 (0.0819, 2)	98.0 (6.44, 2)	17.5 (0.336, 2)	91.6 (8.16, 2)	>9950 (n=1/2)	ND
432	0.0875 (0.00975, 5)	96.7 (2.20, 5)	1.28 (0.177, 5)	103 (1.27, 5)	>9950 (n=1/5)	ND
433	0.136 (0.0247, 3)	100.0 (3.94, 3)	2.63 (0.319, 2)	101 (5.22, 2)	>9950 (n=1/3)	ND
434	0.0994 (0.0113, 5)	97.5 (2.66, 5)	1.73 (0.292, 5)	101 (2.09, 5)	>9950 (n=1/5)	ND
435	0.0873 (0.00638, 5)	98.7 (2.49, 5)	1.63 (0.153, 5)	97.8 (2.96, 5)	>9950 (n=1/5)	ND
436	0.241 (0.0446, 3)	96.0 (0.351, 3)	4.98 (0.430, 3)	100 (3.07, 3)	>9950 (n=1/3)	ND
437	0.461 (0.0212, 2)	96.5 (2.42, 2)	9.65 (2.23, 2)	91.2 (10.9, 2)	>9950 (n=1/2)	ND
438	0.592 (0.100, 2)	90.8 (1.84, 2)	28.0 (1.64, 2)	88.7 (20.6, 2)	>9950 (n=1/2)	ND
439	0.396 (0.0386, 3)	91.7 (2.17, 3)	9.25 (2.51, 3)	97.0 (5.24, 3)	>9950 (n=1/3)	ND
440	0.209 (0.0138, 6)	90.3 (1.85, 6)	2.74 (0.115, 6)	106 (1.98, 6)	>10100 (n=1/6)	ND
441	1.38 (0.172, 4)	83.8 (2.04, 4)	5.75 (0.561, 4)	111 (3.26, 4)	>9950 (n=1/4)	ND
442	0.687 (0.179, 3)	92.1 (4.96, 3)	7.63 (2.89, 3)	106 (1.76, 3)	>9950 (n=1/3)	ND
443	12.2 (1.51, 2)	91.1 (1.74, 2)	133 (5.04, 2)	99.3 (0.923, 2)	>9950 (n=1/2)	ND
444	0.570 (0.0249, 2)	83.6 (0.143, 2)	7.51 (1.10, 2)	98.8 (2.42, 2)	>9950 (n=1/2)	ND
445	1.17 (0.102, 2)	91.4 (0.322, 2)	13.1 (0.359, 2)	100 (0.430, 2)	>9950 (n=1/2)	ND
446	5.14 (1.45, 3)	97.0 (4.46, 3)	33.5 (2.16, 3)	105 (1.85, 3)	>9950 (n=1/3)	ND

447	1.46 (0.413, 3)	101 (2.70, 3)	7.85 (0.457, 3)	98.4 (2.10, 3)	>9950 (n=1/3)	ND
448	1.41 (0.531, 3)	99.2 (0.884, 3)	7.91 (0.258, 3)	99.5 (1.45, 3)	>9950 (n=1/3)	ND
449	0.595 (0.0397, 5)	92.1 (4.58, 5)	7.27 (0.337, 5)	103 (5.19, 5)	>9950 (n=1/5)	ND
450	2.44 (0.532, 5)	91.4 (4.33, 5)	32.3 (4.94, 5)	102 (6.79, 5)	>9950 (n=1/5)	ND
451	0.518 (0.103, 5)	89.5 (2.84, 5)	7.23 (0.798, 5)	108 (5.40, 5)	>9950 (n=1/5)	ND
452	1.21 (0.251, 3)	100 (1.68, 3)	16.8 (2.48, 3)	108 (2.85, 3)	>9950 (n=1/3)	ND
453	0.451 (0.0791, 5)	92.0 (0.901, 5)	5.47 (0.327, 5)	108 (3.80, 5)	>9950 (n=1/5)	ND
454	1.30 (0.201, 4)	91.5 (0.474, 4)	18.6 (1.80, 4)	103 (1.41, 4)	>9950 (n=1/4)	ND
455	0.362 (0.0529, 5)	91.8 (1.84, 5)	5.24 (0.295, 5)	108 (2.00, 5)	>9950 (n=1/5)	ND
456	0.878 (0.170, 3)	94.7 (3.21, 3)	14.7 (1.55, 3)	112 (5.14, 3)	>9950 (n=1/3)	ND
457	0.334 (0.0519, 4)	92.7 (3.24, 4)	4.69 (1.37, 4)	103 (3.76, 4)	>9950 (n=1/4)	ND
458	0.726 (0.0737, 4)	93.1 (2.31, 4)	7.61 (0.921, 4)	106 (2.53, 4)	>9950 (n=1/4)	ND
459	0.323 (0.0736, 4)	89.3 (1.16, 4)	4.87 (0.929, 4)	104 (2.02, 4)	>9950 (n=1/4)	ND
460	0.506 (0.0729, 4)	89.5 (3.45, 4)	6.31 (0.982, 4)	99.5 (3.37, 4)	>9950 (n=1/4)	ND
461	0.247 (0.0520, 4)	98.5 (0.822, 4)	2.76 (0.361, 4)	105 (2.29, 4)	>10100 (n=1/4)	ND
462	0.317 (0.0572, 3)	98.4 (2.45, 3)	3.34 (0.719, 3)	104 (2.72, 3)	>9950 (n=1/3)	ND
463	0.350 (0.0916, 3)	93.7 (3.44, 3)	4.09 (0.287, 2)	103 (7.01, 2)	>9950 (n=1/3)	ND
464	0.316 (0.0436, 4)	95.5 (4.97, 4)	4.48 (0.715, 4)	104 (5.47, 4)	>10100 (n=1/4)	ND
465	3.63 (0.920, 3)	94.4 (1.30, 3)	73.2 (8.31, 3)	93.3 (9.91, 3)	>9950 (n=1/3)	ND
466	0.314 (0.0445, 2)	93.4 (2.04, 2)	3.32 (0.194, 2)	99.8 (9.14, 2)	>10100 (n=1/2)	ND
467	0.35	88.4	2.87	97.9	>10100 (n=1/2)	ND
468	0.222	85.9	1.84	102	>10100 (n=1/2)	ND
469	0.203	82.1	2.33	93.8	>9950 (n=1/2)	ND

470	0.719	93.9	4.54	113	>9950 (n=1/2)	ND
471	0.568	90.1	4.36	110	>9950 (n=1/2)	ND
472	0.663	76.3	7.41	103	>9950 (n=1/2)	ND
473	0.979	92.8	7.07	114	>9950 (n=1/2)	ND
474	0.156	85.6	1.1	104	>9950 (n=1/2)	ND
475	0.211	84.6	1.44	102	>9950 (n=1/2)	ND
476	0.154	81.8	1.5	107	>9950 (n=1/2)	ND
477	0.163	88.1	1.56	110	>9950 (n=1/2)	ND
478	0.517	84	6.16	108	>9950	ND
479	0.196	89.5	2.55	95.3	>9950	ND
480	0.29	99.7	2.65	104	>9950	ND
481	0.467	82.7	6.16	112	>9950	ND
482	0.89	104	4.85	110	>9950 (n=1/2)	ND
483	0.297	92.6	3.33	113	>9950 (n=1/2)	ND
484	0.453	91.3	3.66	103	>9950 (n=1/2)	ND
485	0.536	93.8	3.9	104	>9950	ND
486	0.239	88.2	2	102	>9950 (n=1/2)	ND
487	0.429	89.1	3.16	104	>9950 (n=1/2)	ND
488	0.718 (0.161, 2)	85.5 (1.49, 2)	13.0 (0.709, 2)	106 (4.29, 2)	>9950 (n=1/3)	ND
489	0.578	79.4	13.5	98.7	>9950	ND
490	0.976	97.1	7.68	101	>9950	ND
491	1.08	87.5	5.51	105	>9950	ND
492	0.371	88.7	4.31	104	>9950 (n=1/2)	ND
493	0.591	94.6	7.24	102	>9950	ND
494	0.699 (0.0883, 4)	92.6 (3.07, 4)	9.17 (1.83, 4)	106 (3.43, 4)	>9950 (n=1/4)	ND

ND = Not Determined

^a Expression density is determined using homologous competition binding of [¹²⁵I]GLP-1(7-36)NH₂ at hGLP-1R (112 fmol/mg protein), [¹²⁵I]GCG at hGCGR (98 fmol/mg protein) and [¹²⁵I]GIP(1-42) at hGIPR (124 fmol/mg protein).

^b EC₅₀, nM = the Geometric Mean, followed by the Standard Error of the Mean and the number of observations in parenthesis.

^c E_{max}, % = the Arithmetic Mean ± the Standard Error of the Mean for the percent of maximal response to GLP-1(7-36)NH₂ at hGLP-1R, GCG at hGCGR or GIP(1-42)NH₂ at hGIPR.

5 All values shown are to three (3) significant digits.

IN VIVO STUDIES

Pharmacokinetics in male CD-1 mice

The pharmacokinetics of a test peptide is evaluated following a single
10 subcutaneous administration of 200 nMol/kg to male CD-1 mice. Blood samples are collected over 168 hours and resulting individual plasma concentrations are used to calculate pharmacokinetic parameters. Plasma (K₃ EDTA) concentrations are determined using a qualified LC/MS method that measures the intact mass of the test peptide. Each test peptide and an analog as an internal standard are extracted from 100% mouse plasma
15 using immunoaffinity based precipitation with anti-GIP/GLP1 antibodies. Instruments are combined for LC/MS detection. Mean pharmacokinetic parameters determine if the test peptide is consistent with an extended pharmacokinetic profile.

Insulin Secretion in Male Wistar Rats

20 Male Wistar rats with femoral artery and femoral vein canulas (Envigo, Indianapolis, IN) (280- 320 grams) are single-housed in polycarbonate cages with filter tops. Rats maintained on a 12:12 h light-dark cycle (lights on at 6:00 A.M.) at 21°C and receive food and deionized water ad libitum. Rats are randomized by body weight and dosed 1.5 ml/kg s.c. at test peptide doses of 0.04, 0.1, 0.3, 1, 3, and 10 nmol/kg 16 hours
25 prior to glucose administration then fasted. Animals are weighed and anesthetized with sodium pentobarbital dosed i.p. (65 mg/kg, 30 mg/ml). A time 0 blood sample is collected into EDTA tubes after which glucose is administered i.v. (0.5 mg/kg, 5 ml/kg). Blood samples are collected for glucose and insulin levels at time 2, 4, 6, 10, 20 and 30 min post intravenous administration of glucose. Plasma glucose levels are determined using a
30 clinical chemistry analyzer. Plasma insulin is determined using an electrochemiluminescence assay (Meso Scale, Gaithersburg, MD). Glucose and insulin AUC are examined compared to the vehicle control with n = 5 animals per group. Results are presented (SEM)(N). Results show the test peptide effect on insulin secretion

during intravenous glucose tolerance test. Results show test peptide dose dependent effect on insulin secretion.

Diet-Induced Obese C57/B16 Mice

5 C57/B16 diet-induced obese (DIO) male mice (Taconic, Germantown, NY) weighing 41-50 g are used. Animals are individually housed in a temperature-controlled (24°C) facility with a 12 hour light/dark photoperiod (lights off at 10:00 AM and lights on at 10:00 PM), with free access to food and water. After 2 week acclimatization to the facility, mice are randomized to treatment groups (n=6/group) based on body weight so
10 each group has similar starting mean body weight.

Mice are treated with either vehicle (40 mM Tris-HCl at pH 8.0) or a test peptide between the dose range of about 0.03 nmol/kg to about 10 nmol/kg. Treatments are subcutaneously administered to ad libitum fed DIO mice 30-90 minutes prior to the onset of the dark cycle daily (QD) for 14 days. Monitor body weight and food intake daily.

15 Data are expressed as mean $\pm$ SEM of 5-6 rats per group. Statistical analyses are assessed by one-way ANOVA followed by Dunnett's multiple comparison test to compare treatment groups to vehicle group or each other. Significant differences are identified at $p < 0.05$.

20 Percent Body Weight = $\frac{\text{Body weight after 14-day treatment}}{\text{Body weight before treatment started}} \times 100$

"0" dose group represents the vehicle-treated mice during each study. All data are expressed as mean $\pm$ SEM of 5-6 mice per group. " Δ from vehicle" refers to difference between body weight at day 15 between test and vehicle groups. "% change" refers to percent decrease in body weight between days 1 and 15 in test groups. Record percent
25 decrease in body weight for animals receiving vehicle. The Δ from vehicle and % change data are statistically significantly different ($p < 0.05$) than control for a peptide testing positive in the assay.

Amino Acid Sequences

SEQ ID NO:1

GIP (Human)

YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ-NH₂

5

SEQ ID NO:2

Glucagon (Human)

HSQGTFTSDYSKYLDSRRAQDFVQWLMNT

10 SEQ ID NO:3

GLP-1 (7-36) (Human)

HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-NH₂

SEQ ID NO:4

15 X₁X₂EGTX₆TSDX₁₀X₁₁X₁₂X₁₃LDX₁₆X₁₇AQX₂₀X₂₁X₂₂IX₂₄X₂₅LIX₂₈GX₃₀

SEQ ID NO:5

X₃₁SSG

20 SEQ ID NO:6

X₃₁SSG-R₃

SEQ ID NO:7

X₃₁SSGX₃₅PPPX₃₉

25

SEQ ID NO:8

X₃₁SSGX₃₅PPPX₃₉R₃

SEQ ID NO:9

30 X₃₁SSGX₃₅PPPX₃₉X₄₀

SEQ ID NO:10

X₃₁SSGX₃₅PPPX₃₉X₄₀R₃

SEQ ID NO:11

Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-
5 acetyl)₂-(γ -Glu)-CO-(CH₂)₁₂-CO₂H)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-
Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₂-CO₂H)SSGAPPPS-NH₂

SEQ ID NO:12

Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-
10 acetyl)₂-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-
LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(10-(4-
carboxyphenoxy)decanoyl))SSGAPPPS-NH₂

SEQ ID NO:13

Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-
15 acetyl)₂-(γ -Glu)-(4-(4-iodophenyl)butanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-
[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(4-(4-iodophenyl)butanoyl))SSGAPPPS-
NH₂

20 SEQ ID NO:14

Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-
acetyl)₂-(γ -Glu)-(4-(4-*tert*-butylphenyl)butanoyl))AQ-Aib-EFI-(D-Glu)- α MeY-
LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(4-(4-*tert*-
butylphenyl)butanoyl))SSGAPPPS-NH₂

25

SEQ ID NO:15

Y-Aib-EGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-
acetyl)₂-(γ -Glu)-CO-(CH₂)₁₀-CH₃)AQ-Aib-EFI-(D-Glu)- α MeY-LIEGGK((2-[2-(2-
Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₀-CH₃)SSGAPPPS-NH₂

30

WE CLAIM:

1. A compound of the formula:

$$X_1X_2EGTX_6TSDX_{10}X_{11}X_{12}X_{13}LDX_{16}X_{17}AQX_{20}X_{21}X_{22}IX_{24}X_{25}LIX_{28}GX_{30}$$

5 (SEQ ID NO:505)

wherein

X_1 is selected from the group consisting of Y and R_1Y ;

R_1 is an Ac modification of the N-terminal amino group;

X_2 is Aib;

10 X_6 is selected from the group consisting of α MeF and α MeF(2F);

X_{10} is selected from the group consisting of 4Pal, Y, α MeF, α MeF(2F), α MeL, α MeV, Ac4c, Ac5c, Ac6c, Bip, 1Nal, 2Nal, OMeY, hTyr, Nle, V, 4CPhe, ChG, ChA, Bzt, 2FA, 4TAA, 2TA, 3TA, and KZ_1 ;

X_{11} is selected from the group consisting of S, α MeS, Aib, G, Dap, Ac5c, and Tle;

15 X_{12} is selected from the group consisting of I and KZ_1 ;

X_{13} is selected from the group consisting of α MeL and α MeF;

X_{16} is Orn;

X_{17} is selected from the group consisting of Q, I, and KZ_1 ;

X_{20} is selected from the group consisting of Aib, Orn, 4Pal, α MeF, Ac5c, and
20 Ac6c;

X_{21} is selected from the group consisting of E, KZ_1 , G, Orn, and 4Pal;

X_{22} is selected from the group consisting of F, 2ClPhe, 3ClPhe, 2FPhe, 3FPhe, 3,5FPhe, 1Nal, 2Nal, α MeF(2F), ChA, Bzt, and α MeF;

X_{24} is selected from the group consisting of D-Glu, E, G, and KZ_1 ;

25 X_{25} is selected from the group consisting of Y, α MeY, α MeF, and KZ_1 ;

X_{28} is selected from the group consisting of E, Orn, and KZ_1 ;

X_{30} is selected from the group consisting of G, Orn, KZ_1 , $K(Z_1)R_6$, $OrnR_2$, and GR_2 ;

R_2 is selected from the group consisting of X_{31} , $X_{31}SSG$ (SEQ ID NO:5), $X_{31}SSG-$

30 R_3 (SEQ ID NO:6), $X_{31}SSGX_{35}PPPX_{39}$ (SEQ ID NO:7), $X_{31}SSGX_{35}PPPX_{39}R_3$

(SEQ ID NO:8), $X_{31}SSGX_{35}PPPX_{39}X_{40}$ (SEQ ID NO:9), $X_{31}SSGX_{35}PPPX_{39}X_{40}R_3$

(SEQ ID NO:10), and a modification of the c-terminal group wherein the modification is NH₂;

R₆ is selected from the group consisting of PSSG (SEQ ID NO:506), PSSG-R₃ (SEQ ID NO:507), PSSGX₃₅PPPX₃₉ (SEQ ID NO:508), PSSGX₃₅PPPX₃₉R₃ (SEQ ID NO:509), PSSGX₃₅PPPX₃₉X₄₀ (SEQ ID NO:510), PSSGX₃₅PPPX₃₉X₄₀R₃ (SEQ ID NO:511), and a modification of the c-terminal group wherein the modification is NH₂;

X₃₁ is selected from the group consisting of P, and KZ₁;

X₃₅ is selected from the group consisting of A and Orn;

X₃₉ is selected from the group consisting of S and Orn;

X₄₀ is KZ₁;

R₃ is a modification of the C-terminal group, wherein the modification is NH₂; wherein two, and only two, of X₁₀, X₁₂, X₁₇, X₂₁, X₂₄, X₂₅, X₂₈, X₃₀, X₃₁, and X₄₀ are KZ₁ or K(Z₁)R₆;

Z₁ is selected from the group consisting of R₅ and -R₄R₅;

R₄ is a linker; and

R₅ is a fatty acid; or

a pharmaceutically acceptable salt thereof.

2. A compound, or a pharmaceutically acceptable salt thereof, as claimed by Claim 1 wherein

X₃₀ is selected from the group consisting of G, Orn, KZ₁, and GR₂; and

R₂ is selected from the group consisting of X₃₁SSG (SEQ ID NO:5), X₃₁SSG-R₃ (SEQ ID NO:6), X₃₁SSGX₃₅PPPX₃₉ (SEQ ID NO:7), X₃₁SSGX₃₅PPPX₃₉R₃ (SEQ ID NO:8), X₃₁SSGX₃₅PPPX₃₉X₄₀ (SEQ ID NO:9), X₃₁SSGX₃₅PPPX₃₉X₄₀R₃ (SEQ ID NO:10), and a modification of the c-terminal group wherein the modification is NH₂.

3. A compound, or pharmaceutically acceptable salt thereof, as claimed by Claim 1 or 2, wherein Z₁ is -R₄R₅.

4. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 3 wherein R₅ is selected from the group consisting of -CO-(CH₂)₁₂-CO₂H, CO-(CH₂)₁₄-CO₂H, -CO-(CH₂)₁₀-CO₂H, -(10-(4-carboxyphenoxy)decanoyl), -(4-(4-iodophenyl)butanoyl), -(4-(4-*tert*-

butylphenyl)butanoyl), -CO-(CH₂)₁₄-CH₃, -CO-(CH₂)₁₂-CH₃, -CO-(CH₂)₁₀-CH₃, -
(7-(4-carboxyphenoxy)heptanoyl), -(11-(4-carboxyphenoxy)undecanoyl), -(12-(4-
carboxyphenoxy)dodecanoyl), and -(8-(4-carboxyphenoxy)octanoyl).

5. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one
5 of Claims 1 to 4 wherein R₅ is selected from the group consisting of
-CO-(CH₂)₁₂-CO₂H, -CO-(CH₂)₁₀-CO₂H, -(10-(4-carboxyphenoxy)decanoyl), -(4-
(4-iodophenyl)butanoyl), -(4-(4-*tert*-butylphenyl)butanoyl), -CO-(CH₂)₁₄-CH₃, -
CO-(CH₂)₁₂-CH₃, -CO-(CH₂)₁₀-CH₃, -(7-(4-carboxyphenoxy)heptanoyl), and -(8-
(4-carboxyphenoxy)octanoyl).
- 10 6. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one
of Claims 1 to 4 wherein R₅ is selected from the group consisting of
CO-(CH₂)₁₄-CO₂H, -(11-(4-carboxyphenoxy)undecanoyl), and -(12-(4-
carboxyphenoxy)dodecanoyl).
- 15 7. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one
of Claims 1 to 6 wherein R₄ is -(εK)_{a1}-(γ-Glu)_{a2}-(2-[2-(2-Amino-ethoxy)-
ethoxy]-acetyl)_{a3}-(εK)_{b1}-(γ-Glu)_{b2};
a₁ is selected from the group consisting of 0, 1, and 2;
a₂ is selected from the group consisting of 0, 1, and 2;
a₃ is selected from the group consisting of 0, 1, 2, and 3;
20 b₁ is 0 or 1; and
b₂ is 0 or 1.
8. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one
of Claims 1 to 6 wherein R₄ is selected from the group consisting of
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-,
25 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)₂-,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₃-(γ-Glu)-,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(εK)-,
30 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(εK)-(γ-Glu)-,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(εK)-(γ-Glu)-,

- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Trx-(γ -Glu)-,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-Trx-(γ -Glu)-,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-(γ -Glu)-,
 5 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Ahx-(γ -Glu)-,
 -PEG3-(γ -Glu)-,
 -PEG4-(γ -Glu)-,
 -PEG5-(γ -Glu)-,
 -PEG6-(γ -Glu)-,
 10 -Ahx-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-,
 -Aoc-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-,
 -(ϵ K)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-,
 -(ϵ K)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-,
 -(ϵ K)-(γ -Glu)-,
 15 -(ϵ K)-(γ -Glu)-(γ -Glu)-,
 -(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-,
 -(ϵ K)-(ϵ K)-(γ -Glu)-,
 -(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-,
 -(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-,
 20 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-, and
 25 (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-.
9. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 6 wherein R₄ is selected from the group consisting of
 30 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-,

- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₃-(γ-Glu)-,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(εK)-,
 5 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(εK)-(γ-Glu)-,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(εK)-(γ-Glu)-,
 -(εK)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-,
 -(εK)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-,
 -(εK)-(γ-Glu)-,
 10 -(εK)-(γ-Glu)-(γ-Glu)-,
 -(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-,
 -(εK)-(εK)-(γ-Glu)-,
 -(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-, and
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-
 15 ethoxy]-acetyl)-.
10. A compound, or pharmaceutically acceptable salt thereof, as claimed by any one
 of Claims 2, and 4 to 9, wherein Z₁ is selected from the group consisting of
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₀-CO₂H,
 20 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(10-(4-
 carboxyphenoxy)decanoyl),
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(4-(4-iodophenyl)butanoyl),
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(4-(4-*tert*-
 butylphenyl)butanoyl),
 25 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₄-CH₃,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₂-CH₃,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₀-CH₃,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-CO-(CH₂)₁₂-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(10-(4-carboxyphenoxy)decanoyl),
 30 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,

- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH₂)₁₄-CH₃,
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH₂)₁₀-CH₃,
- 5 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₃-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₃-(γ-Glu)-CO-(CH₂)₁₄-CH₃,
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(εK)-CO-(CH₂)₁₂-CO₂H,
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(εK)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(εK)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
- 10 - (εK)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
- (εK)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
- (εK)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
- (εK)-(γ-Glu)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
- (γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-CO-(CH₂)₁₂-CO₂H,
- 15 - (εK)-(εK)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
- (γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO-(CH₂)₁₂-CO₂H,
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO-(CH₂)₁₂-CO₂H,
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(7-(4-carboxyphenoxy)heptanoyl),
- 20 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(8-(4-carboxyphenoxy)octanoyl),
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(4-(4-tert-butylphenyl)butanoyl),
- 25 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(11-(4-carboxyphenoxy)undecanoyl),
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₃-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO-(CH₂)₁₂-CO₂H,
- 30

- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-CO-(CH₂)₁₂-CO₂H,
 - PEG3-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 - PEG4-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 5 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₃-(γ-Glu)-CO-(CH₂)₁₀-CH₃,
 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(11-(4-carboxyphenoxy)undecanoyl),
 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₄-CO₂H,
 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Ahx-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 10 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 - Ahx-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 - Aoc-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Ahx-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
 15 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
 - Ahx-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
 - Aoc-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
 20 - PEG4-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
 - PEG3-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-CO-(CH₂)₁₂-CO₂H,
 - PEG6-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 25 - PEG5-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 - PEG6-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
 - PEG5-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-Trx-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-Trx-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
 30

- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Trx-(γ -Glu)-CO-(CH₂)₁₂-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Trx-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl),
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)₂-CO-(CH₂)₁₂-CO₂H,
 5 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)₂-(10-(4-carboxyphenoxy)decanoyl),
 -(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₂-CO₂H,
 -(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl),
 10 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH₂)₁₂-CO₂H, and
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl).
11. A compound, or a pharmaceutically acceptable salt thereof, as claimed by Claim
- 15 10 wherein Z₁ is selected from the group consisting of:
- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₂-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₀-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl),
 20 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(4-(4-iodophenyl)butanoyl),
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(4-(4-*tert*-butylphenyl)butanoyl),
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₄-CH₃,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₂-CH₃,
 25 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₀-CH₃,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-CO-(CH₂)₁₂-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(10-(4-carboxyphenoxy)decanoyl),
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH₂)₁₂-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl),
 30

- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH₂)₁₄-CH₃,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH₂)₁₀-CH₃,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₃-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₃-(γ-Glu)-CO-(CH₂)₁₄-CH₃,
 5 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(εK)-CO-(CH₂)₁₂-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(εK)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(εK)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 -(εK)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 -(εK)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 10 -(εK)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 -(εK)-(γ-Glu)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 -(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-CO-(CH₂)₁₂-CO₂H,
 -(εK)-(εK)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 -(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO-(CH₂)₁₂-CO₂H,
 15 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-
 ethoxy]-acetyl)-CO-(CH₂)₁₂-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(7-(4-
 carboxyphenoxy)heptanoyl),
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(8-(4-
 20 carboxyphenoxy)octanoyl), and
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(4-(4-tert-
 butylphenyl)butanoyl).
12. A compound, or a pharmaceutically acceptable salt thereof, as claimed by Claim 10 wherein Z₁ is selected from the group consisting of:
- 25 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(11-(4-
 carboxyphenoxy)undecanoyl),
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₃-(γ-Glu)-(10-(4-
 carboxyphenoxy)decanoyl),
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-
 30 ethoxy]-acetyl)-CO-(CH₂)₁₂-CO₂H,

- (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-CO-(CH₂)₁₂-CO₂H,
 - PEG3-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 - PEG4-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 5 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₃-(γ-Glu)-CO-(CH₂)₁₀-CH₃,
 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(11-(4-carboxyphenoxy)undecanoyl),
 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₄-CO₂H,
 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Ahx-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 10 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 - Ahx-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 - Aoc-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Ahx-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
 15 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
 - Ahx-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
 - Aoc-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
 20 - PEG4-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
 - PEG3-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-CO-(CH₂)₁₂-CO₂H,
 - PEG6-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 25 - PEG5-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 - PEG6-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
 - PEG5-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-Trx-(γ-Glu)-CO-(CH₂)₁₂-CO₂H,
 - (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-Trx-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
 30

-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Trx-(γ -Glu)-CO-(CH₂)₁₂-CO₂H,
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Trx-(γ -Glu)-(10-(4-
 carboxyphenoxy)decanoyl),
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)₂-CO-(CH₂)₁₂-CO₂H,
 5 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)₂-(10-(4-
 carboxyphenoxy)decanoyl),
 -(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-CO-(CH₂)₁₂-CO₂H,
 -(γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ -Glu)-(10-(4-
 carboxyphenoxy)decanoyl),
 10 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(2-[2-(2-Amino-ethoxy)-
 ethoxy]-acetyl)-(γ -Glu)-CO-(CH₂)₁₂-CO₂H, and
 -(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-(2-[2-(2-Amino-ethoxy)-
 ethoxy]-acetyl)-(γ -Glu)-(10-(4-carboxyphenoxy)decanoyl).

13. A compound, or pharmaceutically acceptable salt thereof, as claimed by any one
 15 of Claims 1 to 12 wherein:

X₁ is Y;

X₆ is α MeF(2F);

X₁₀ is selected from the group consisting of 4Pal, Y, and KZ₁;

X₁₁ is selected from the group consisting of S, α MeS, and Aib;

20 X₁₂ is I;

X₁₃ is α MeL;

X₁₆ is Orn;

X₁₇ is selected from the group consisting of I and KZ₁;

X₂₀ is Aib;

25 X₂₁ is E or KZ₁;

X₂₂ is selected from the group consisting of F and α MeF;

X₂₄ is selected from the group consisting of D-Glu and KZ₁;

X₂₅ is α MeY;

X₂₈ is selected from the group consisting of E and KZ₁;

30 X₃₀ is selected from the group consisting of G and GR₂;

R₂ is selected from the group consisting of X₃₁SSGX₃₅PPPX₃₉ (SEQ ID NO:7), X₃₁SSGX₃₅PPPX₃₉R₃ (SEQ ID NO:8), and X₃₁SSGX₃₅PPPX₃₉X₄₀ (SEQ ID NO:9), and a modification of the c-terminal group wherein the modification is NH₂;

5 or a pharmaceutically acceptable salt thereof.

14. A compound or pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 13 wherein

X₃₀ is GR₂; and

R₂ is selected from the group consisting of X₃₁SSGX₃₅PPPX₃₉ (SEQ ID NO:7), X₃₁SSGX₃₅PPPX₃₉R₃ (SEQ ID NO:8), and X₃₁SSGX₃₅PPPX₃₉X₄₀ (SEQ ID NO:9).

15. A compound, or pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 14 wherein X₁₇ and X₃₁ are each KZ₁.

16. A compound, or pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 14 wherein X₁₇ and X₂₄ are each KZ₁.

17. A compound, or pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 14 wherein X₁₇ and X₂₁ are each KZ₁.

18. A compound, or pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 14 wherein X₁₇ and X₂₈ are each KZ₁.

19. A compound, or pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 14 wherein X₂₁ and X₂₈ are each KZ₁.

20. A compound, or pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 14 wherein X₂₄ and X₂₈ are each KZ₁.

21. A compound, or pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 14 wherein X₁₇ and X₄₀ are each KZ₁.

22. A compound, or pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 14 wherein X₂₁ and X₄₀ are each KZ₁.

23. A compound, or pharmaceutically acceptable salt thereof, as claimed by Claim 1 wherein the compound is selected from the group consisting of

Y-Aib-EGT-αMeF(2F)-TSD-4Pal-SI-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₂-CO₂H)AQ-Aib-EFI-(D-Glu)-αMeY-

LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₂-CO₂H)SSGAPPPS-NH₂,

Y-Aib-EGT-aMeF(2F)-TSD-4Pal-SI-aMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)-aMeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl))SSGAPPPS-NH₂,

Y-Aib-EGT-aMeF(2F)-TSD-4Pal-SI-aMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(4-(4-iodophenyl)butanoyl))AQ-Aib-EFI-(D-Glu)-aMeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(4-(4-iodophenyl)butanoyl))SSGAPPPS-NH₂,

Y-Aib-EGT-aMeF(2F)-TSD-4Pal-SI-aMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(4-(4-*tert*-butylphenyl)butanoyl))AQ-Aib-EFI-(D-Glu)-aMeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(4-(4-*tert*-butylphenyl)butanoyl))SSGAPPPS-NH₂, and

Y-Aib-EGT-αMeF(2F)-TSD-4Pal-SI-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₀-CH₃)AQ-Aib-EFI-(D-Glu)-αMeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₀-CH₃)SSGAPPPS-NH₂.

24. A compound, or pharmaceutically acceptable salt thereof, as claimed by Claim 23 wherein the compound is Y-Aib-EGT-αMeF(2F)-TSD-4Pal-SI-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₀-CH₃)AQ-Aib-EFI-(D-Glu)-αMeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₀-CH₃)SSGAPPPS-NH₂.

25. A compound, or pharmaceutically acceptable salt thereof, as claimed by Claim 23 wherein the compound is Y-Aib-EGT-aMeF(2F)-TSD-4Pal-SI-aMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(4-(4-*tert*-butylphenyl)butanoyl))AQ-Aib-EFI-(D-Glu)-aMeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(4-(4-*tert*-butylphenyl)butanoyl))SSGAPPPS-NH₂.

26. A compound, or pharmaceutically acceptable salt thereof, as claimed by Claim 23 wherein the compound is Y-Aib-EGT-aMeF(2F)-TSD-4Pal-SI-aMeL-LD-Orn-

K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(4-(4-iodophenyl)butanoyl))AQ-Aib-EFI-(D-Glu)-aMeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(4-(4-iodophenyl)butanoyl))SSGAPPPS-NH₂.

27. A compound, or pharmaceutically acceptable salt thereof, as claimed by Claim 23 wherein the compound is Y-Aib-EGT-aMeF(2F)-TSD-4Pal-SI-aMeL-LD-Orn-

K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)-aMeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl))SSGAPPPS-NH₂.

28. A compound, or pharmaceutically acceptable salt thereof, as claimed by Claim 23 wherein the compound is Y-Aib-EGT-αMeF(2F)-TSD-4Pal-SI-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₂-CO₂H)AQ-Aib-EFI-(D-Glu)-αMeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γ-Glu)-CO-(CH₂)₁₂-CO₂H)SSGAPPPS-NH₂.

29. A method for treating a condition selected from the group consisting of type 2 diabetes mellitus, obesity, NAFLD, nonalcoholic steatohepatitis, dyslipidemia, and metabolic syndrome, comprising administering to a patient in need thereof, an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 28.

30. A method for treating obesity, comprising administering to a patient in need thereof, an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 28.

31. A method for providing therapeutic weight loss, comprising administering to a subject in need thereof, an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 28.

32. A method for treating type 2 diabetes mellitus comprising administering to a subject in need thereof, an effective amount of the compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 28.

33. A pharmaceutical composition comprising the compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 28, and at least one pharmaceutically acceptable carrier, diluent, or excipient.

34. A pharmaceutical composition as claimed by Claim 33 wherein the composition is administered as a subcutaneous injection.

35. A pharmaceutical composition as claimed by Claim 33 wherein the composition is administered orally.

5 36. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 28 for use as a medicament.

37. A compound, or pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 28 for use in treating a condition selected from the group consisting of type 2 diabetes mellitus, obesity, NAFLD, nonalcoholic steatohepatitis,
10 dyslipidemia, and metabolic syndrome.

38. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 28 for use in treating type 2 diabetes mellitus.

39. The use of a compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 28 in the manufacture of a medicament for treating a
15 condition selected from the group consisting of type 2 diabetes mellitus, obesity, NAFLD, nonalcoholic steatohepatitis, dyslipidemia, and metabolic syndrome.

40. The use of a compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 28 in the manufacture of a medicament for treating type
20 2 diabetes mellitus.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2021/014302

A. CLASSIFICATION OF SUBJECT MATTER INV. C07K14/605 A61K38/00 A61K38/26 A61P3/04 A61P3/10 A61P1/00 A61P1/16 A61P3/06 A61P3/08 A61P9/10 A61P9/12 A61P25/30																	
According to International Patent Classification (IPC) or to both national classification and IPC																	
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C07K A61K A61P Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, BIOSIS, EMBASE, WPI Data																	
C. DOCUMENTS CONSIDERED TO BE RELEVANT <table border="1"> <thead> <tr> <th>Category*</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td>X</td> <td>WO 2016/209707 A1 (LILLY CO ELI [US]) 29 December 2016 (2016-12-29) claims 1-16 -----</td> <td>1-40</td> </tr> <tr> <td>X</td> <td>WO 2016/111971 A1 (LILLY CO ELI [US]) 14 July 2016 (2016-07-14) claims 1-13 -----</td> <td>1-40</td> </tr> <tr> <td>X</td> <td>WO 2011/119657 A1 (LILLY CO ELI [US]; ALSINA-FERNANDEZ JORGE [US] ET AL.) 29 September 2011 (2011-09-29) claims 1-5 -----</td> <td>1-40</td> </tr> <tr> <td>X</td> <td>WO 2015/067715 A2 (ZEALAND PHARMA AS [DK]) 14 May 2015 (2015-05-14) claims 1-21 ----- -/-</td> <td>1-40</td> </tr> </tbody> </table>			Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	X	WO 2016/209707 A1 (LILLY CO ELI [US]) 29 December 2016 (2016-12-29) claims 1-16 -----	1-40	X	WO 2016/111971 A1 (LILLY CO ELI [US]) 14 July 2016 (2016-07-14) claims 1-13 -----	1-40	X	WO 2011/119657 A1 (LILLY CO ELI [US]; ALSINA-FERNANDEZ JORGE [US] ET AL.) 29 September 2011 (2011-09-29) claims 1-5 -----	1-40	X	WO 2015/067715 A2 (ZEALAND PHARMA AS [DK]) 14 May 2015 (2015-05-14) claims 1-21 ----- -/-	1-40
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.															
X	WO 2016/209707 A1 (LILLY CO ELI [US]) 29 December 2016 (2016-12-29) claims 1-16 -----	1-40															
X	WO 2016/111971 A1 (LILLY CO ELI [US]) 14 July 2016 (2016-07-14) claims 1-13 -----	1-40															
X	WO 2011/119657 A1 (LILLY CO ELI [US]; ALSINA-FERNANDEZ JORGE [US] ET AL.) 29 September 2011 (2011-09-29) claims 1-5 -----	1-40															
X	WO 2015/067715 A2 (ZEALAND PHARMA AS [DK]) 14 May 2015 (2015-05-14) claims 1-21 ----- -/-	1-40															
☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.																	
* Special categories of cited documents : <table> <tr> <td> "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family </td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family													
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family																
Date of the actual completion of the international search		Date of mailing of the international search report															
7 May 2021		25/05/2021															
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer Tudor, Mark															

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2021/014302

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
- a. ☒ forming part of the international application as filed:
- ☒ in the form of an Annex C/ST.25 text file.
- ☐ on paper or in the form of an image file.
- b. ☐ furnished together with the international application under PCT Rule 13~~ter~~.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
- c. ☐ furnished subsequent to the international filing date for the purposes of international search only:
- ☐ in the form of an Annex C/ST.25 text file (Rule 13~~ter~~.1(a)).
- ☐ on paper or in the form of an image file (Rule 13~~ter~~.1(b) and Administrative Instructions, Section 713).
2. ☐ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2021/014302

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2012/167744 A1 (BEIJING HANMI PHARMACEUTICAL CO LTD [CN]; MA TAO [CN] ET AL.) 13 December 2012 (2012-12-13) claims 1-25 -----	1-40
X	WO 2014/096145 A1 (SANOFI SA [FR]) 26 June 2014 (2014-06-26) claims 1-19 -----	1-40

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2021/014302

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2016209707	A1	29-12-2016	AR 104932 A1 23-08-2017
			AU 2016283984 A1 23-11-2017
			BR 112017024684 A2 11-09-2018
			CA 2987489 A1 29-12-2016
			CL 2017003185 A1 01-06-2018
			CN 107735100 A 23-02-2018
			CO 2018000078 A2 28-03-2018
			CR 20170534 A 27-02-2018
			DK 3310371 T3 12-10-2020
			DO P2017000303 A 15-01-2018
			EA 201792562 A1 31-05-2018
			EC SP17084280 A 28-02-2018
			EP 3310371 A1 25-04-2018
			EP 3785724 A1 03-03-2021
			HK 1245669 A1 31-08-2018
			HR P20201881 T1 22-01-2021
			JO 3686 B1 27-08-2020
			JP 6585197 B2 02-10-2019
			JP 2018521043 A 02-08-2018
			JP 2020007338 A 16-01-2020
			KR 20180004276 A 10-01-2018
			KR 20190119676 A 22-10-2019
			LT 3310371 T 28-12-2020
			MA 46219 B1 31-12-2020
			MD 3310371 T2 31-12-2020
			NZ 737050 A 30-08-2019
			PE 20180523 A1 14-03-2018
			PH 12017502359 A1 25-06-2018
			PL 3310371 T3 08-03-2021
			PT 3310371 T 15-12-2020
			SI 3310371 T1 30-11-2020
			SV 2017005594 A 24-04-2018
			TN 2017000531 A1 12-04-2019
			TW 201716431 A 16-05-2017
			TW 201906857 A 16-02-2019
			UA 122692 C2 28-12-2020
			US 2016368960 A1 22-12-2016
			WO 2016209707 A1 29-12-2016
WO 2016111971	A1	14-07-2016	AR 103242 A1 26-04-2017
			AU 2016205435 A1 08-06-2017
			BR 112017010596 A2 06-03-2018
			CA 2973352 A1 14-07-2016
			CL 2017001760 A1 16-03-2018
			CN 107207576 A 26-09-2017
			CN 112608377 A 06-04-2021
			DK 3242887 T3 02-09-2019
			DO P2017000153 A 15-07-2017
			EA 201791281 A1 30-11-2017
			EA 201892057 A1 28-02-2019
			EA 202090392 A2 31-05-2020
			EC SP17043648 A 30-11-2017
			EP 3242887 A1 15-11-2017
			EP 3597662 A1 22-01-2020
			ES 2747928 T3 12-03-2020
			HR P20191614 T1 13-12-2019
			HU E045860 T2 28-01-2020
			IL 252499 A 31-08-2020

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2021/014302

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
		JO 3575 B1	05-07-2020	
		JP 6219534 B2	25-10-2017	
		JP 6545766 B2	17-07-2019	
		JP 6754867 B2	16-09-2020	
		JP 2017507124 A	16-03-2017	
		JP 2018052933 A	05-04-2018	
		JP 2019203000 A	28-11-2019	
		KR 20170092661 A	11-08-2017	
		KR 20190026967 A	13-03-2019	
		LT 3242887 T	11-11-2019	
		MA 41315 B1	29-11-2019	
		MD 3242887 T2	30-11-2019	
		ME 03494 B	20-01-2020	
		NZ 732000 A	30-11-2018	
		PE 20170954 A1	13-07-2017	
		PH 12017501252 A1	30-10-2017	
		PL 3242887 T3	28-02-2020	
		PT 3242887 T	29-10-2019	
		SG 11201705603Y A	30-08-2017	
		SI 3242887 T1	30-10-2019	
		SV 2017005453 A	27-08-2018	
		TN 2017000198 A1	19-10-2018	
		TW 201636362 A	16-10-2016	
		UA 118239 C2	10-12-2018	
		US 2016199438 A1	14-07-2016	
		WO 2016111971 A1	14-07-2016	
		ZA 201703930 B	26-06-2019	

WO 2011119657	A1	29-09-2011	AR 080592 A1	18-04-2012
			AU 2011232597 A1	30-08-2012
			BR 112012024373 A2	10-01-2017
			CA 2794664 A1	29-09-2011
			CL 2012002635 A1	21-12-2012
			CN 102821779 A	12-12-2012
			CO 6630128 A2	01-03-2013
			CR 20120457 A	16-10-2012
			DO P2012000244 A	15-02-2013
			EA 201270723 A1	30-01-2013
			EC SP12012181 A	30-11-2012
			EP 2552471 A1	06-02-2013
			ES 2568796 T3	04-05-2016
			GT 201200263 A	05-12-2013
			JP 5887335 B2	16-03-2016
			JP 2013523647 A	17-06-2013
			KR 20120133402 A	10-12-2012
			MA 34077 B1	05-03-2013
			PE 20130523 A1	25-04-2013
			SG 184289 A1	29-11-2012
			TN 2012000432 A1	30-01-2014
			TW 201201829 A	16-01-2012
			US 2011237503 A1	29-09-2011
			WO 2011119657 A1	29-09-2011
			ZA 201206832 B	26-03-2014

WO 2015067715	A2	14-05-2015	AU 2014345569 B2	13-08-2020
			BR 112016009889 A2	05-12-2017
			CA 2929459 A1	14-05-2015
			CN 105849122 A	10-08-2016

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2021/014302

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		EA 201690660 A1	31-03-2017
		EP 3065767 A2	14-09-2016
		JP 6682432 B2	15-04-2020
		JP 2016540741 A	28-12-2016
		JP 2020040979 A	19-03-2020
		KR 20160079875 A	06-07-2016
		TW 201605888 A	16-02-2016
		US 2016280754 A1	29-09-2016
		US 2019218270 A1	18-07-2019
		WO 2015067715 A2	14-05-2015

WO 2012167744 A1	13-12-2012	CN 103764673 A	30-04-2014
		EP 2718317 A1	16-04-2014
		JP 5914641 B2	11-05-2016
		JP 2014516994 A	17-07-2014
		KR 20140043780 A	10-04-2014
		US 2014162945 A1	12-06-2014
		WO 2012167744 A1	13-12-2012

WO 2014096145 A1	26-06-2014	AR 094178 A1	15-07-2015
		AR 094180 A1	15-07-2015
		AR 094181 A1	15-07-2015
		AR 099912 A1	31-08-2016
		AR 105816 A2	15-11-2017
		AU 2013360721 A1	09-07-2015
		AU 2013366690 A1	09-07-2015
		AU 2013366691 A1	09-07-2015
		AU 2013366692 A1	09-07-2015
		BR 112015013809 A2	14-11-2017
		BR 112015014510 A2	21-11-2017
		BR 112015014800 A2	10-10-2017
		CA 2894765 A1	26-06-2014
		CA 2895156 A1	26-06-2014
		CA 2895755 A1	26-06-2014
		CA 2895875 A1	26-06-2014
		CL 2015001751 A1	21-09-2015
		CL 2016002182 A1	12-01-2018
		CN 104870009 A	26-08-2015
		CN 104902918 A	09-09-2015
		CN 104902919 A	09-09-2015
		CN 104902920 A	09-09-2015
		CR 20150358 A	16-09-2015
		CY 1120030 T1	12-12-2018
		CY 1121153 T1	29-05-2020
		DK 2934567 T3	13-08-2018
		DK 2934568 T3	22-01-2018
		DO P2015000156 A	31-08-2015
		EA 201591174 A1	31-03-2016
		EC SP15031141 A	30-11-2015
		EP 2934566 A1	28-10-2015
		EP 2934567 A1	28-10-2015
		EP 2934568 A1	28-10-2015
		EP 2934569 A1	28-10-2015
		EP 3400957 A1	14-11-2018
		ES 2653765 T3	08-02-2018
		ES 2688367 T3	02-11-2018
		HK 1211231 A1	20-05-2016
		HK 1211232 A1	20-05-2016

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2021/014302

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		HK 1211233 A1	20-05-2016
		HK 1213483 A1	08-07-2016
		HR P20180092 T1	23-02-2018
		HR P20181300 T1	05-10-2018
		HU E035803 T2	28-05-2018
		HU E038748 T2	28-11-2018
		JP 6391589 B2	19-09-2018
		JP 6408998 B2	17-10-2018
		JP 2016503770 A	08-02-2016
		JP 2016503771 A	08-02-2016
		JP 2016503772 A	08-02-2016
		JP 2016506401 A	03-03-2016
		KR 20150096398 A	24-08-2015
		KR 20150096433 A	24-08-2015
		KR 20150096684 A	25-08-2015
		KR 20150099548 A	31-08-2015
		LT 2934567 T	10-09-2018
		LT 2934568 T	12-02-2018
		MA 38276 A1	30-06-2017
		MX 360317 B	29-10-2018
		MX 362190 B	08-01-2019
		PE 20151239 A1	08-09-2015
		PH 12015501291 A1	24-08-2015
		PL 2934567 T3	31-10-2018
		PL 2934568 T3	30-03-2018
		PT 2934567 T	01-10-2018
		PT 2934568 T	04-01-2018
		RU 2015129696 A	27-01-2017
		RU 2015129788 A	30-01-2017
		RU 2015129815 A	27-01-2017
		SG 10201705097P A	28-07-2017
		SG 11201503524P A	29-06-2015
		SG 11201503526U A	29-06-2015
		SG 11201503576X A	29-06-2015
		SG 11201504215P A	29-06-2015
		SI 2934567 T1	30-10-2018
		SI 2934568 T1	30-03-2018
		TN 2015000283 A1	03-10-2016
		TW 201429985 A	01-08-2014
		TW 201441251 A	01-11-2014
		TW 201441252 A	01-11-2014
		TW 201443080 A	16-11-2014
		UA 116553 C2	10-04-2018
		US 2014206608 A1	24-07-2014
		US 2014206609 A1	24-07-2014
		US 2014213513 A1	31-07-2014
		US 2014221281 A1	07-08-2014
		US 2017216406 A1	03-08-2017
		UY 35231 A	31-07-2014
		UY 35232 A	31-07-2014
		UY 35233 A	31-07-2014
		UY 35234 A	31-07-2014
		WO 2014096145 A1	26-06-2014
		WO 2014096148 A1	26-06-2014
		WO 2014096149 A1	26-06-2014
		WO 2014096150 A1	26-06-2014
		ZA 201503914 B	21-12-2016